"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_INRCA",2000,66,7.33333333333333,2.06060606060606,0.393939393939394,0.303030303030303,0.393939393939394,1.43157894736842,1.08333333333333,1.17647058823529,1.08333333333333,0.212121212121212,3,29,16,3,15,0.44,0.24,0.05,0.23,100.02,2.20633122788452,NA,0.272727272727273,0.893939393939394,0.441,0.34,0.408,0.34,"CLAUDIO FRANCESCHI;LUIGI FERRUCCI;MASSIMILIANO BONAFÉ;JACK M. GURALNIK;SUZANNE G. LEVEILLE;WALTER MALORNI;ROBERTO TESTA;L. PIANTANELLI;DANIELA MONTI;DANIELE FUMELLI;STEFANO SALVIOLI;LUIGI GOFFI;ROBERTO GHISELLI;MAURO PROVINCIALI;LUCIANO GALEAZZI;STEFANO VOLPATO;P COSER;LIANA SPAZZAFUMO;CLAUDIO FRANCESCHI;A AMBROSINI","10;8;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","L. PIANTANELLI;LUIGI FERRUCCI;CLAUDIO FRANCESCHI;ANNAMARIA ZAIA;MARIA CARLA RE;ANNA VESPA;CLAUDIO CHILLEMI LUIGI DE PALMA;MAURO PROVINCIALI;JACK M. GURALNIK;ROBERTO TESTA;KATY ARGENTATI;SUZANNE G. LEVEILLE;MARIA CHIARA MAGNONE;ROSA SQUADRONI;G. ROSSOLINI;NORMA BARBINI;PAOLO MIGANI;MASSIMILIANO BONAFÉ;LUCIANO GALEAZZI;LUIGI GOFFI","1.5;1.15;1.09;1;1;1;1;0.63;0.56;0.54;0.53;0.53;0.5;0.5;0.5;0.5;0.5;0.48;0.47;0.44","CLAUDIO FRANCESCHI;LUIGI FERRUCCI;ROBERTO TESTA;L. PIANTANELLI;DANIELE FUMELLI;LUIGI GOFFI;ROBERTO GHISELLI;MAURO PROVINCIALI;LUCIANO GALEAZZI;LIANA SPAZZAFUMO;CLAUDIO FRANCESCHI;ANNAMARIA ZAIA;ANTONIO DOMENICO PROCOPIO;ATTILIO OLIVIERI;VITTORIO SABA;CARLO BERTONI–FREDDARI;KATY ARGENTATI;G. ROSSOLINI;TIZIANA CASOLI;I TESTA","10;8;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","L. PIANTANELLI;LUIGI FERRUCCI;CLAUDIO FRANCESCHI;ANNAMARIA ZAIA;MARIA CARLA RE;ANNA VESPA;CLAUDIO CHILLEMI LUIGI DE PALMA;MAURO PROVINCIALI;ROBERTO TESTA;KATY ARGENTATI;G. ROSSOLINI;NORMA BARBINI;LUCIANO GALEAZZI;LUIGI GOFFI;ROBERTO GHISELLI;DANIELE FUMELLI;LIANA SPAZZAFUMO;SERGIO GIUNTA;E PACIARONI;ROBERTO ANTONICELLI","1.5;1.15;1.09;1;1;1;1;0.63;0.54;0.53;0.5;0.5;0.47;0.44;0.44;0.42;0.39;0.34;0.33;0.33","LUIGI FERRUCCI;JACK M. GURALNIK;SUZANNE G. LEVEILLE;ROBERT B. WALLACE;CARL F. PIEPER;G. V. OSTIR;KYRIAKOS S. MARKIDES;LISA BERKMAN;STEPHANIE A. STUDENSKI;CLAUDIO FRANCESCHI;TAMARA B. HARRIS;STEFANIA BANDINELLI;ANGELO DI IORIO;CLAUDIO MACCHI;ENRICO BENVENUTI;A CASTI;FRANCESCO FAGNONI;GIAMPAOLO LAVAGETTO;GIOVANNI BOLOGNA;GIOVANNI PASSERI","3918;3773;2842;2810;2646;2646;2646;2646;2646;1148;949;828;761;761;761;511;511;511;511;511","LUIGI FERRUCCI;CLAUDIO FRANCESCHI;STEFANIA BANDINELLI;ENRICO BENVENUTI;A CASTI;FRANCESCO FAGNONI;GIAMPAOLO LAVAGETTO;GIOVANNI BOLOGNA;GIOVANNI PASSERI;MARIO PASSERI;MARIO PEDRAZZONI;PAOLO SANSONI;ROSANNA VESCOVINI;FABRIZIA LATTANZIO;RICCARDO SARZANI;RICHARD J. HAVLIK;MARIO ANICHINI;MAURO PROVINCIALI;FABIOLA OLIVIERI;ANDREA CORSONELLO","3918;1066;828;761;511;511;511;511;511;511;511;511;511;458;224;164;159;147;127;88","CLAUDIO FRANCESCHI;LUIGI FERRUCCI;L. PIANTANELLI;ROBERTO TESTA;LUCIANO GALEAZZI;MAURO PROVINCIALI;ANNAMARIA ZAIA;ANTONIO DOMENICO PROCOPIO;ATTILIO OLIVIERI;CARLO BERTONI–FREDDARI;G. ROSSOLINI;KATY ARGENTATI;LIANA SPAZZAFUMO;LUIGI GOFFI;P. FUMELLI;PATRIZIA FATTORETTI;SERGIO GIUNTA;STEFANIA BANDINELLI;TIZIANA CASOLI;A CASTI","11;10;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;ENGINEERING;MATHEMATICS;PHYSICS;ART;BUSINESS;GEOGRAPHY;GEOLOGY;MATERIALS SCIENCE;PHILOSOPHY","52;36;16;8;6;5;4;4;3;2;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;CELL BIOLOGY;GERONTOLOGY;PATHOLOGY;PHYSICAL THERAPY;GASTROENTEROLOGY;NEUROSCIENCE;PSYCHIATRY;SURGERY;CANCER RESEARCH;DEMOGRAPHY;CHROMATOGRAPHY;MOLECULAR BIOLOGY;ONCOLOGY;ANATOMY;CARDIOLOGY;COMPUTATIONAL BIOLOGY;DEVELOPMENTAL PSYCHOLOGY;MECHANICAL ENGINEERING;MICROBIOLOGY;NURSING","37;19;17;17;10;10;9;8;8;7;6;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3","GENE;POPULATION;IN VITRO;IMMUNE SYSTEM;RECEPTOR;DIABETES MELLITUS;APOPTOSIS;DISEASE;INSULIN;ACTIVITIES OF DAILY LIVING;EPIDEMIOLOGY;ANTIBIOTICS;BLOOD PRESSURE;COGNITION;CORTEX (ANATOMY);CYTOKINE;ENZYME;EXTRACELLULAR MATRIX;LYMPHOMA;MITOCHONDRION;ODDS RATIO;OXIDATIVE STRESS","13;13;9;7;7;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","CYTOTOXIC T CELL;GENOTYPE;CD8;INSULIN RESISTANCE;T CELL;INTERLEUKIN 2;ADENOSINE DEAMINASE;AGONIST;ALLELE;ALZHEIMER'S DISEASE;APOLIPOPROTEIN E;GENE EXPRESSION;GENETIC ENHANCEMENT;GLUTAMATE RECEPTOR;GLUTATHIONE;GLYCOPEPTIDE;INTERLEUKIN;PROGRAMMED CELL DEATH;SEROTONIN;STAPHYLOCOCCUS AUREUS;TRANSPORTER","5;5;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADENOSINE KINASE;ADENOSINE RECEPTOR;INSULIN RECEPTOR;INTERLEUKIN 21;IONOTROPIC EFFECT;NUCLEOSIDE TRANSPORTER;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS EPIDERMIDIS;VANCOMYCIN;ADIPOKINE;ALLELE FREQUENCY;AMPA RECEPTOR;AMYLOID PRECURSOR PROTEIN;CARPOMETACARPAL JOINT;CD28;CROSSMODAL;CUTANEOUS T-CELL LYMPHOMA;DNA VACCINATION;GLUCOSE TOLERANCE TEST;GLUTAMATERGIC;GLUTATHIONE DISULFIDE;GLUTATHIONE S-TRANSFERASE;GRANZYME B;HAPLOTYPE;HER2/NEU;INSULIN SENSITIVITY;INTERLEUKIN 12;INTERLEUKIN 15;INTERLEUKIN 1Β;KAINIC ACID;LEPTIN RECEPTOR;LEUKAPHERESIS;LIPOPROTEIN(A);METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;METHYLENETETRAHYDROFOLATE REDUCTASE;MONOAMINE NEUROTRANSMITTER;MONOAMINERGIC;NATURAL KILLER CELL;NUCLEAR DNA;NUCLEAR GENE;NUCLEAR MATRIX;PERFORIN;PERIPHERAL T-CELL LYMPHOMA;PLACENTA;POLYMORPHISM (COMPUTER SCIENCE);PRIMARY MOTOR CORTEX;PROMOTER;SENILE PLAQUES;SILENT PERIOD;STAUROSPORINE;T-CELL RECEPTOR;TAUROURSODEOXYCHOLIC ACID;THYMIC INVOLUTION;TOTAL BODY IRRADIATION","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;;ADULT;AGING;ANIMALS;AGED, 80 AND OVER;APOPTOSIS;ALZHEIMER DISEASE;INTERLEUKIN-2;ACTIVITIES OF DAILY LIVING;CELL NUCLEUS;GERIATRIC ASSESSMENT;ITALY;MICE;BLOOD PLATELETS;RATS","42;32;30;24;19;14;13;13;11;10;9;8;8;7;7;7;7;7;6;6","MECHANISMS OF ALZHEIMER'S DISEASE;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;CHEMISTRY AND APPLICATIONS OF FULLERENES;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;MOLECULAR PHYSIOLOGY OF PURINERGIC SIGNALLING;REGULATORY T CELL DEVELOPMENT AND FUNCTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIGITAL EPIDEMIOLOGY AND DISEASE SURVEILLANCE;DNA NANOTECHNOLOGY AND BIOANALYTICAL APPLICATIONS","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","AGING;PROTEIN MISFOLDING;ADENOSINE KINASE;ADENOSINE RECEPTORS;APOLIPOPROTEIN E;BLOOD PRESSURE;CORTICAL PARCELLATION;HYPERTENSION;NUCLEOSIDE TRANSPORTER;PATHOGENESIS;PERIPROSTHETIC JOINT INFECTION;PHYSICAL PERFORMANCE;SAMPLE (MATERIAL);STROKE (ENGINE);ACINAR CELL;ACUTE PANCREATITIS;AGING BRAIN;AGING POPULATION;AGING SOCIETIES;AGING WORKFORCE","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","AGING MICE;NON-HODGKINS LYMPHOMA;PERIPHERAL BLOOD;AGGRESSIVE NON-HODGKINS;APOPTOSIS INDUCED;ASTROCYTOMA CELL;CELL LINE;CIRRHOTIC PATIENTS;CLINICAL RELEVANCE;DIABETIC PATIENTS;DIFFERENTIAL MECHANISMS;EXTREMITY FUNCTION;HUMAN ASTROCYTOMA;INSULIN RECEPTORS;LINE DIFFERENTIAL;LOWER EXTREMITY;TYPE DIABETIC;ACID ADMINISTRATION;ACID RECEPTORS;ACTIVATOR INHIBITOR;ACTIVE LIFE;ADENOCARCINOMA CELLS;ADJUVANT THERAPY;ADV NSCLC;ADVANCED NON-SMALL-CELL;ADVERSE HEALTH;AFFECTING Α-ANTICHYMOTRYPSIN;AGE-RELATED EFFECTS;AGE-RELATED IMPAIRMENTS;AGE-RELATED PHENOMENON","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CROSSREF PUBMED;PUBMED SCOPUS;HUMAN KERATINOCYTES;ΜM CF;PUBMED GOOGLE;INVEST DERMATOL;PROTECTS HUMAN;UVB IRRADIATION;CF UVB;CF ΜM;CROSSREF SCOPUS;DEPOLARIZED MITOCHONDRIA;FLOW CYTOMETRY;CF-PRETREATED CELLS;CHEM SOC;COMMUN -CROSSREF;DERMATOL -CROSSREF;HAAKE AR;HAND OA;MITOCHONDRIAL MEMBRANE;SUBCONFLUENT KERATINOCYTES;TSA PC;UVB IRRADIATED;UVB MJ;ACAD SCI;AFFINITY RECEPTOR;BCL- PROTEIN;CELL COLUMNS;CELL DEATH;CELLS TREATED","26;25;19;13;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4",13,0.2,6,2,0,2,0,1,3,0,1.75,2,0,0,2.5,0,1,1,0,3,0,0,0,145,145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2001,68,7.0735294117647,3.08823529411765,0.455882352941176,0.441176470588235,0.470588235294118,1.77118644067797,1.24,1.2,1.23076923076923,0.235294117647059,2,33,18,4,7,0.49,0.26,0.06,0.1,47.74,1.04470905003929,NA,0.264705882352941,0.852941176470588,0.503,0.533,0.489,0.53,"CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;MORENO SOLAZZI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;NATASCIA GRACCIOTTI;CLAUDIO FRANCESCHI;FIORENZA ORLANDO;MASSIMILIANO BONAFÉ;VITTORIO SABA;FEDERICO MOCCHEGIANI;ROBERTO TESTA;GIORGIO SCALISE;ROBERTO GHISELLI;PIERLUIGI POMPEI;OSCAR CIRIONI;DANIELA MONTI;ANNA RITA BONFIGLI;ANNAMARIA ZAIA;GIORGIO FELZANI","15;13;12;11;11;10;8;4;4;4;4;4;4;4;4;4;3;3;3;3","CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;MORENO SOLAZZI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;NATASCIA GRACCIOTTI;ISABELLA PAOLETTI;G. B. FERRARA;CLAUDIO FRANCESCHI;PIERLUIGI POMPEI;ROBERTO TESTA;NICOLA MAGNAVITA;A. FILENI;FEDERICO MOCCHEGIANI;GIORGIO SCALISE;ROBERTO GHISELLI;OSCAR CIRIONI;ANNAMARIA ZAIA;ANDREA BASSO;G. ROSSOLINI","2.36;2.05;1.9;1.75;1.75;1.56;1;1;0.85;0.55;0.54;0.5;0.5;0.49;0.49;0.49;0.49;0.48;0.48;0.48","CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;MORENO SOLAZZI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;NATASCIA GRACCIOTTI;CLAUDIO FRANCESCHI;FIORENZA ORLANDO;VITTORIO SABA;FEDERICO MOCCHEGIANI;ROBERTO TESTA;GIORGIO SCALISE;ROBERTO GHISELLI;PIERLUIGI POMPEI;OSCAR CIRIONI;ANNA RITA BONFIGLI;ANNAMARIA ZAIA;ANDREA BASSO;MAURIZIO MARRA;CARLO PIERI","15;13;12;11;11;10;8;4;4;4;4;4;4;4;4;3;3;3;3;3","CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;MORENO SOLAZZI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;NATASCIA GRACCIOTTI;ISABELLA PAOLETTI;CLAUDIO FRANCESCHI;PIERLUIGI POMPEI;ROBERTO TESTA;A. FILENI;FEDERICO MOCCHEGIANI;GIORGIO SCALISE;ROBERTO GHISELLI;OSCAR CIRIONI;ANNAMARIA ZAIA;ANDREA BASSO;G. ROSSOLINI;ANNA PIANTANELLI;L. PIANTANELLI","2.36;2.05;1.9;1.75;1.75;1.56;1;0.85;0.55;0.54;0.5;0.49;0.49;0.49;0.49;0.48;0.48;0.48;0.48;0.48","ANGELO SCUTERI;ANNE CAPRIOTTI;DAVID A. KASS;EDWARD G. LAKATTA;EDWARD P. SHAPIRO;MIHO KAWAGUCHI;ROBERT C. DEGROOF;CLAUDIO FRANCESCHI;VITTORIO SABA;ANDREA MEZZETTI;ANNALISA IEZZI;BARBARA PINI;CESARIA PRONTERA;DOMENICO DE CESARE;FRANCESCO CHIARELLI;FRANCESCO CIPOLLONE;FRANCO CUCCURULLO;GIANFRANCO BOCCOLI;MARIA FAZIA;MATTEO MARINI","707;707;707;707;707;707;707;484;415;348;348;348;348;348;348;348;348;348;348;348","ANGELO SCUTERI;ANNE CAPRIOTTI;DAVID A. KASS;EDWARD G. LAKATTA;EDWARD P. SHAPIRO;MIHO KAWAGUCHI;ROBERT C. DEGROOF;VITTORIO SABA;ANDREA MEZZETTI;ANNALISA IEZZI;BARBARA PINI;CESARIA PRONTERA;DOMENICO DE CESARE;FRANCESCO CHIARELLI;FRANCESCO CIPOLLONE;FRANCO CUCCURULLO;GIANFRANCO BOCCOLI;MARIA FAZIA;MATTEO MARINI;S UCCHINO","707;707;707;707;707;707;707;415;348;348;348;348;348;348;348;348;348;348;348;348","PATRIZIA FATTORETTI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;CARLO BERTONI–FREDDARI;MORENO SOLAZZI;NATASCIA GRACCIOTTI;CLAUDIO FRANCESCHI;FIORENZA ORLANDO;ROBERTO TESTA;VITTORIO SABA;LUIGI FERRUCCI;ANDREA BASSO;ANNA PIANTANELLI;ANNAMARIA ZAIA;FEDERICO MOCCHEGIANI;G. ROSSOLINI;L. PIANTANELLI;ROBERTO GHISELLI;MAURIZIO MARRA;ANNA RITA BONFIGLI","15;11;11;10;7;7;6;4;4;4;3;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;PHYSICS;PHILOSOPHY;SOCIOLOGY;ENGINEERING;ECONOMICS;GEOLOGY;MATERIALS SCIENCE","56;37;11;7;7;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;BIOCHEMISTRY;GENETICS;PATHOLOGY;CELL BIOLOGY;IMMUNOLOGY;NEUROSCIENCE;PSYCHIATRY;GERONTOLOGY;CARDIOLOGY;SURGERY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;PHARMACOLOGY;PHYSICAL THERAPY;ARTIFICIAL INTELLIGENCE;DEMOGRAPHY;EVOLUTIONARY BIOLOGY;GASTROENTEROLOGY;ORGANIC CHEMISTRY;STATISTICS","42;20;19;13;13;9;9;9;8;7;6;6;5;4;4;4;3;3;3;3;3;3","GENE;ENZYME;DIABETES MELLITUS;DISEASE;POPULATION;AGEING;IMMUNOHISTOCHEMISTRY;LONGEVITY;MITOCHONDRION;ANTIBIOTICS;ANTIGEN;BLOOD PRESSURE;CANCER;COMORBIDITY;HIPPOCAMPUS;IMMUNE SYSTEM;INSULIN;ALTERNATIVE MEDICINE;BACTERIA;CELL;CEREBELLUM;COGNITION;HIPPOCAMPAL FORMATION;PATHOLOGICAL;PLATELET;RECEPTOR;SALINE","12;8;7;7;7;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","SUCCINATE DEHYDROGENASE;ALLELE;DENTATE GYRUS;GENE EXPRESSION;GENOTYPE;HUMAN LEUKOCYTE ANTIGEN;ANTIBIOTIC RESISTANCE;CYTOCHEMISTRY;CYTOCHROME C OXIDASE;DEMENTIA;GLUTATHIONE;HEART RATE;IMMUNOSENESCENCE;MESSENGER RNA;MITOCHONDRIAL DNA;PLACEBO;QUARTILE;SEPTIC SHOCK;STAPHYLOCOCCUS AUREUS;SUCCINIC DEHYDROGENASE;TYPE 2 DIABETES MELLITUS;VASCULAR ENDOTHELIAL GROWTH FACTOR","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMIPENEM;IN SITU HYBRIDIZATION;ADVANCED GLYCATION END-PRODUCT;ALPHA (FINANCE);BASIC FIBROBLAST GROWTH FACTOR;CECROPIN;EXTENDED AMYGDALA;GENE EXPRESSION PROFILING;GENE POLYMORPHISM;GLUT1;GRANULE CELL;HAPLOTYPE;HISTOCOMPATIBILITY TESTING;MEAN ARTERIAL PRESSURE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MOLECULAR MEDICINE;ONCOGENE;PERCEPTUAL DISORDERS;PIPERACILLIN;PLATELET ADHESIVENESS;PLEURAL DISEASE;PON1;PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS EPIDERMIDIS;SUBSTANCE P;T-CELL RECEPTOR;VANCOMYCIN","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;AGED;FEMALE;AGING;MIDDLE AGED;ADULT;ANIMALS;;AGED, 80 AND OVER;RATS;HIPPOCAMPUS;BLOOD PLATELETS;DIABETES MELLITUS, TYPE 2;HYPERTENSION;MITOCHONDRIA;RATS, WISTAR;ARTERIOSCLEROSIS;ITALY;MONOCYTES","36;31;26;26;24;19;18;16;15;13;13;12;9;9;9;8;8;7;7;7","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;REGULATORY T CELL DEVELOPMENT AND FUNCTION;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;ROLE OF MAGNESIUM IN HEALTH AND DISEASE;AMINO ACID TRANSPORT AND METABOLISM IN HEALTH AND DISEASE;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CHOLINESTERASE INHIBITORS IN NEURODEGENERATIVE DISEASES;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EFFECTIVENESS OF PLAY THERAPY INTERVENTIONS WITH CHILDREN;ELECTROSPUN NANOFIBERS IN BIOMEDICAL APPLICATIONS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT","4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","AGING;ALZHEIMER'S DISEASE;COGNITIVE DECLINE;COMPREHENSIVE GERIATRIC ASSESSMENT;CYTOCHEMISTRY;DIABETES;GERIATRIC ASSESSMENT;HEART RATE VARIABILITY;HYPERTENSION;IMMUNOSENESCENCE;INTRAPERITONEAL INJECTION;LIFE SPAN;LONGEVITY;MAGNESIUM;MITOCHONDRIA;MITOCHONDRIAL FUNCTION;MITOCHONDRIAL FUSION;NERVE CELLS;NEURODEGENERATION;ORGANELLE","5;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ALZHEIMERS DISEASE;SUCCINIC DEHYDROGENASE;ANIMAL MODEL;BALBC-NU MICE;CHRONIC HEPATITIS;DEHYDROGENASE ACTIVITY;DIABETIC PATIENTS;EUTHYMIC BALBC-NU;GENE EXPRESSION;GRAFT INFECTION;ITALIAN CENTENARIANS;LONG-LIVE EUTHYMIC;PLATELET ACTIVATION;QUANTITATIVE CYTOCHEMICAL;QUANTITATIVE IMMUNOHISTOCHEMISTRY;RAT HIPPOCAMPUS;SERUM LEVELS;VASCULAR GRAFT;ACTIVATOR INHIBITOR;ACUTE PULMONARY;ADULT RAT;ADULT VITAMIN-E;ADVANCED GLYCATION;AGE SPECIFICITY;AGE-RELATED EFFECTS;AGED PEOPLE;AGING PROVIDE;AGING-LIKE ALTERATIONS;ALCOHOL CONSUMPTION;ANTIGEN CLASS","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;PPT-A MRNA;NITRIC OXIDE;INSULIN RESISTANCE;HEART RATE;MM HG;BLOOD CELL;CELL COUNT;GAP- MRNA;PLATELET NITRIC;RED BLOOD;AMYLOID FRAGMENT;ARTERIAL COMPLIANCE;HEALTHY SUBJECTS;IBOTENIC ACID;MRNA LEVELS;OXIDE PRODUCTION;STATISTICALLY SIGNIFICANT;SYMPTOMATIC PLAQUES;AMINO ACID;CARDIOVASCULAR EVENT;CARDIOVASCULAR EVENTS;CARDIOVASCULAR RISK;CONTROL SUBJECTS;COX- PGES;DIABETIC SUBJECTS;DRB DRB;HEAVY CHAIN;OXIDE RELEASE;RESISTANCE SYNDROME","13;10;9;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",7,0.1,3.25,4,0,0,0,0,7,0,1.75,4,0,0,2,0,2.5,0,0,2,0,0,0,99.5,99.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,731360,108867.54,4,6,5,1,2,54433.7714285714,1.24922448354016,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;BISPEBJERG HOSPITAL;CONSORZIO PER LA RICERCA E L'EDUCAZIONE PERMANENTE;ETH ZURICH;JÖNKÖPING UNIVERSITY;NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT;ROESSINGH RESEARCH AND DEVELOPMENT;RWTH AACHEN UNIVERSITY;UNIVERSITY OF BRESCIA;UNIVERSITY OF BRISTOL;UNIVERSITY OF JYVÄSKYLÄ","2;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME)","2;1;1","35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY","1;1;1;1","AGING","2",NA,NA,"2.4 SURVEILLANCE AND DISTRIBUTION","1",NA,NA,NA,NA,"A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;B12 ENGINEERING","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2002,83,7.46987951807229,2.8433734939759,0.493975903614458,0.325301204819277,0.506024096385542,1.8503937007874,1.51851851851852,1.22727272727273,1.55555555555556,0.180722891566265,1,37,19,7,16,0.45,0.23,0.08,0.19,63.02,1.14238842625569,NA,0.216867469879518,0.807228915662651,0.44,0.467,0.421,0.469,"PATRIZIA FATTORETTI;CARLO BERTONI–FREDDARI;LUIGI FERRUCCI;TIZIANA CASOLI;CLAUDIO FRANCESCHI;MORENO SOLAZZI;MAURO PROVINCIALI;JACK M. GURALNIK;VITTORIO SABA;FEDERICO MOCCHEGIANI;GIORGIO SCALISE;ROBERTO GHISELLI;OSCAR CIRIONI;KATY ARGENTATI;GIUSEPPINA DI STEFANO;ALESSIA DONNINI;FIORENZA ORLANDO;UGO CASELLI;BEATRICE BARTOZZI;BELINDA GIORGETTI","12;11;10;8;8;8;8;6;6;6;6;6;6;5;5;5;4;4;4;4","PATRIZIA FATTORETTI;CARLO BERTONI–FREDDARI;MORENO SOLAZZI;TIZIANA CASOLI;LUIGI FERRUCCI;MAURO PROVINCIALI;GABRIELE ZELONI;CLAUDIO FRANCESCHI;GIUSEPPINA DI STEFANO;JACK M. GURALNIK;UGO CASELLI;LAZZARO REPETTO;KATY ARGENTATI;ALESSIA DONNINI;VITTORIO SABA;FEDERICO MOCCHEGIANI;GIORGIO SCALISE;ROBERTO GHISELLI;OSCAR CIRIONI;BELINDA GIORGETTI","1.91;1.74;1.25;1.19;1.14;1.01;1;0.84;0.77;0.73;0.69;0.69;0.67;0.67;0.64;0.64;0.64;0.64;0.64;0.6","PATRIZIA FATTORETTI;CARLO BERTONI–FREDDARI;LUIGI FERRUCCI;TIZIANA CASOLI;CLAUDIO FRANCESCHI;MORENO SOLAZZI;MAURO PROVINCIALI;VITTORIO SABA;FEDERICO MOCCHEGIANI;ROBERTO GHISELLI;KATY ARGENTATI;GIUSEPPINA DI STEFANO;ALESSIA DONNINI;FIORENZA ORLANDO;UGO CASELLI;BEATRICE BARTOZZI;BELINDA GIORGETTI;LAZZARO REPETTO;FABIOLA OLIVIERI;GIOVANNI BERNARDINI","12;11;10;8;8;8;8;6;6;6;5;5;5;4;4;4;4;4;4;4","PATRIZIA FATTORETTI;CARLO BERTONI–FREDDARI;MORENO SOLAZZI;TIZIANA CASOLI;LUIGI FERRUCCI;MAURO PROVINCIALI;GABRIELE ZELONI;CLAUDIO FRANCESCHI;GIUSEPPINA DI STEFANO;UGO CASELLI;LAZZARO REPETTO;KATY ARGENTATI;ALESSIA DONNINI;VITTORIO SABA;FEDERICO MOCCHEGIANI;ROBERTO GHISELLI;BELINDA GIORGETTI;SERGIO GIUNTA;BEATRICE BARTOZZI;GIOVANNI BERNARDINI","1.91;1.74;1.25;1.19;1.14;1.01;1;0.84;0.77;0.69;0.69;0.67;0.67;0.64;0.64;0.64;0.6;0.57;0.56;0.56","LUIGI FERRUCCI;JACK M. GURALNIK;LAZZARO REPETTO;MATTI AAPRO;WALTER GIANNI;ANTONELLA VENTURINO;DENISE DAL LAGO;DIEGO SERRAINO;FLORA GIOIA;LUCIA FRATINO;MARINA VERCELLI;RICCARDO A. AUDISIO;S. MONFARDINI;STEFANO PARODI;VITTORINA ZAGONEL;LINDA P. FRIED;STEFANO VOLPATO;CLAUDIO FRANCESCHI;JENNIFER L. BALFOUR;BRENDA W.J.H. PENNINX","1729;1377;1295;1293;1292;1290;1290;1290;1290;1290;1290;1290;1290;1290;1290;879;811;711;667;599","LUIGI FERRUCCI;LAZZARO REPETTO;WALTER GIANNI;ANTONELLA VENTURINO;DENISE DAL LAGO;DIEGO SERRAINO;FLORA GIOIA;LUCIA FRATINO;MARINA VERCELLI;MATTI AAPRO;RICCARDO A. AUDISIO;S. MONFARDINI;STEFANO PARODI;VITTORINA ZAGONEL;LUCA CAVALLONE;KATY ARGENTATI;CLAUDIO FRANCESCHI;FABIOLA OLIVIERI;MAURO PROVINCIALI;ALESSIA DONNINI","1729;1295;511;509;509;509;509;509;509;509;509;509;509;509;316;314;288;288;268;225","CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;LUIGI FERRUCCI;MAURO PROVINCIALI;MORENO SOLAZZI;TIZIANA CASOLI;KATY ARGENTATI;ALESSIA DONNINI;BELINDA GIORGETTI;CLAUDIO FRANCESCHI;FABIOLA OLIVIERI;FIORENZA ORLANDO;GIUSEPPINA DI STEFANO;LAZZARO REPETTO;ALESSIA DELFINO;BENEDETTA BARTALI;CLAUDIO VITICCHI;COSIMO ROBERTO RUSSO;FEDERICO MOCCHEGIANI;ROBERTO GHISELLI","11;11;10;7;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;ENGINEERING;ART;PHYSICS;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;POLITICAL SCIENCE","72;42;26;12;5;3;3;3;2;2;2;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;GENETICS;GERONTOLOGY;PATHOLOGY;IMMUNOLOGY;NEUROSCIENCE;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;SURGERY;PSYCHIATRY;CELL BIOLOGY;MICROBIOLOGY;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION;ANESTHESIA;CANCER RESEARCH;ECOLOGY;ONCOLOGY","49;24;24;19;19;13;12;11;10;9;9;8;7;6;5;5;5;5;4;4;4;4","GENE;IN VITRO;POPULATION;CANCER;AGEING;DISEASE;IMMUNE SYSTEM;ANTIBIOTICS;APOPTOSIS;COHORT;COHORT STUDY;DIABETES MELLITUS;ENZYME;INTRACELLULAR;BACTERIA;INSULIN;MITOCHONDRION;RECEPTOR;ACTIVITIES OF DAILY LIVING;AMYLOID (MYCOLOGY);ANKLE;ANTIGEN;BIOPSY;BLOOD PRESSURE;CELL;COMORBIDITY;CONFIDENCE INTERVAL;GERIATRICS;HIPPOCAMPUS;IN VIVO;LOGISTIC REGRESSION;LONGEVITY;MEMBRANE;NITRIC OXIDE;ORGANELLE;SALINE;SEPSIS","16;11;11;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CYTOTOXIC T CELL;GENOTYPE;ALLELE;IMMUNOSENESCENCE;ANTIBIOTIC RESISTANCE;BREAST CANCER;CENTENARIAN;CYTOTOXICITY;LOCUS (GENETICS);STAPHYLOCOCCUS AUREUS;TRANSGENE;ALZHEIMER'S DISEASE;ANTIBACTERIAL AGENT;APOLIPOPROTEIN E;ARGININE;CELL CYCLE;CONGO RED;ESCHERICHIA COLI;ESSENTIAL HYPERTENSION;GENE EXPRESSION;GERIATRIC ONCOLOGY;HAZARD RATIO;INSULIN RESISTANCE;PERFORMANCE STATUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PROGRAMMED CELL DEATH;PSEUDOMONAS AERUGINOSA;SEPTIC SHOCK;T CELL;TYPE 2 DIABETES;VITAMIN E","5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENETICALLY MODIFIED MOUSE;IMIPENEM;MAMMARY GLAND;MAMMARY TUMOR;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;ONCOGENE;STAPHYLOCOCCUS EPIDERMIDIS;VANCOMYCIN;ADENOVIRIDAE;ALLELE FREQUENCY;AMPLICON;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIGEN PRESENTATION;ANTIGEN-PRESENTING CELL;ASYMMETRIC DIMETHYLARGININE;ATRIAL TACHYCARDIA;BACTERIAL OUTER MEMBRANE;CALCIUM-SENSING RECEPTOR;CAPECITABINE;CD40;CD86;DNA FRAGMENTATION;ENOS;FAS LIGAND;FAS RECEPTOR;GESTATIONAL DIABETES;GLUT1;GLYCATED HEMOGLOBIN;GUANINE;HAMILTON DEPRESSION SCALE;HAPLOTYPE;HER2/NEU;IBUTILIDE;INSULIN SENSITIVITY;LAURDAN;MAGAININ;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROCOCCACEAE;NATEGLINIDE;NPR1;NPR2;PANCREATIC HORMONE;PEROXYNITRITE;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);PORTAL VENOUS PRESSURE;PROMOTER;PROSTATE BIOPSY;REPAGLINIDE;SERUM AMYLOID P COMPONENT;SILENT PERIOD;SINGLE-NUCLEOTIDE POLYMORPHISM;THIOBARBITURIC ACID;TRANSRECTAL ULTRASONOGRAPHY;VASCULAR DEMENTIA;VINORELBINE;VITAMIN E DEFICIENCY;WAIST–HIP RATIO;Β AMYLOID","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;AGING;MALE;AGED;HYPERTENSION;;MIDDLE AGED;ADULT;ANIMALS;AGED, 80 AND OVER;SYNAPSES;HIPPOCAMPUS;RATS;ALZHEIMER DISEASE;ANTIOXIDANTS;AMYLOID BETA-PEPTIDES;APOPTOSIS;CELL DIVISION;INTERLEUKIN-6","49;38;35;32;30;20;19;18;17;17;15;15;11;10;8;8;7;7;7;7","ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;MECHANISMS OF ALZHEIMER'S DISEASE;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;NEURAL BASIS OF SPATIAL NEGLECT AND RECOVERY;NEURONAL OSCILLATIONS IN CORTICAL NETWORKS;REGULATORY T CELL DEVELOPMENT AND FUNCTION;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;ANALYSIS OF SYNTHETIC FOOD COLORANTS IN FOOD PRODUCTS;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE;BONE TISSUE ENGINEERING AND BIOMATERIALS","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","AGING;IMMUNOSENESCENCE;AMYLOID (MYCOLOGY);CANCER IN OLDER ADULTS;CENTENARIAN;ELDERLY PATIENTS;HYPERTENSION;ORGANELLE;SYNAPTIC PLASTICITY;VITAMIN E;ALZHEIMER'S DISEASE;APOLIPOPROTEIN E;APOPTOSIS;CATIONIC PEPTIDES;COMPREHENSIVE GERIATRIC ASSESSMENT;CONGO RED;CONTINUOUS GLUCOSE MONITORING;DEPRESSION (ECONOMICS);DIABETES;ESSENTIAL HYPERTENSION","9;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ALZHEIMERS DISEASE;DIABETIC PATIENTS;LOWER EXTREMITY;ADDS INFORMATION;AGED PEOPLE;AORTIC ENDOTHELIAL;ASSESSMENT ADDS;BLOOD CELLS;CANCER PATIENTS;CATIONIC PEPTIDES;COMPREHENSIVE GERIATRIC;COOPERATIVE ONCOLOGY;EASTERN COOPERATIVE;ELDERLY CANCER;ELDERLY PATIENTS;ENDOTHELIAL CELLS;FUNCTIONAL ALTERATIONS;GERIATRIC ASSESSMENT;GERIATRIC ONCOLOGY;GRAFT INFECTION;HUMAN AORTIC;HUMAN RED;ONCOLOGY STUDY;PERFORMANCE STATUS;PROTECTS HUMAN;RAT MODEL;RED BLOOD;SEPTIC SHOCK;TYPE DIABETIC;VASCULAR GRAFT","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GRAFTS SOAKED;BACTERIAL GROWTH;CA EXCRETION;DACRON GRAFTS;VANCOMYCIN HYDROCHLORIDE;GRAFT INFECTION;MOBILITY DISABILITY;PLASMA ENDOTOXIN;RAT MODEL;TNF-Α CONCENTRATIONS;CASR GENE;ESCHERICHIA COLI;EXTENSOR STRENGTH;GLYCEMIC CONTROL;HEALTHY SUBJECTS;IL SERUM;KNEE EXTENSOR;LDL GLYCLDL;MAIN OUTCOME;NECROSIS FACTOR;PHYSICAL DISABILITY;STONE FORMERS;TUMOR NECROSIS;VISUOSPATIAL NEGLECT;A-SOAKED GRAFT;ABDOMINAL EXUDATE;ADULT MALE;AGING STUDY;ALPHA TNF-Α;ANTIBIOTIC PROPHYLAXIS","6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",13,0.16,6,5,0,1,0,1.75,1,0,2,5,0,0,10,1,10,1,2,7,1,0,0,56,56,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,6,6975,0.99,0,0,304,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;NUTRITION","1;1;1;1;1","CARDIOVASCULAR","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2003,82,7.85365853658537,2.5609756097561,0.353658536585366,0.280487804878049,0.390243902439024,1.77966101694915,1.11538461538462,1.27777777777778,1.14285714285714,0.231707317073171,2,39,23,6,12,0.48,0.28,0.07,0.15,63.37,1.19721076421056,NA,0.378048780487805,0.902439024390244,0.429,0.32,0.51,0.407,"LUIGI FERRUCCI;CLAUDIO FRANCESCHI;JACK M. GURALNIK;STEFANIA BANDINELLI;MASSIMILIANO BONAFÉ;FIORENZA ORLANDO;BENEDETTA BARTALI;STEFANO VOLPATO;LIANA SPAZZAFUMO;GIUSEPPE PASSARINO;VITTORIO SABA;CARLO BERTONI–FREDDARI;COSIMO ROBERTO RUSSO;FEDERICO MOCCHEGIANI;FRANCESCO BENVENUTI;FABIOLA OLIVIERI;SERENA DATO;GIORGIO SCALISE;ROBERTO GHISELLI;FULVIO LAURETANI","15;15;9;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","LUIGI FERRUCCI;CLAUDIO FRANCESCHI;JACK M. GURALNIK;A SCUTER;SAMER S. NAJJAR;STEFANIA BANDINELLI;FABRIZIO BAMBINI;LUCA GIANNETTI;UGO CONSOLO;BENEDETTA BARTALI;CARLO BERTONI–FREDDARI;MORENO SOLAZZI;PATRIZIA FATTORETTI;FIORENZA ORLANDO;FRANCESCO BENVENUTI;ANTONIO CHERUBINI;STEFANO VOLPATO;GIUSEPPE GERMANÒ;ROSA SQUADRONI;ROBERTO ANTONICELLI","1.98;1.55;1.24;1;1;0.86;0.67;0.67;0.67;0.64;0.62;0.62;0.62;0.57;0.57;0.53;0.5;0.5;0.5;0.5","LUIGI FERRUCCI;CLAUDIO FRANCESCHI;JACK M. GURALNIK;STEFANIA BANDINELLI;FIORENZA ORLANDO;BENEDETTA BARTALI;LIANA SPAZZAFUMO;VITTORIO SABA;CARLO BERTONI–FREDDARI;COSIMO ROBERTO RUSSO;FEDERICO MOCCHEGIANI;FRANCESCO BENVENUTI;FABIOLA OLIVIERI;ROBERTO GHISELLI;FULVIO LAURETANI;MORENO SOLAZZI;PATRIZIA FATTORETTI;MARIO MUZZIOLI;ANTONIO CHERUBINI;ROBERTINA GIACCONI","15;15;9;7;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","LUIGI FERRUCCI;CLAUDIO FRANCESCHI;JACK M. GURALNIK;A SCUTER;SAMER S. NAJJAR;STEFANIA BANDINELLI;FABRIZIO BAMBINI;BENEDETTA BARTALI;CARLO BERTONI–FREDDARI;MORENO SOLAZZI;PATRIZIA FATTORETTI;FIORENZA ORLANDO;FRANCESCO BENVENUTI;ANTONIO CHERUBINI;ROBERTO ANTONICELLI;NORMA BARBINI;FIORENZO CONTI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;COSIMO ROBERTO RUSSO","1.98;1.55;1.24;1;1;0.86;0.67;0.64;0.62;0.62;0.62;0.57;0.57;0.53;0.5;0.5;0.5;0.45;0.45;0.44","LUIGI FERRUCCI;JACK M. GURALNIK;CLAUDIO FRANCESCHI;STEFANIA BANDINELLI;STEFANO VOLPATO;MASSIMILIANO BONAFÉ;ROBERTO TESTA;BENEDETTA BARTALI;COSIMO ROBERTO RUSSO;FULVIO LAURETANI;DAN K. KIELY;JONATHAN F. BEAN;SUZANNE G. LEVEILLE;ALBERTO FASOLI;C. MANSI;DOMENICO RISSO;EDOARDO G. GIANNINI;EMANUELA TESTA;FEDERICA BOTTA;M.R. MELE","2074;1904;1152;1086;651;623;540;537;537;537;472;472;472;464;464;464;464;464;464;464","LUIGI FERRUCCI;STEFANIA BANDINELLI;CLAUDIO FRANCESCHI;ROBERTO TESTA;BENEDETTA BARTALI;COSIMO ROBERTO RUSSO;FULVIO LAURETANI;E FERACO;VINCENZO MARI;FABIOLA OLIVIERI;CHIARA CAVAZZINI;JACK M. GURALNIK;FRANCESCO BENVENUTI;LARA BALZINI;LUCA VANNUCCHI;L. P. FRIED;S. VOLAPTO;SARAH E LAMB;LUCA CAVALLONE;LIANA SPAZZAFUMO","1682;1086;561;540;537;537;376;372;372;323;298;290;254;232;232;229;229;229;215;207","LUIGI FERRUCCI;CLAUDIO FRANCESCHI;STEFANIA BANDINELLI;BENEDETTA BARTALI;FIORENZA ORLANDO;CARLO BERTONI–FREDDARI;COSIMO ROBERTO RUSSO;FABIOLA OLIVIERI;FRANCESCO BENVENUTI;LIANA SPAZZAFUMO;MORENO SOLAZZI;PATRIZIA FATTORETTI;CHIARA CAVAZZINI;ANDREA CORSONELLO;FULVIO LAURETANI;MAURO PROVINCIALI;ROBERTO TESTA;E FERACO;GIUSEPPINA DI STEFANO;TIZIANA CASOLI","11;10;7;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;ENGINEERING;SOCIOLOGY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;ART;GEOGRAPHY;PHILOSOPHY;BUSINESS;GEOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE","59;40;15;9;8;7;7;6;4;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;GERONTOLOGY;PHYSICAL THERAPY;CELL BIOLOGY;MOLECULAR BIOLOGY;PATHOLOGY;PSYCHIATRY;DEMOGRAPHY;CARDIOLOGY;NEUROSCIENCE;PHYSICAL MEDICINE AND REHABILITATION;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;STATISTICS","42;24;19;19;17;16;13;12;10;8;8;8;7;6;6;6;6;5;5;5","GENE;POPULATION;DISEASE;IMMUNE SYSTEM;AGEING;DIABETES MELLITUS;IN VITRO;LONGEVITY;DNA;ANTIBODY;INFLAMMATION;ACTIVITIES OF DAILY LIVING;ANTIBIOTICS;BACTERIA;BLOOD PRESSURE;COHORT;CYTOKINE;ENZYME;ANTIGEN;APOPTOSIS;CANCER;CEREBELLUM;CHOLESTEROL;EPIDEMIOLOGY;HIPPOCAMPUS;IN VIVO;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;ODDS RATIO;POISON CONTROL;REHABILITATION;STROKE (ENGINE)","22;16;11;9;7;7;7;7;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GENOTYPE;ALLELE;ALZHEIMER'S DISEASE;CD8;CENTENARIAN;DEMENTIA;DNA DAMAGE;HEAT SHOCK PROTEIN;INTERLEUKIN 6;PERIPHERAL BLOOD MONONUCLEAR CELL;STAPHYLOCOCCUS AUREUS;APOLIPOPROTEIN B;APOLIPOPROTEIN E;BONE DENSITY;CELL CYCLE;CODING REGION;CYTOTOXIC T CELL;CYTOTOXICITY;DNA REPAIR;DYSLIPIDEMIA;EXON;GLYCOPEPTIDE;HUMAN FACTORS AND ERGONOMICS;IMMUNITY;IMMUNIZATION;INTERLEUKIN;MESSENGER RNA;METALLOTHIONEIN;MOTOR CORTEX;ODDS;PULSE WAVE VELOCITY;TRANSCRANIAL MAGNETIC STIMULATION","8;7;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HAPLOTYPE;DNA VACCINATION;POLYMORPHISM (COMPUTER SCIENCE);QUANTITATIVE COMPUTED TOMOGRAPHY;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCAL INFECTIONS;VANCOMYCIN;ABDOMINAL OBESITY;ANTI-DSDNA ANTIBODIES;APHIDICOLIN;ASYMMETRIC DIMETHYLARGININE;BENIGN EARLY REPOLARIZATION;BRANCHIOPODA;COGNITIVE DECLINE;CROSSMODAL;CUMULATIVE TRAUMA DISORDER;ESOPHAGEAL VARICES;GASTRIC VARICES;GENOME INSTABILITY;GERIATRIC DEPRESSION SCALE;GESTATIONAL DIABETES;GLUCOSE TOLERANCE TEST;GLUT1;GRANULE CELL;HEAT SHOCK;HERPESVIRIDAE;HSP70;HSP90;HUMAN GENOME;IN SITU HYBRIDIZATION;INSULIN SENSITIVITY;KARYOTYPE;LEPTIN RECEPTOR;LNCAP;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MISSENSE MUTATION;MOLECULAR MEDICINE;ONCOGENE;PCA3;PIPERACILLIN;POLY ADP RIBOSE POLYMERASE;POLYARTERITIS NODOSA;PRIMARY MOTOR CORTEX;PROSTATECTOMY;QUORUM SENSING;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;SIRTUIN;STAPHYLOCOCCUS EPIDERMIDIS;STREPTOCOCCUS AGALACTIAE;TELOMERASE REVERSE TRANSCRIPTASE;UNTRANSLATED REGION;VARIABLE NUMBER TANDEM REPEAT;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VENTRICULAR REPOLARIZATION","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;AGING;AGED, 80 AND OVER;ITALY;ADULT;INTERLEUKIN-6;MIDDLE AGED;;LONGEVITY;ANIMALS;APOLIPOPROTEINS E;CEREBELLUM;HIPPOCAMPUS;RNA, MESSENGER;EPITHELIAL CELLS;POLYMORPHISM, GENETIC;ALZHEIMER DISEASE","57;39;38;36;36;24;22;20;18;16;14;13;11;11;11;11;10;9;9;8","MOLECULAR MECHANISMS OF AGING AND LONGEVITY;COPPER AND ZINC IN HEALTH AND DISEASE;MECHANISMS OF ALZHEIMER'S DISEASE;NATURAL KILLER CELLS IN IMMUNITY;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ASSESSMENT OF SURFACE WATER QUALITY;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE","4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","AGING;CENTENARIAN;DIABETES;HEAT SHOCK PROTEINS;METALLOTHIONEIN;STROKE (ENGINE);APOLIPOPROTEIN E;CELL STRESS;CODING REGION;CROSS-SECTIONAL STUDY;DIETARY PATTERNS;DYSLIPIDEMIA;HEALTHY AGING;HEALTHY EATING INDEX;HYPERTENSION;INFLAMMATION;INSULIN RESISTANCE;LINKAGE DISEQUILIBRIUM;LONGEVITY;MEMORY T CELLS","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INCHIANTI STUDY;ALZHEIMERS DISEASE;CLINICAL CHARACTERISTICS;DIABETIC PATIENTS;DIETARY INTAKE;GROWTH FACTOR;MATHEMATICAL MODEL;METALLOTHIONEIN III;MILD COGNITIVE;MIRROR MOVEMENTS;ORAL MUCOSA;RISK FACTORS;A- TIP;ACCELERATED HYPERTENSION;ADULT RAT;AFFECT DIETARY;AFFECTS INTERLEUKIN;AFFECTS PLATELET;AGE-ASSOCIATED INCREASES;AGEING PEOPLE;AGEING ROLE;AGING BONE;ALDOSTERONE-SECRETING ADENOMAS;ALLELE A-;ALLELES AFFECT;ANCHORAGE-INDEPENDENT GROWTH;ANTI-OXIDIZED LDL;ANTIBACTERIAL PEPTIDE;ANTIENDOTOXIN ACTIVITY;ANTIGENIC STRESS","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MELANOMA PATIENTS;PUBMED SCOPUS;CROSSREF PUBMED;HEALTHY SUBJECTS;CELLS PRODUCING;PUBMED GOOGLE;PERIPHERAL BLOOD;SIGNIFICANTLY REDUCED;EXPANSION INDEX;CD LYMPHOCYTES;CUTANEOUS PRIMARY;IMMUNOL -CROSSREF;AL POCCIA;CIRCULATING ΓΔ;COUNTSPLEEN DIAMETER;CYTOKINE PRODUCTION;DIAMETER RATIO;HEALTHY CONTROLS;IMMUNE RESPONSE;IMMUNOL -PUBMED;PLATELET COUNTSPLEEN;TUMOR CELLS;VITRO EXPANSION;CELL LINE;CONTROL SUBJECTS;HEALTHY DONORS;MUSCLE POWER;REGRESSION MODELS;RISK FACTORS;SIGNIFICANTLY LOWER","42;30;26;24;10;10;9;9;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5",15,0.18,7.07,2,1,1,0,0,3.25,0,1,3.5,0,0,2.25,1,1,0,0,3.5,1,0,0,159,159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2004,82,8.82926829268293,2.63414634146341,0.378048780487805,0.268292682926829,0.463414634146341,1.85344827586207,1.29166666666667,1.375,1.31034482758621,0.24390243902439,1,34,25,10,10,0.41,0.3,0.12,0.12,53.04,1.12715224026311,NA,0.402439024390244,0.890243902439024,0.448,0.409,0.417,0.386,"CLAUDIO FRANCESCHI;EUGENIO MOCCHEGIANI;CARLO BERTONI–FREDDARI;LUIGI FERRUCCI;PATRIZIA FATTORETTI;FIORENZA ORLANDO;JACK M. GURALNIK;MARCO MALAVOLTA;VITTORIO SABA;ROBERTINA GIACCONI;MARIA CARLA RE;ANTONIO CHERUBINI;BENEDETTA BARTALI;MARTA BALIETTI;LAZZARO REPETTO;ROBERTO TESTA;MIRIAM CAPRI;GIORGIO SCALISE;ROBERTO GHISELLI;FULVIO LAURETANI","14;10;9;8;8;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","EUGENIO MOCCHEGIANI;CARLO BERTONI–FREDDARI;LAZZARO REPETTO;CLAUDIO FRANCESCHI;PATRIZIA FATTORETTI;ROBERTO TESTA;LUIGI FERRUCCI;MARCO MALAVOLTA;EDOARDO G. GIANNINI;ROBERTINA GIACCONI;MARTA BALIETTI;JACK M. GURALNIK;VITTORIO SABA;FIORENZA ORLANDO;CATIA CIPRIANO;BELINDA GIORGETTI;MORENO SOLAZZI;FULVIO LAURETANI;STEFANIA BANDINELLI;GIUSEPPINA DI STEFANO","1.76;1.63;1.45;1.3;1.3;0.92;0.89;0.84;0.64;0.64;0.62;0.58;0.52;0.49;0.49;0.48;0.48;0.46;0.46;0.45","CLAUDIO FRANCESCHI;EUGENIO MOCCHEGIANI;CARLO BERTONI–FREDDARI;LUIGI FERRUCCI;PATRIZIA FATTORETTI;FIORENZA ORLANDO;JACK M. GURALNIK;MARCO MALAVOLTA;VITTORIO SABA;ROBERTINA GIACCONI;ANTONIO CHERUBINI;BENEDETTA BARTALI;MARTA BALIETTI;LAZZARO REPETTO;ROBERTO TESTA;ROBERTO GHISELLI;FULVIO LAURETANI;STEFANIA BANDINELLI;CATIA CIPRIANO;STEFANO VOLPATO","14;10;9;8;8;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3","EUGENIO MOCCHEGIANI;CARLO BERTONI–FREDDARI;LAZZARO REPETTO;CLAUDIO FRANCESCHI;PATRIZIA FATTORETTI;ROBERTO TESTA;LUIGI FERRUCCI;MARCO MALAVOLTA;ROBERTINA GIACCONI;MARTA BALIETTI;JACK M. GURALNIK;VITTORIO SABA;FIORENZA ORLANDO;CATIA CIPRIANO;BELINDA GIORGETTI;MORENO SOLAZZI;FULVIO LAURETANI;STEFANIA BANDINELLI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI","1.76;1.63;1.45;1.3;1.3;0.92;0.89;0.84;0.64;0.62;0.58;0.52;0.49;0.49;0.48;0.48;0.46;0.46;0.45;0.45","CLAUDIO FRANCESCHI;LUIGI FERRUCCI;GIOVANNA DE BENEDICTIS;E FERACO;VINCENZO MARI;DINA BELLIZZI;GIUSEPPE PASSARINO;GIUSEPPINA ROSE;SERENA DATO;ANGELO SCUTERI;DENIS C. MULLER;E. JEFFREY METTER;EDWARD G. LAKATTA;HIDETAKA HOUGAKU;REUBIN ANDRES;SAMER S. NAJJAR;FRANCESCO DE RANGO;GIUSEPPINA COVELLO;MARCELLO MAGGIOLINI;PAOLA CAVALCANTE","1380;678;590;466;466;446;446;446;446;434;434;434;434;434;434;434;369;349;349;349","CLAUDIO FRANCESCHI;LUIGI FERRUCCI;E FERACO;VINCENZO MARI;ANGELO SCUTERI;FABIOLA OLIVIERI;EUGENIO MOCCHEGIANI;LAZZARO REPETTO;COSIMO ROBERTO RUSSO;ROBERTINA GIACCONI;CATIA CIPRIANO;BENEDETTA BARTALI;ELEANOR M. SIMONSICK;JACK M. GURALNIK;MARCO PAHOR;R. FELLIN;STEFANO VOLPATO;STEPHEN B. KRITCHEVSKY;TAMARA B. HARRIS;ATTILIO OLIVIERI","735;584;466;466;434;318;305;288;244;243;194;182;168;168;168;168;168;168;168;167","EUGENIO MOCCHEGIANI;CARLO BERTONI–FREDDARI;CLAUDIO FRANCESCHI;PATRIZIA FATTORETTI;FIORENZA ORLANDO;MARCO MALAVOLTA;LAZZARO REPETTO;ROBERTINA GIACCONI;BENEDETTA BARTALI;CATIA CIPRIANO;FULVIO LAURETANI;LUIGI FERRUCCI;MARTA BALIETTI;ROBERTO TESTA;STEFANIA BANDINELLI;A CORSI;BELINDA GIORGETTI;E FERACO;FABIOLA OLIVIERI;GIUSEPPINA DI STEFANO","9;8;8;8;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;MATHEMATICS;PHYSICS;BUSINESS;GEOGRAPHY;POLITICAL SCIENCE","68;39;23;6;5;5;4;4;4;3;2;2","INTERNAL MEDICINE;ENDOCRINOLOGY;BIOCHEMISTRY;IMMUNOLOGY;GENETICS;GERONTOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;CELL BIOLOGY;SURGERY;NEUROSCIENCE;CARDIOLOGY;MICROBIOLOGY;NURSING;PSYCHIATRY;DEMOGRAPHY;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;STATISTICS;UROLOGY","52;28;25;21;17;10;9;9;9;8;8;7;5;5;5;5;4;4;4;4;4","GENE;IMMUNE SYSTEM;POPULATION;CANCER;DISEASE;IN VITRO;DIABETES MELLITUS;LONGEVITY;AGEING;ANTIBIOTICS;OXIDATIVE STRESS;ANTIGEN;ANTIOXIDANT;BACTERIA;CHEMOTHERAPY;HIPPOCAMPUS;HORMONE;IN VIVO;INFLAMMATION;RECEPTOR","18;13;10;8;8;8;7;7;6;5;5;4;4;4;4;4;4;4;4;4","GENOTYPE;ALLELE;T CELL;CD8;BREAST CANCER;CYTOTOXICITY;DEMENTIA;MIDBRAIN;STAPHYLOCOCCUS AUREUS;ARGININE;BAYESIAN MULTIVARIATE LINEAR REGRESSION;BIOFILM;BONE DENSITY;BONE MINERAL;CORTICOSTERONE;CYTOCHROME C OXIDASE;CYTOTOXIC T CELL;DENTATE GYRUS;GENE EXPRESSION;GENE ISOFORM;IMMUNOSENESCENCE;LIPID PEROXIDATION;METALLOTHIONEIN;PARAOXONASE;PERIPHERAL BLOOD MONONUCLEAR CELL;PROGRESSIVE DISEASE;RNA;TYPE 2 DIABETES","9;7;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","POLYMORPHISM (COMPUTER SCIENCE);STAPHYLOCOCCUS EPIDERMIDIS;T-CELL RECEPTOR;HAPLOTYPE;PON1;QUANTITATIVE COMPUTED TOMOGRAPHY;QUORUM SENSING;STAPHYLOCOCCUS;ANEMIA OF CHRONIC DISEASE;CARDIOLIPIN;CD28;CHEMOKINE RECEPTOR;ENHANCER;EPIRUBICIN;ESTROGEN RECEPTOR;HEAT SHOCK;HERPESVIRIDAE;HSP70;INTESTINAL MALABSORPTION;IRON STATUS;LANGERIN;LEPTIN RECEPTOR;LYMPHOCYTE ACTIVATION;MEMORY T CELL;MISSENSE MUTATION;MOSSY FIBER (HIPPOCAMPUS);NATURAL KILLER T CELL;PARKIN;RANKL;SINGLE-NUCLEOTIDE POLYMORPHISM;SIRTUIN;STAPHYLOCOCCAL INFECTIONS;THIOBARBITURIC ACID;THYMIC INVOLUTION","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;AGED;FEMALE;AGING;MIDDLE AGED;AGED, 80 AND OVER;ADULT;ANIMALS;HIPPOCAMPUS;INTERLEUKIN-6;LONGEVITY;RATS;ZINC;BRAIN;;MITOCHONDRIA;RATS, WISTAR;LYMPHOCYTES;METALLOTHIONEIN","52;47;43;42;36;26;21;20;19;18;17;14;14;14;13;12;12;12;11;11","COPPER AND ZINC IN HEALTH AND DISEASE;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;BIOLOGICAL EFFECTS OF ELECTROMAGNETIC FIELDS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;MECHANISMS OF ALUMINUM TOXICITY AND TOLERANCE IN PLANTS;OSTEOPOROSIS;REGULATORY T CELL DEVELOPMENT AND FUNCTION;ROLE OF ERYTHROPOIETIN IN DISEASE TREATMENT AND MANAGEMENT;ROLE OF PARAOXONASE ENZYMES IN ATHEROSCLEROSIS AND OXIDATIVE STRESS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BODY COMPOSITION ASSESSMENT AND ANALYSIS;CHEMICAL COMPOSITION AND HEALTH EFFECTS OF COCONUT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS","4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","AGING;MEMORY T CELLS;PONS;ALUMINUM TOXICITY;ARYLDIALKYLPHOSPHATASE;BONE MINERAL DENSITY;BREAST CANCER;BREAST TUMOURS;CORTICOSTERONE;DEPRESSION (ECONOMICS);IMMUNOSENESCENCE;MEDULLA;METALLOTHIONEIN;MITOCHONDRIAL FUNCTION;MOBILE PHONE RADIATION;MORTALITY RISK;NK CELL RECOGNITION;ORGANELLE;PARAOXONASE;POSTURAL STABILITY","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ELDERLY PATIENTS;DIABETIC PATIENTS;INCHIANTI STUDY;TYPE DIABETIC;BONE DENSITY;BREAST CANCER;CANCER PATIENTS;GERIATRIC MEDICINE;HEART FAILURE;HEMOGLOBIN LEVELS;ISOFORMS III;METALLOTHIONEIN ISOFORMS;MULTIPLE LETTERS;PERSONS RESULTS;RHVEGF ADMINISTRATION;SUCCESSFUL AGEING;SYNAPTIC MITOCHONDRIA;THYMULIN PRODUCTION;ACTIVATOR INHIBITIOR-;ACUTE GRAFT-VERSUS-HOST;ADMINISTRATION ENHANCES;ADULT WELL-BEING;ADVANCED BLADDER;ADVANCED BREAST;ADVANCED MULTIPLE;ADVANCED PELVIC;AFFECT HUMAN;AGE-ASSOCIATED INCREASES;AGE-RELATED ALTERATIONS;AGE-RELATED DECLINE","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;LOWER EXTREMITY;NEUROLOGICAL SIGNS;HEALTHY SUBJECTS;COGNITIVE IMPAIRMENT;CROSSREF PUBMED;DIABETIC PATIENTS;GAIT DISORDERS;ION BIOAVAILABILITY;NEUROLOGICAL EXAMINATION;PON ACTIVITY;POOR MOBILITY;THYMIC INVOLUTION;ZINC ION;ALCOHOL INTAKE;NEUROLOGICAL DISEASE;TYPE DIABETIC;CAREFUL NEUROLOGICAL;CONFIDENCE INTERVAL;ERYTHROCYTE MEMBRANES;EXTREMITY FUNCTION;EXTREMITY PERFORMANCE;GURALNIK JM;LIFE SATISFACTION;LIPID HYDROPEROXIDES;M-MCROSSREF PUBMED;MAIN OUTCOME;MED -CROSSREF;OXIDATIVE DAMAGE;PHYSICAL PERFORMANCE","10;8;8;7;6;6;6;6;6;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4",19,0.23,6.12,8,14,3,0,75.75,7.75,1,1,8,0,0,4.25,1,8.5,0,2,2.75,1,0,0,85,85.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,30,0.91,0,0,5,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;LUNG","1;1;1;1","INFECTION;RESPIRATORY","1;1",NA,NA,NA,NA,NA,NA,2,5041150,254711.36,5.5,19,9.5,1,10,147297.732467532,0.556695603023451,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;NATIONAL HELLENIC RESEARCH FOUNDATION;AARHUS UNIVERSITY;D.F. CHEBOTAREV INSTITUTE OF GERONTOLOGY;EPPENDORF (BELGIUM);FINNISH INSTITUTE FOR HEALTH AND WELFARE;FIRC INSTITUTE OF MOLECULAR ONCOLOGY;FONDATION JEAN DAUSSET-CEPH;HAROKOPIO UNIVERSITY;INSTYTUT BIOLOGII DOŚWIADCZALNEJ IM. MARCELEGO NENCKIEGO;ISTITUTO ORTOPEDICO RIZZOLI;LEIDEN UNIVERSITY MEDICAL CENTER;MAX PLANCK SOCIETY;MEDICAL UNIVERSITY OF LODZ;NEWCASTLE UNIVERSITY;QUEEN'S UNIVERSITY BELFAST;ROMA TRE UNIVERSITY;SEMMELWEIS UNIVERSITY;SPANISH NATIONAL CANCER RESEARCH CENTRE;TAMPERE UNIVERSITY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP6-2002-FOOD-1 (CALL FOR PROPOSAL);FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-FOOD - FOOD QUALITY AND SAFETY: THEMATIC PRIORITY 5 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IP - INTEGRATED PROJECT (FUNDING SCHEME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1;1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY","2;1;1;1;1;1","AGING;GENETICS;BIOTECHNOLOGY;HUMAN GENOME;NUTRITION;PREVENTION","2;2;1;1;1;1","GENERIC HEALTH RELEVANCE","2","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.3 NUTRITION AND CHEMOPREVENTION","1;1;1","NOT SITE-SPECIFIC CANCER","1","1.1 NORMAL FUNCTIONING;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS","1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2005,88,8.57954545454546,2.77272727272727,0.443181818181818,0.375,0.409090909090909,1.84848484848485,1.18181818181818,1.5,1.2,0.306818181818182,1,36,23,7,13,0.41,0.26,0.08,0.15,55.08,1.04034126183236,NA,0.363636363636364,0.920454545454545,0.427,0.362,0.422,0.38,"CLAUDIO FRANCESCHI;FIORENZA ORLANDO;VITTORIO SABA;LUIGI FERRUCCI;CLAUDIO PEDONE;ROBERTO GHISELLI;MAURO PROVINCIALI;LIANA SPAZZAFUMO;FRANCESCO CORICA;RAFFAELE ANTONELLI INCALZI;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;STEFANIA BANDINELLI;PIERUGO CARBONIN;CALOGERO CARUSO;LUIGI TARANTINI;GIOVANNI PULIGNANO;FEDERICO MOCCHEGIANI;FABIOLA OLIVIERI;GIOVANNI CIOFFI","9;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5","LIANA SPAZZAFUMO;CLAUDIO PEDONE;UO GERIATRIA;FRANCESCO CORICA;RAFFAELE ANTONELLI INCALZI;ANDREA CORSONELLO;CLAUDIO FRANCESCHI;LUIGI FERRUCCI;MAURO PROVINCIALI;FIORENZA ORLANDO;EUGENIO MOCCHEGIANI;ROSA SQUADRONI;NORMA BARBINI;VITTORIO SABA;PIERUGO CARBONIN;ROBERTO GHISELLI;STEFANIA BANDINELLI;ANGELO SCUTERI;LUIGI TARANTINI;GIOVANNI PULIGNANO","1.41;1.08;1;0.97;0.97;0.97;0.95;0.92;0.9;0.89;0.89;0.83;0.83;0.82;0.77;0.75;0.67;0.62;0.61;0.61","CLAUDIO FRANCESCHI;FIORENZA ORLANDO;VITTORIO SABA;LUIGI FERRUCCI;ROBERTO GHISELLI;MAURO PROVINCIALI;LIANA SPAZZAFUMO;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;STEFANIA BANDINELLI;PIERUGO CARBONIN;FEDERICO MOCCHEGIANI;FABIOLA OLIVIERI;DONATELLA DEL SINDACO;MARCO MALAVOLTA;MASSIMO BOEMI;ROBERTINA GIACCONI;ROBERTO ANTONICELLI;ANGELO SCUTERI;MARCO GUIDI","9;8;8;7;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4","LIANA SPAZZAFUMO;UO GERIATRIA;ANDREA CORSONELLO;CLAUDIO FRANCESCHI;LUIGI FERRUCCI;MAURO PROVINCIALI;FIORENZA ORLANDO;EUGENIO MOCCHEGIANI;NORMA BARBINI;VITTORIO SABA;PIERUGO CARBONIN;ROBERTO GHISELLI;STEFANIA BANDINELLI;ANGELO SCUTERI;DONATELLA DEL SINDACO;MARCO GUIDI;E. GUFFANTI;FABIOLA OLIVIERI;PATRIZIA FATTORETTI;O. SCARPINO","1.41;1;0.97;0.95;0.92;0.9;0.89;0.89;0.83;0.82;0.77;0.75;0.67;0.62;0.61;0.61;0.53;0.51;0.51;0.5","CLAUDIO FRANCESCHI;CALOGERO CARUSO;DOMENICO LIO;GIUSEPPINA CANDORE;GIUSEPPINA COLONNA‐ROMANO;CLAUDIO PEDONE;LUIGI FERRUCCI;STEFANIA BANDINELLI;JACK M. GURALNIK;ANGELO SCUTERI;ELISA PORCELLINI;FEDERICO LICASTRO;FIORENZA ORLANDO;PIERUGO CARBONIN;RAFFAELE ANTONELLI INCALZI;VITTORIO SABA;ROBERTO GHISELLI;ANDREA CORSONELLO;FRANCESCO CORICA;EUGENIO MOCCHEGIANI","865;626;575;537;537;518;514;502;467;464;446;446;414;394;368;367;364;341;341;313","CLAUDIO FRANCESCHI;ANGELO SCUTERI;FIORENZA ORLANDO;STEFANIA BANDINELLI;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;MAURO PROVINCIALI;FULVIO LAURETANI;FABIOLA OLIVIERI;ANTONIO CHERUBINI;MARCO MALAVOLTA;ROBERTINA GIACCONI;MAURIZIO CARDELLI;LIANA SPAZZAFUMO;VITTORIO SABA;ROBERTO GHISELLI;ARIANNA SMORLESI;ELISA MUTI;NAZZARENA GASPARINI;CATIA CIPRIANO","748;464;414;394;341;313;299;280;277;266;230;230;203;197;197;194;191;180;180;179","FIORENZA ORLANDO;CLAUDIO FRANCESCHI;MAURO PROVINCIALI;EUGENIO MOCCHEGIANI;LIANA SPAZZAFUMO;ANDREA CORSONELLO;DONATELLA DEL SINDACO;FABIOLA OLIVIERI;MARCO MALAVOLTA;MASSIMO BOEMI;ROBERTINA GIACCONI;VITTORIO SABA;ANGELO SCUTERI;STEFANIA BANDINELLI;ARIANNA SMORLESI;FRANCESCA MARCHEGIANI;FULVIO LAURETANI;ROBERTO ANTONICELLI;ALESSIA DONNINI;CATIA CIPRIANO","8;7;7;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","75;35;15;9;9;5;5;5;4;3;2;1;1;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;CARDIOLOGY;PHYSICAL THERAPY;SURGERY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;PSYCHIATRY;GERONTOLOGY;BIOTECHNOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;ORGANIC CHEMISTRY;PHARMACOLOGY;CELL BIOLOGY;CANCER RESEARCH;MATHEMATICAL ANALYSIS;MICROBIOLOGY;NEUROSCIENCE;PEDIATRICS","58;27;22;21;15;13;12;12;11;10;8;8;7;6;6;6;6;6;5;4;4;4;4;4","GENE;DISEASE;POPULATION;DIABETES MELLITUS;IMMUNE SYSTEM;HEART FAILURE;INFLAMMATION;ODDS RATIO;BLOOD PRESSURE;CANCER;COGNITION;IN VITRO;IN VIVO;RISK FACTOR;ACTIVITIES OF DAILY LIVING;APOPTOSIS;CONFIDENCE INTERVAL;LONGEVITY;PROSPECTIVE COHORT STUDY;ANTIBIOTICS;BACTERIA;COMORBIDITY;ENZYME;MYOCARDIAL INFARCTION;STIMULATION","14;12;11;10;10;7;7;7;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","GENOTYPE;ALLELE;DEMENTIA;BREAST CANCER;INSULIN RESISTANCE;STAPHYLOCOCCUS AUREUS;ARTERIAL STIFFNESS;CYTOTOXICITY;EJECTION FRACTION;T CELL;TRANSGENE;ACUTE CORONARY SYNDROME;AUTOIMMUNE DISEASE;CARDIOMYOPATHY;CD8;CENTRAL VENOUS CATHETER;DIASTOLE;DYSLIPIDEMIA;EXON;HAZARD RATIO;IMMUNIZATION;IMMUNOSENESCENCE;LACTATE DEHYDROGENASE;MUTATION;PHENOTYPE;PROINFLAMMATORY CYTOKINE;PULSE WAVE VELOCITY;TOLERABILITY;TYPE 2 DIABETES;VIABILITY ASSAY;VITAMIN E","9;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COGNITIVE DECLINE;HER2/NEU;POLYMORPHISM (COMPUTER SCIENCE);DNA VACCINATION;INSULIN SENSITIVITY;MONTREAL COGNITIVE ASSESSMENT;AGGRESSIVE LYMPHOMA;ASYMMETRIC DIMETHYLARGININE;AUTOIMMUNE THYROIDITIS;BILIARY CIRRHOSIS;CANCER VACCINE;CARDIAC RESYNCHRONIZATION THERAPY;CASPASE;CD28;CD3;CHOLESTERYLESTER TRANSFER PROTEIN;DNA FRAGMENTATION;DNA MISMATCH REPAIR;FACET (PSYCHOLOGY);FEBRILE NEUTROPENIA;FRACTAL ANALYSIS;GENE DELIVERY;GENE MUTATION;GENE POLYMORPHISM;GENETICALLY MODIFIED MOUSE;GERIATRIC DEPRESSION SCALE;HAPLOTYPE;HUMAN BREAST;IMIPENEM;JURKAT CELLS;LACUNARITY;LRRK2;MAMMARY GLAND;MAMMARY TUMOR;METASTATIC BREAST CANCER;MICROSATELLITE;MUSCULOSKELETAL DISORDER;NATIONAL CHOLESTEROL EDUCATION PROGRAM;PERMISSIVENESS;PEROXYNITRITE;PHORBOL;PROBAND;PROGENITOR;PYRIN DOMAIN;RECEPTOR ANTAGONIST;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL INTERFERING RNA;VANCOMYCIN;VINCRISTINE;WORK-RELATED MUSCULOSKELETAL DISORDERS","3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;AGED, 80 AND OVER;MIDDLE AGED;ADULT;AGING;ANIMALS;;COGNITION DISORDERS;ITALY;DIABETES MELLITUS, TYPE 2;HEART FAILURE;INTERLEUKIN-6;INFLAMMATION;RISK FACTORS;APOPTOSIS;NEUTROPHILS;ARGININE","60;49;45;39;23;22;18;18;17;16;14;14;13;13;13;12;12;11;11;10","ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;COPPER AND ZINC IN HEALTH AND DISEASE;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;IMMUNOBIOLOGY OF DENDRITIC CELLS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;OSTEOPOROSIS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;STANDARDISATION AND MANAGEMENT OF COPD;ADVANCED TECHNIQUES IN BIOIMAGE ANALYSIS AND MICROSCOPY;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ASTHMA;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","COGNITIVE DECLINE;GERIATRIC ASSESSMENT;INFLAMMATION;AGING;AORTIC STIFFNESS;ARTERIAL STIFFNESS;HER2/NEU;STROKE (ENGINE);VASCULAR AGING;ANTICHOLINERGIC BURDEN;CENTRAL VENOUS CATHETER;COMPREHENSIVE GERIATRIC ASSESSMENT;CORTICAL EXCITABILITY;DIABETES;DYSLIPIDEMIA;ELECTRICAL STIMULATION;FECAL INCONTINENCE;HYPERTENSION;IMMUNOSENESCENCE;INSULIN RESISTANCE","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ELDERLY PATIENTS;COGNITIVE IMPAIRMENT;HEART FAILURE;RISK FACTOR;ADVERSE DRUG;ARTERIAL STIFFNESS;BILE DUCT;CARDIOVASCULAR EVENTS;CATHETER-RELATED INFECTION;CENTRAL VENOUS;CHRONIC HEART;CONCEALED RENAL;DRUG REACTIONS;GIFA STUDY;HOSPITALIZED PATIENTS;HUMAN NEUTROPHIL;INCHIANTI STUDY;INDEPENDENT RISK;INSULIN RESISTANCE;INTERLEUKIN- GGTC;LONGITUDINAL STUDY;MAMMARY CARCINOMA;MURINE MODEL;MYOCARDIAL INFARCTION;PILOT STUDY;PLASMA LEVELS;RECEPTOR POLYMORPHISMS;TRANSGENIC MURINE;TYPE DIABETES;ACCURATE PREDICTION","7;5;5;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","METABOLIC SYNDROME;HEART FAILURE;CREATININE LEVELS;REVERSE REMODELING;ADVANCED AGE;COGNITIVE IMPAIRMENT;IMMUNE SYSTEM;INCREASED RISK;SERUM CREATININE;URIC ACID;ATPIII CRITERIA;CONFIDENCE INTERVAL;DIABETES MELLITUS;ELDERLY PATIENTS;FECAL INCONTINENCE;GENETIC BACKGROUND;GERIATRIC SYNDROMES;HYDROSOLUBLE DRUGS;LDL-CHOLESTEROL LEVELS;LV REVERSE;METASTATIC CANCER;MIN NA;NORMAL SERUM;ODDS RATIO;PATIENTS AGED;PRESSURE SORES;REGRESSION ANALYSIS;RISK FACTOR;SOLID TUMORS;URINARY INCONTINENCE","9;8;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",18,0.2,6.75,3,0,0,0,1,3,1,2,5.25,0,0,4,0,1,1,1,4,1,0,0,83.5,83.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,5.5,576.5,1.56,1,0.5,57.5,0,0,1,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,1,0,2,0,0,0,0,0,0,0,0,0,"Italy;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;BREAST CANCER;CANCER;PATIENT SAFETY;REHABILITATION","2;2;1;1;1;1;1","CANCER","2","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","2;1","BREAST CANCER;STOMACH CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2006,94,8.09574468085106,2.52127659574468,0.361702127659574,0.297872340425532,0.382978723404255,2.40816326530612,1.36,1.27272727272727,1.33333333333333,0.234042553191489,2,36,27,18,8,0.38,0.29,0.19,0.09,41.72,0.81685334232539,NA,0.340425531914894,0.872340425531915,0.459,0.484,0.464,0.468,"EUGENIO MOCCHEGIANI;CLAUDIO FRANCESCHI;MARCO MALAVOLTA;VITTORIO SABA;FIORENZA ORLANDO;GIORGIO SCALISE;ROBERTO GHISELLI;OSCAR CIRIONI;FEDERICO MOCCHEGIANI;CARMELA SILVESTRI;CARLO BERTONI–FREDDARI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;PATRIZIA FATTORETTI;CALOGERO CARUSO;BELINDA GIORGETTI;ROBERTINA GIACCONI;MARTA BALIETTI;YESSICA GROSSI;DOMENICO LIO","14;13;12;10;9;9;9;9;8;8;7;7;7;7;6;6;6;6;6;6","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;CLAUDIO FRANCESCHI;LAZZARO REPETTO;FIORELLA MARCELLINI;A. FILENI;SERGIO GIUNTA;ANTONIO DOMENICO PROCOPIO;CARLO BERTONI–FREDDARI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;PATRIZIA FATTORETTI;VITTORIO SABA;MASSIMO BOEMI;BELINDA GIORGETTI;MARTA BALIETTI;YESSICA GROSSI;FIORENZA ORLANDO;GIORGIO SCALISE;ROBERTO GHISELLI","2.08;1.99;1.37;1.33;1.04;1;1;0.94;0.91;0.91;0.91;0.91;0.85;0.77;0.76;0.76;0.76;0.75;0.75;0.75","EUGENIO MOCCHEGIANI;CLAUDIO FRANCESCHI;MARCO MALAVOLTA;VITTORIO SABA;FIORENZA ORLANDO;ROBERTO GHISELLI;FEDERICO MOCCHEGIANI;CARLO BERTONI–FREDDARI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;PATRIZIA FATTORETTI;BELINDA GIORGETTI;ROBERTINA GIACCONI;MARTA BALIETTI;YESSICA GROSSI;CATIA CIPRIANO;MASSIMO BOEMI;LAURA COSTARELLI;ELISA MUTI;FIORELLA MARCELLINI","14;13;12;10;9;9;8;7;7;7;7;6;6;6;6;6;5;5;5;5","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;CLAUDIO FRANCESCHI;LAZZARO REPETTO;FIORELLA MARCELLINI;A. FILENI;SERGIO GIUNTA;ANTONIO DOMENICO PROCOPIO;CARLO BERTONI–FREDDARI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;PATRIZIA FATTORETTI;VITTORIO SABA;MASSIMO BOEMI;BELINDA GIORGETTI;MARTA BALIETTI;YESSICA GROSSI;FIORENZA ORLANDO;ROBERTO GHISELLI;ANDREA CORSONELLO","2.08;1.99;1.37;1.33;1.04;1;1;0.94;0.91;0.91;0.91;0.91;0.85;0.77;0.76;0.76;0.76;0.75;0.75;0.7","CLAUDIO FRANCESCHI;EUGENIO MOCCHEGIANI;ANGELO SCUTERI;ALAN B. ZONDERMAN;ALEXEI A. SHAROV;ANTONIO CAO;ANTONIO TERRACCIANO;CINZIA MAMELI;DAVID SCHLESSINGER;EDWARD G. LAKATTA;GIANLUCA USALA;GIUSEPPE ALBAI;GIUSEPPE PILIA;GONÇALO R. ABECASIS;LOREDANA VACCA;MANILA DEIANA;MARCO MASALA;MARCO ORRÚ;MARIANO DEI;MONICA LAI","730;575;555;547;547;547;547;547;547;547;547;547;547;547;547;547;547;547;547;547","CLAUDIO FRANCESCHI;EUGENIO MOCCHEGIANI;ANGELO SCUTERI;MARCO MALAVOLTA;FIORENZA ORLANDO;VITTORIO SABA;ROBERTO GHISELLI;CATIA CIPRIANO;ROBERTINA GIACCONI;ELISA MUTI;LAURA COSTARELLI;FEDERICO MOCCHEGIANI;ANDREA CORSONELLO;FIORELLA MARCELLINI;ANTONIO CHERUBINI;GIULIANO ENZI;ROBERTA PAPA;CRISTINA GAGLIARDI;ANTONIO DOMENICO PROCOPIO;F. SORVILLO","600;559;555;505;402;291;273;225;225;215;215;213;210;207;194;180;180;164;146;107","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;CLAUDIO FRANCESCHI;FIORENZA ORLANDO;CARLO BERTONI–FREDDARI;GIUSEPPINA DI STEFANO;PATRIZIA FATTORETTI;TIZIANA CASOLI;BELINDA GIORGETTI;MARTA BALIETTI;YESSICA GROSSI;CATIA CIPRIANO;ROBERTINA GIACCONI;ELISA MUTI;FIORELLA MARCELLINI;LAURA COSTARELLI;MASSIMO BOEMI;VITTORIO SABA;ANTONIO DOMENICO PROCOPIO;ANDREA CORSONELLO","13;12;9;9;7;7;7;7;6;6;6;6;6;5;5;5;4;4;4;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;SOCIOLOGY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;GEOGRAPHY;ART;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","74;56;20;11;10;7;5;4;3;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;GERONTOLOGY;PATHOLOGY;ENDOCRINOLOGY;CELL BIOLOGY;DEMOGRAPHY;ENVIRONMENTAL HEALTH;NEUROSCIENCE;ANATOMY;ORGANIC CHEMISTRY;PHARMACOLOGY;MICROBIOLOGY;PSYCHIATRY;SURGERY;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;CARDIOLOGY;GASTROENTEROLOGY;PHYSICAL THERAPY","49;30;28;19;14;14;13;12;10;9;9;8;8;8;7;7;7;6;6;5;5;5","GENE;IMMUNE SYSTEM;POPULATION;ANTIBIOTICS;CANCER;BACTERIA;LOGISTIC REGRESSION;LONGEVITY;RECEPTOR;AGEING;APOPTOSIS;BLOOD PRESSURE;COGNITION;DISEASE;INFLAMMATION;MITOCHONDRION;ZINC;ANTIBODY;ANTIGEN;CELL;CYTOKINE;DIABETES MELLITUS;ENZYME;IN VITRO;IN VIVO;SEPSIS;STIMULATION;ULTRASTRUCTURE","21;16;12;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","ALLELE;GENOTYPE;IMMUNOSENESCENCE;T CELL;ANTIBIOTIC RESISTANCE;INNATE IMMUNE SYSTEM;STAPHYLOCOCCUS AUREUS;ZINC DEFICIENCY (PLANT DISORDER);ALZHEIMER'S DISEASE;CANCER CELL;CENTENARIAN;CYTOCHROME C OXIDASE;DEMENTIA;DENTATE GYRUS;INSULIN RESISTANCE;PROGRAMMED CELL DEATH;PROINFLAMMATORY CYTOKINE;ACQUIRED IMMUNE SYSTEM;B CELL;BACTEREMIA;BIOFILM;CD8;CENTRAL VENOUS CATHETER;CHEMOKINE;CYTOCHEMISTRY;DEPRESSIVE SYMPTOMS;ESCHERICHIA COLI;FUNCTIONAL ELECTRICAL STIMULATION;GENOME;HUMAN LEUKOCYTE ANTIGEN;IMMUNITY;LOCUS (GENETICS);METABOLIC SYNDROME;METASTASIS;PHENOTYPE;PLACEBO;PSEUDOMONAS AERUGINOSA;SEPTIC SHOCK;SURVIVIN;WAIST","8;8;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SINGLE-NUCLEOTIDE POLYMORPHISM;GLUCOSE TOLERANCE TEST;IMIPENEM;VANCOMYCIN;CATHELICIDIN;CD28;GERIATRIC DEPRESSION SCALE;IL-2 RECEPTOR;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);AGGRESSIVE LYMPHOMA;AIRBORNE ALLERGEN;ALLELE FREQUENCY;AMBROSIA ARTEMISIIFOLIA;ARACHIDONATE 5-LIPOXYGENASE;BORRELIA;CROSSOVER STUDY;CXCR4;DEMENTIA WITH LEWY BODIES;DISMUTASE;EXTERNAL ANAL SPHINCTER;FAS RECEPTOR;GABA TRANSPORTER;GASTRIC BYPASS;GENETIC CORRELATION;GENOTYPING;GESTATIONAL DIABETES;GLUTAMATERGIC;GLUTATHIONE PEROXIDASE;GRAM-NEGATIVE BACTERIA;GRANULE CELL;HAPLOTYPE;HERPESVIRIDAE;HUMAN GENOME;IMMUNOGLOBULIN D;IMMUNOGLOBULIN M;INSULIN SENSITIVITY;MARGINAL ZONE;METABOTROPIC GLUTAMATE RECEPTOR;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROCOCCACEAE;MICRONUCLEUS;MITOTIC CATASTROPHE;NUCLEAR DNA;PERIRHINAL CORTEX;PEROXYNITRITE;PLEIOTROPY;PLEURAL DISEASE;PON1;QUORUM SENSING;SENILE PLAQUES;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS;T-CELL RECEPTOR;THYMIC INVOLUTION;THYROTROPIN RECEPTOR;TRAB;TRYPSINIZATION","4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AGING;HUMANS;MALE;FEMALE;AGED;AGED, 80 AND OVER;MIDDLE AGED;ZINC;ADULT;ITALY;;ANIMALS;LONGEVITY;HYPERTENSION;ANTIMICROBIAL CATIONIC PEPTIDES;TUMOR NECROSIS FACTOR-ALPHA;ANTI-BACTERIAL AGENTS;STAPHYLOCOCCAL INFECTIONS;BIOMARKERS;BLOOD GLUCOSE","63;63;55;46;33;30;27;23;21;18;16;16;16;15;14;14;13;13;12;11","COPPER AND ZINC IN HEALTH AND DISEASE;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;PHYSIOLOGICAL EFFECTS OF SPACE TRAVEL AND MICROGRAVITY;REGULATORY T CELL DEVELOPMENT AND FUNCTION;ROLE OF PARAOXONASE ENZYMES IN ATHEROSCLEROSIS AND OXIDATIVE STRESS;WORK-RELATED STRESS AND HEALTH IMPACT;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;BIOAVAILABILITY AND HEALTH EFFECTS OF CURCUMIN;BIOLOGICAL EFFECTS OF ELECTROMAGNETIC FIELDS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER","9;6;6;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","ZINC;AGING;IMMUNOSENESCENCE;ANTIMICROBIAL PEPTIDES;FUNCTIONAL DECLINE;INSULIN RESISTANCE;MEMORY T CELLS;MITOCHONDRIAL FUSION;CENTENARIAN;CONTINUOUS GLUCOSE MONITORING;DIABETES;FRAILTY;GLUCOSE TOLERANCE TEST;HYPERTENSION;METABOLIC SYNDROME;ORGANELLE;PROINFLAMMATORY CYTOKINE;SYNAPTIC PLASTICITY;VANCOMYCIN RESISTANCE;ALZHEIMER'S DISEASE","7;6;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2","ZINC STATUS;CLINICAL PRACTICE;ALZHEIMERS DISEASE;ANTIMICROBIAL PEPTIDE;ARTERIAL HYPERTENSION;CATHELICIDIN BMAP-;CELL LINES;CENTRAL VENOUS;CYTOCHROME OXIDASE;ELDERLY SUBJECTS;EUROPEAN COUNTRIES;EXPERIMENTAL RAT;GLUCOSE TOLERANCE;GRAM-NEGATIVE BACTERIA;HEALTHY ELDERLY;HEART FAILURE;HUMAN LYMPHOCYTES;METABOLIC SYNDROME;NEURONAL DEATH;ORAL GLUCOSE;RAT MODELS;SEPTIC SHOCK;STRUCTURAL DYNAMICS;SUCCESSFUL AGING;THYROTROPIN RECEPTOR;TOLERANCE TEST;ACTIVITY PATTERNS;ACUTE ISCHEMIC;ADOLESCENTS ENGAGED;ADULT MALES","6;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","IMMUNE SYSTEM;NECROSIS FACTOR;PLASMA LEVELS;TUMOR NECROSIS;BACTERIAL GROWTH;ESCHERICHIA COLI;FACTOR ALPHA;HUMAN MPM;INTRACELLULAR ZINC;MM CELLS;PARAOXONASE ACTIVITY;RAT MODELS;SEPTIC SHOCK;CARDIOVASCULAR FUNCTION;CHLORIDE SOLUTION;COLI LPS;ISOTONIC SODIUM;LETHALITY RATES;MAIN OUTCOME;NORMOTENSIVE SUBJECTS;NUDE MICE;PRIMARY CARE;PRINCIPAL CELLS;RAGWEED POLLEN;SODIUM CHLORIDE;ZINC HOMEOSTASIS;ADL DISABILITY;ADULT MALE;AIRBORNE POLLEN;ALPHA TNF-Α","5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2",19,0.2,4.75,2,0,1,0,5,1.5,0,1,2,1,1,1,0,1,0,0,1,0,0,0,72.5,72.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;3105 GENETICS;4202 EPIDEMIOLOGY;5202 BIOLOGICAL PSYCHOLOGY;5205 SOCIAL AND PERSONALITY PSYCHOLOGY","2;2;2;1;1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;GENETIC TESTING;GENETICS;HUMAN GENOME;PREVENTION","1;1;1;1;1;1","CARDIOVASCULAR","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,"PUBLIC HEALTH","1",NA,NA,NA,NA
"IRCCS_INRCA",2007,84,9.04761904761905,3.26190476190476,0.464285714285714,0.297619047619048,0.476190476190476,2.140625,1.3,1.31578947368421,1.29032258064516,0.345238095238095,2,33,29,12,4,0.39,0.35,0.14,0.05,57.92,1.09740557467762,NA,0.44047619047619,0.869047619047619,0.45,0.437,0.453,0.436,"FIORENZA ORLANDO;VITTORIO SABA;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;FEDERICO MOCCHEGIANI;ANGELO SCUTERI;CLAUDIO FRANCESCHI;ANDREA GIACOMETTI;MAURIZIO MARRA;ROBERTO TESTA;ANDREA CORSONELLO;CARLO BERTONI–FREDDARI;MARTA BALIETTI;LUIGI FERRUCCI;WOJCIECH KAMYSZ;PATRIZIA FATTORETTI","11;11;11;10;10;9;9;9;8;8;7;7;6;6;6;5;5;5;5;5","EUGENIO MOCCHEGIANI;ROBERTO TESTA;ANDREA CORSONELLO;MARCO MALAVOLTA;ANGELO SCUTERI;FIORENZA ORLANDO;ROBERTO GHISELLI;VITTORIO SABA;RAFFAELE ANTONELLI INCALZI;CLAUDIO PEDONE;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;MARIA CLAUDIA LUCCHETTI;FEDERICO MOCCHEGIANI;MAURO PROVINCIALI;CARLO BERTONI–FREDDARI;MARTA BALIETTI;PATRIZIA FATTORETTI;CLAUDIO FRANCESCHI","2.16;1.48;1.19;1.16;1.14;1.13;0.94;0.93;0.82;0.82;0.77;0.77;0.77;0.71;0.69;0.68;0.66;0.66;0.66;0.65","FIORENZA ORLANDO;VITTORIO SABA;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;FEDERICO MOCCHEGIANI;ANGELO SCUTERI;CLAUDIO FRANCESCHI;ANDREA GIACOMETTI;MAURIZIO MARRA;ROBERTO TESTA;ANDREA CORSONELLO;CARLO BERTONI–FREDDARI;MARTA BALIETTI;LUIGI FERRUCCI;PATRIZIA FATTORETTI;BELINDA GIORGETTI","11;11;11;10;10;9;9;9;8;8;7;7;6;6;6;5;5;5;5;4","EUGENIO MOCCHEGIANI;ROBERTO TESTA;ANDREA CORSONELLO;MARCO MALAVOLTA;ANGELO SCUTERI;FIORENZA ORLANDO;ROBERTO GHISELLI;VITTORIO SABA;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;MARIA CLAUDIA LUCCHETTI;FEDERICO MOCCHEGIANI;MAURO PROVINCIALI;CARLO BERTONI–FREDDARI;MARTA BALIETTI;PATRIZIA FATTORETTI;CLAUDIO FRANCESCHI;LUIGI FERRUCCI;MAURIZIO MARRA","2.16;1.48;1.19;1.16;1.14;1.13;0.94;0.93;0.77;0.77;0.77;0.71;0.69;0.68;0.66;0.66;0.66;0.65;0.61;0.61","ANGELO SCUTERI;SAMER S. NAJJAR;ROBERTO GHISELLI;VITTORIO SABA;LIANA SPAZZAFUMO;LUIGI FERRUCCI;STEFANIA BANDINELLI;ALAN B. ZONDERMAN;JULIAN F. THAYER;S. CARRINGTON RICE;SHARI R. WALDSTEIN;CARMELA SILVESTRI;DONATO F. ALTOMARE;GIORGIO SCALISE;GIUSEPPE DODI;MARCELLA RINALDI;OSCAR CIRIONI;EUGENIO MOCCHEGIANI;G. BIAGINI;MARCO MALAVOLTA","1049;729;688;553;505;492;446;433;433;433;433;430;430;430;430;430;430;424;413;398","ANGELO SCUTERI;ROBERTO GHISELLI;VITTORIO SABA;LIANA SPAZZAFUMO;ALAN B. ZONDERMAN;JULIAN F. THAYER;S. CARRINGTON RICE;SAMER S. NAJJAR;SHARI R. WALDSTEIN;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FIORENZA ORLANDO;FEDERICO MOCCHEGIANI;ANDREA CORSONELLO;FIORENZA ORLANDI;SERGIO DI PIETRO;MAURIZIO MARRA;MAURO PROVINCIALI;ROBERTO TESTA;DONATELLA DEL SINDACO","1036;643;508;505;433;433;433;433;433;403;398;342;330;318;248;229;173;165;158;152","MARCO MALAVOLTA;EUGENIO MOCCHEGIANI;FIORENZA ORLANDO;VITTORIO SABA;ANGELO SCUTERI;ROBERTO GHISELLI;ANDREA CORSONELLO;MAURIZIO MARRA;ROBERTO TESTA;CARLO BERTONI–FREDDARI;FEDERICO MOCCHEGIANI;MARTA BALIETTI;PATRIZIA FATTORETTI;BELINDA GIORGETTI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;C. SIROLLA;CLAUDIO FRANCESCHI;LAURA COSTARELLI;MAURO PROVINCIALI","10;10;10;8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;GEOGRAPHY;MATHEMATICS;PHYSICS;POLITICAL SCIENCE;ENGINEERING;HISTORY","73;41;15;10;5;4;3;3;3;3;3;1;1","INTERNAL MEDICINE;GENETICS;BIOCHEMISTRY;ENDOCRINOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;CELL BIOLOGY;PSYCHIATRY;GERONTOLOGY;SURGERY;CARDIOLOGY;MICROBIOLOGY;NEUROSCIENCE;ORGANIC CHEMISTRY;PHYSICAL THERAPY;CANCER RESEARCH;NURSING;PHARMACOLOGY;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;PHYSICAL MEDICINE AND REHABILITATION","54;24;20;18;15;14;13;10;10;9;9;8;8;8;8;7;5;5;5;4;4;4","DISEASE;POPULATION;GENE;DIABETES MELLITUS;IN VITRO;BACTERIA;BLOOD PRESSURE;INFLAMMATION;ZINC;COGNITION;QUALITY OF LIFE (HEALTHCARE);ANTIBIOTICS;CANCER;HEART FAILURE;IMMUNE SYSTEM;CELL;CONFIDENCE INTERVAL;INSULIN;PLATELET;ANTIOXIDANT;COMORBIDITY;CROSS-SECTIONAL STUDY;DEPRESSION (ECONOMICS);IN VIVO;OBESITY;ODDS RATIO;OXIDATIVE STRESS;PEPTIDE;PERCEPTION;PROSPECTIVE COHORT STUDY;PSYCHOLOGICAL INTERVENTION;WOUND HEALING","13;13;12;10;10;9;8;8;7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ALLELE;PERIPHERAL BLOOD MONONUCLEAR CELL;TYPE 2 DIABETES;ALZHEIMER'S DISEASE;ARTERIAL STIFFNESS;STAPHYLOCOCCUS AUREUS;BIOFILM;DEMENTIA;GENOTYPE;INSULIN RESISTANCE;PSEUDOMONAS AERUGINOSA;PULSE WAVE VELOCITY;BRACHIAL ARTERY;CARCINOGENESIS;CHEMOKINE;CHITIN;COLISTIN;CYTOTOXICITY;GENE EXPRESSION;HAEMATOPOIESIS;IMMUNOSENESCENCE;METABOLIC SYNDROME;MUTATION;NEUROPSYCHOLOGY;OFFSPRING;PARKINSON'S DISEASE;PLASMINOGEN ACTIVATOR INHIBITOR-1;PLATELET ACTIVATION;PROGENITOR CELL;PROINFLAMMATORY CYTOKINE;PULSE PRESSURE;SUPEROXIDE DISMUTASE;TRANSCRIPTION FACTOR","6;6;6;5;5;5;4;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VANCOMYCIN;COGNITIVE DECLINE;HAPLOTYPE;DISEASE MANAGEMENT;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;PIPERACILLIN;QUORUM SENSING;SENILE PLAQUES;ABDOMINOPERINEAL RESECTION;ADIPONECTIN;ALLELE FREQUENCY;AMYLOID PRECURSOR PROTEIN;AUTONOMIC NERVOUS SYSTEM;BACTERIAL CIRCADIAN RHYTHMS;CATENIN;CD28;CXCR4;DEFENSIVE MEDICINE;DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;DISMUTASE;ENOS;ENTEROCOCCUS FAECALIS;EXECUTIVE DYSFUNCTION;GATA2;GENETICALLY MODIFIED MOUSE;GENOME INSTABILITY;GERIATRIC DEPRESSION SCALE;GLUTATHIONE PEROXIDASE;HER2/NEU;HETEROPLASMY;HUMAN BREAST;HYPERTRIGLYCERIDEMIA;IMIPENEM;IMPAIRED GLUCOSE TOLERANCE;INSULIN RECEPTOR;LAMIVUDINE;LIGHT EFFECTS ON CIRCADIAN RHYTHM;MAMMARY GLAND;MAMMARY TUMOR;MASS CYTOMETRY;METHIONINE SULFOXIDE;METHIONINE SULFOXIDE REDUCTASE;MICROCOCCACEAE;MINI–MENTAL STATE EXAMINATION;MORBID OBESITY;NEUROPSYCHOLOGICAL TEST;POLY ADP RIBOSE POLYMERASE;POLYMORPHISM (COMPUTER SCIENCE);PROMOTER;PROTEIN CARBONYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCAL INFECTIONS;SYNAPTIC CLEFT;ZIDOVUDINE;ZINC FINGER","4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;DIABETES MELLITUS, TYPE 2;ZINC;AGED, 80 AND OVER;AGING;;ADULT;ANTI-BACTERIAL AGENTS;ITALY;ANIMALS;BIOFILMS;LEUKOCYTES, MONONUCLEAR;TRACE ELEMENTS;BLOOD PLATELETS;COGNITION DISORDERS;ANTIMICROBIAL CATIONIC PEPTIDES","50;46;41;32;26;23;23;22;22;21;20;18;18;15;14;14;14;13;13;11","COPPER AND ZINC IN HEALTH AND DISEASE;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;DIAGNOSIS AND TREATMENT OF HEART FAILURE;MECHANISMS OF ALZHEIMER'S DISEASE;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;IMPACT OF SOCIAL FACTORS ON HEALTH OUTCOMES;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;STANDARDISATION AND MANAGEMENT OF COPD;WOUND HEALING AND REGENERATION;;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANORECTAL SURGICAL PROCEDURES;BIOAVAILABILITY AND HEALTH EFFECTS OF CURCUMIN;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;COLORECTAL CANCER RESEARCH AND TREATMENT;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES","10;6;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ZINC;AGING;AORTIC STIFFNESS;ARTERIAL STIFFNESS;COGNITIVE DECLINE;BRACHIAL ARTERY;CROSS-SECTIONAL STUDY;DEPRESSION (ECONOMICS);DIABETES;TREATMENT;VASCULAR AGING;AMYLOID (MYCOLOGY);BLOOD PRESSURE;CANCER;CANCER CELL METABOLISM;COLISTIN;CONCOMITANT;COPD;DIAGNOSIS;DISEASE MANAGEMENT","8;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","HEART FAILURE;ARTERIAL STIFFNESS;COGNITIVE IMPAIRMENT;DIABETIC PATIENTS;ELDERLY PATIENTS;PERIPHERAL BLOOD;TACHYPLESIN III;ZINC SUPPLEMENTATION;ACTIVATOR INHIBITOR;CELL CARCINOMA;DIABETES MELLITUS;DISEASE MANAGEMENT;EUROPEAN COUNTRIES;GENE EXPRESSION;INHIBITOR TYPE;METABOLIC SYNDROME;NITRIC OXIDE;OXIDE PRODUCTION;PLASMINOGEN ACTIVATOR;PLATELET NITRIC;POUCH MODEL;PULSE PRESSURE;URETERAL STENT;ABSTRACT PULSE;ACID LEVELS;ACUTE CARE;ACUTE CORONARY;ACUTE IMPAIRMENT;ADJUSTABLE TOTALLY;ADULT-ONSET AUTOIMMUNE","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","ZN SUPPLEMENTATION;URIC ACID;AUTOIMMUNE DIABETES;EXTREMITY FUNCTION;IMMUNE PLASTICITY;IMMUNE RESPONSES;LOWER EXTREMITY;CELL CYTOTOXICITY;CELLULAR POLYADP-RIBOSYLATION;ELDERLY SUBJECTS;GADA TITERS;GROWTH ARREST;NK CELL;PERIPHERAL BLOOD;PLASMA ZN;PULSE PRESSURE;PULSE WAVE;SENESCENT-LIKE GROWTH;TRANSGENIC MICE;WAVE VELOCITY;ZINC DEFICIENCY;ZINC STATUS;ZINC SUPPLEMENTATION;ACID LEVELS;AGED MONKEYS;ALLELE FREQUENCIES;ARTERIAL STIFFNESS;BLOOD LYMPHOCYTES;CENTRAL ITALY;CHROMOSOMAL REGIONS","7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3",19,0.23,5.42,4,1,1,0,1,4,0,1,4.5,0,0,2,0,1.5,1,0,2,1,0,0,88.5,88.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2008,78,9.83333333333333,3.06410256410256,0.346153846153846,0.269230769230769,0.333333333333333,2.27619047619048,1.17391304347826,1.61538461538462,1.18181818181818,0.294871794871795,1,33,16,21,6,0.42,0.21,0.27,0.08,79.26,1.4443905276553,NA,0.371794871794872,0.91025641025641,0.498,0.487,0.436,0.479,"EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FIORENZA ORLANDO;VITTORIO SABA;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;ROBERTINA GIACCONI;CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;GEORGE DEDOUSSIS;MARTA BALIETTI;FEDERICO MOCCHEGIANI;LOTHAR RINK;LAURA COSTARELLI;ELISA MUTI;ANDREA CORSONELLO;ALESSANDRA RIVA;JOLANTA JAJTE","14;13;12;11;10;9;9;9;7;6;6;5;5;5;5;5;5;5;5;5","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FIORENZA ORLANDO;G SERGIO;ANDREA CORSONELLO;VITTORIO SABA;CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;ROBERTINA GIACCONI;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;MARTA BALIETTI;RAFFAELE ANTONELLI INCALZI;CLAUDIO PEDONE;FABRIZIA LATTANZIO;MAURO PROVINCIALI;BELINDA GIORGETTI;GIUSEPPINA DI STEFANO","2.22;2.12;1.03;1;0.93;0.91;0.83;0.83;0.82;0.81;0.75;0.75;0.75;0.67;0.59;0.58;0.53;0.5;0.47;0.47","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FIORENZA ORLANDO;VITTORIO SABA;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;ROBERTINA GIACCONI;CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;MARTA BALIETTI;FEDERICO MOCCHEGIANI;LAURA COSTARELLI;ELISA MUTI;ANDREA CORSONELLO;ANDREA GIACOMETTI;SILVIA TESEI;MARIA CARLA RE;BELINDA GIORGETTI","14;13;12;11;10;9;9;9;7;6;6;5;5;5;5;5;5;4;4;4","EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FIORENZA ORLANDO;G SERGIO;ANDREA CORSONELLO;VITTORIO SABA;CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;ROBERTINA GIACCONI;ROBERTO GHISELLI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;MARTA BALIETTI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;BELINDA GIORGETTI;GIUSEPPINA DI STEFANO;TIZIANA CASOLI;SARA PIERPAOLI","2.22;2.12;1.03;1;0.93;0.91;0.83;0.83;0.82;0.81;0.75;0.75;0.75;0.67;0.53;0.5;0.47;0.47;0.47;0.46","LUIGI FERRUCCI;ANGELO SCUTERI;EDWARD G. LAKATTA;AARTI SURTI;AMY J. SWIFT;ANNE JACKSON;BENJAMIN F. VOIGHT;CANDACE GUIDUCCI;CHRISTOPHER J. O’DONNELL;CRISTEN J. WILLER;DAVID ALTSHULER;DAVID SCHLESSINGER;DERRICK BENNETT;DIANA ZÉLÉNIKA;ERIC E. SCHADT;FRANCIS S. COLLINS;G.M. LATHROP;GABRIEL CRAWFORD;GINA M. PELOSO;GONÇALO R. ABECASIS","1914;1862;1862;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342;1342","ANGELO SCUTERI;ROBERTO TESTA;MASSIMO BOEMI;MARCO MALAVOLTA;EUGENIO MOCCHEGIANI;FIORENZA ORLANDO;VITTORIO SABA;ROBERTO GHISELLI;ROBERTINA GIACCONI;ANTONIO CHERUBINI;ANDREA CORSONELLO;ELISA MUTI;LAURA COSTARELLI;SILVIA TESEI;CARMELA SILVESTRI;GIORGIO SCALISE;OSCAR CIRIONI;ANDREA GIACOMETTI;ANNA RITA BONFIGLI;MADANAHALLY D. KIRAN","1862;1296;1176;568;537;426;391;367;312;254;219;213;213;201;196;196;196;183;183;183","MARCO MALAVOLTA;EUGENIO MOCCHEGIANI;FIORENZA ORLANDO;VITTORIO SABA;ROBERTO GHISELLI;ROBERTINA GIACCONI;CARLO BERTONI–FREDDARI;PATRIZIA FATTORETTI;ANDREA CORSONELLO;MARTA BALIETTI;ELISA MUTI;LAURA COSTARELLI;ANGELO SCUTERI;BELINDA GIORGETTI;CATIA CIPRIANO;FEDERICO MOCCHEGIANI;FRANCESCO PIACENZA;GIUSEPPINA DI STEFANO;SARA PIERPAOLI;SILVIA TESEI","13;11;10;9;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;ECONOMICS;COMPUTER SCIENCE;SOCIOLOGY;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;PHYSICS;POLITICAL SCIENCE;BUSINESS","68;39;17;13;6;5;4;2;2;2;2;2;2;1","INTERNAL MEDICINE;GENETICS;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;NEUROSCIENCE;PATHOLOGY;PHARMACOLOGY;MICROBIOLOGY;CELL BIOLOGY;ORGANIC CHEMISTRY;PSYCHIATRY;GASTROENTEROLOGY;GERONTOLOGY;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;CANCER RESEARCH;CARDIOLOGY;DEMOGRAPHY;ECONOMIC GROWTH;ONCOLOGY;SURGERY","54;23;21;15;14;12;12;11;10;9;9;8;6;6;5;5;4;4;4;4;4;4","GENE;ZINC;BACTERIA;DISEASE;CANCER;IMMUNE SYSTEM;DIABETES MELLITUS;ANTIBIOTICS;BODY MASS INDEX;INFLAMMATION;POPULATION;RECEPTOR;COGNITION;AGEING;ANTIMICROBIAL;CHEMOTHERAPY;CONFIDENCE INTERVAL;HIPPOCAMPAL FORMATION;HIPPOCAMPUS;HOMEOSTASIS;IN VIVO;INSULIN","16;10;9;9;8;8;7;6;6;6;6;6;5;4;4;4;4;4;4;4;4;4","GENOTYPE;STAPHYLOCOCCUS AUREUS;BASAL (MEDICINE);NITRIC OXIDE SYNTHASE;PSEUDOMONAS AERUGINOSA;TYPE 2 DIABETES;ZINC DEFICIENCY (PLANT DISORDER);ACUTE CARE;ALLELE;ALZHEIMER'S DISEASE;BIOFILM;COLORECTAL CANCER;DEMENTIA;EXON;GEMCITABINE;GRANULATION TISSUE;HAZARD RATIO;IMMUNOTHERAPY;INSULIN RESISTANCE;LYMPHOCYTOPENIA;METABOLIC SYNDROME;MYCOSIS FUNGOIDES;QUARTILE;RECOGNITION MEMORY;SYNAPTIC PLASTICITY;VASCULAR ENDOTHELIAL GROWTH FACTOR;VISUAL MEMORY","5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","POLYMORPHISM (COMPUTER SCIENCE);VANCOMYCIN;NITROTYROSINE;QUORUM SENSING;ALLELE FREQUENCY;BOSENTAN;CANCER VACCINE;CARDIOLIPIN;CD52;CHLAMYDOPHILA PNEUMONIAE;CUTANEOUS T-CELL LYMPHOMA;DNA VACCINATION;DOCOSAHEXAENOIC ACID;ENTEROCOCCUS FAECALIS;GENETICALLY MODIFIED MOUSE;GERMLINE MUTATION;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;GLUCOSE TOLERANCE TEST;GRAM-POSITIVE COCCI;HAPLOTYPE;HER2/NEU;HMG-COA REDUCTASE;INSULIN RESPONSE;INSULIN SENSITIVITY;LYMPHOVASCULAR INVASION;MAGAININ;MDX MOUSE;MEDULLARY CARCINOMA;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NEURAL FACILITATION;NEURONAL NITRIC OXIDE SYNTHASE;PANCREATIC HORMONE;PIPERACILLIN;POINT MUTATION;PROBAND;REPETITION PRIMING;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;SERTRALINE;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS EPIDERMIDIS;THORACIC AORTIC ANEURYSM;VARIABLE NUMBER TANDEM REPEAT;VERBAL FLUENCY TEST;VISUAL SHORT-TERM MEMORY;ZINC FINGER","4;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGING;AGED;MIDDLE AGED;AGED, 80 AND OVER;ZINC;ANIMALS;ANTI-BACTERIAL AGENTS;ANTIMICROBIAL CATIONIC PEPTIDES;STAPHYLOCOCCAL INFECTIONS;ADULT;METALLOTHIONEIN;DIABETES MELLITUS, TYPE 2;RATS;STAPHYLOCOCCUS AUREUS;SYNAPSES;SEPSIS;","53;51;46;39;33;33;22;22;20;20;14;14;13;12;11;11;11;11;10;9","COPPER AND ZINC IN HEALTH AND DISEASE;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EFFECTS OF KETOGENIC DIET ON HEALTH;EFFECTS OF STRESS ON BRAIN FUNCTION AND HEALTH;MECHANISMS OF ALZHEIMER'S DISEASE;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;STANDARDISATION AND MANAGEMENT OF COPD;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CANCER IMMUNOTHERAPY;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION","10;6;4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ZINC;BASAL (MEDICINE);HOMEOSTASIS;NUTRITIONAL STATUS;ANTIMICROBIAL PEPTIDES;DIABETES;HYPERTENSION;LONGITUDINAL STUDY;MEMORY;METABOLIC SYNDROME;TEICOPLANIN;ACUTE CARE;AGING;COPD;DEPRESSION (ECONOMICS);ENDOTHELIAL DYSFUNCTION;GERIATRIC ASSESSMENT;GRANULATION TISSUE;INTRAPERITONEAL INJECTION;LYMPHOCYTOPENIA","9;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","RAT MODELS;ZINC SUPPLEMENTATION;AGED RATS;ALZHEIMERS DISEASE;BALTIMORE LONGITUDINAL;BASAL METABOLIC;CANCER PATIENTS;COGNITIVE IMPAIRMENT;ENDOTHELIAL FUNCTION;HYPOXEMIC COPD;LONGITUDINAL STUDY;LUNG CANCER;METABOLIC RATE;METABOLIC SYNDROME;MOUSE MODEL;OXIDATIVE STRESS;PSEUDOMONAS AERUGINOSA;RECOGNITION MEMORY;TYPE DIABETES;ZINCAGE STUDY;ACCELERATED MUSCLE;ACMEPLUS INSTRUMENT;ACTIVATOR RECEPTOR;ACUTE CORONARY;ACUTE HOSPITAL;ACUTE MEDICAL;ADVANCED CUTANEOUS;AERUGINOSA INFECTION;AG- POLYMORPHISM;AGE-RELATED MITOCHONDRIAL","4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","METABOLIC SYNDROME;PHYSICAL FUNCTION;C- CARRIERS;METABOLIC RATE;PLASMA ZINC;TACHYPLESIN III;BASAL METABOLIC;CIRCULATING ZINC;HDL CHOLESTEROL;IMMUNE RESPONSE;INCIDENT METABOLIC;LDL CHOLESTEROL;NT INDIVIDUALS;OBESE PATIENTS;OXIDATIVE STRESS;PERFORMANCE BATTERY;PHYSICAL PERFORMANCE;RIP-SOAKED ALLEVYN;SHORT PHYSICAL;UPAR EXPRESSION;ZN SUPPLEMENTATION;AGE-RELATED DISEASES;BATTERY SCORE;BED RESTMEDIATED;DEMENTIA BPSD;ENERGY BALANCE;GENOME-WIDE ASSOCIATION;LARGER AOD;LRRK PRC;LYTIC ACTIVITY","18;8;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3",18,0.23,9.01,7.5,2.5,2,1,1,5,1,1,7.5,0,0,7,4,5.5,1,14.5,3,6.25,0,0,143.75,143.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,1650,0.98,0,0,72,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","CLINICAL RESEARCH;HEALTH SERVICES;PATIENT SAFETY","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,3,5243043.33,308785.58,4.33333333333333,14,8.33333333333333,1,16,261051.224372294,0.298791933221357,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;UNIVERSITY OF BOLOGNA;AALBORG UNIVERSITY;AARHUS UNIVERSITY;AB.ACUS (ITALY);ASTON UNIVERSITY;AUSTRIAN ACADEMY OF SCIENCES;BIOTESYS (GERMANY);CENTRE DE RECHERCHES SUR LES ARTS ET LE LANGAGE;CRANFIELD UNIVERSITY;ERASMUS MC;IMEC THE NETHERLANDS;IMPERIAL COLLEGE LONDON;INSTYTUT BIOLOGII DOŚWIADCZALNEJ IM. MARCELEGO NENCKIEGO;JAGIELLONIAN UNIVERSITY;LEIDEN UNIVERSITY MEDICAL CENTER;LINNAEUS UNIVERSITY;MARTIN LUTHER UNIVERSITY HALLE-WITTENBERG;NATIONAL HELLENIC RESEARCH FOUNDATION;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-A (CALL FOR PROPOSAL);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2007-1 (CALL FOR PROPOSAL);FP7-SSH - SPECIFIC PROGRAMME ""COOPERATION"": SOCIO-ECONOMIC SCIENCES AND HUMANITIES (PROGRAMME);FP7-SSH-2007-1 (CALL FOR PROPOSAL)","1;1;1;1;1;1;1;1;1","42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY;4403 DEMOGRAPHY;46 INFORMATION AND COMPUTING SCIENCES","2;1;1;1;1;1;1","AGING;CLINICAL RESEARCH;GENETICS;HUMAN GENOME;PEDIATRIC RESEARCH INITIATIVE;REHABILITATION","2;1;1;1;1;1","GENERIC HEALTH RELEVANCE","2","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C20 SOCIAL WORK AND SOCIAL POLICY","1;1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2009,78,10.6410256410256,2.98717948717949,0.448717948717949,0.294871794871795,0.538461538461538,2.04385964912281,1.16666666666667,1.53333333333333,1.23529411764706,0.346153846153846,4,29,33,10,6,0.37,0.42,0.13,0.08,42.77,0.924595743422833,NA,0.294871794871795,0.91025641025641,0.45,0.445,0.431,0.442,"FABRIZIA LATTANZIO;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FRANCESCO PIACENZA;ROBERTINA GIACCONI;ANDREA CORSONELLO;SILVIA TESEI;ROBERTO TESTA;ANGELO SCUTERI;LAURA COSTARELLI;SARA PIERPAOLI;CATIA CIPRIANO;ROBERTA PAPA;E. ROSA RIZZOTTO;LIANA SPAZZAFUMO;FIORENZA ORLANDO;IOANNIS PETRIDIS;RAFFAELE ANTONELLI INCALZI;WALTER GIANNI;CARLO BERTONI–FREDDARI","12;9;8;7;7;7;6;6;6;6;6;6;5;4;4;4;4;4;4;4","ANDREA CORSONELLO;FABRIZIA LATTANZIO;LAZZARO REPETTO;GABRIELLA BETTELLI;SERGIO GIUNTA;ROBERTO TESTA;FABIOLA OLIVIERI;EUGENIO MOCCHEGIANI;GIOVANNI LAMURA;NICOLA MAGNAVITA;A. FILENI;MARCO MALAVOLTA;RAFFAELE ANTONELLI INCALZI;ROBERTA PAPA;FRANCESCO PIACENZA;ANGELO SCUTERI;LIANA SPAZZAFUMO;CARLO BERTONI–FREDDARI;MARTA BALIETTI;PATRIZIA FATTORETTI","2.01;1.16;1;1;1;0.99;0.81;0.73;0.67;0.67;0.67;0.63;0.62;0.61;0.56;0.54;0.53;0.5;0.5;0.5","FABRIZIA LATTANZIO;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FRANCESCO PIACENZA;ROBERTINA GIACCONI;ANDREA CORSONELLO;SILVIA TESEI;ROBERTO TESTA;ANGELO SCUTERI;LAURA COSTARELLI;SARA PIERPAOLI;CATIA CIPRIANO;ROBERTA PAPA;LIANA SPAZZAFUMO;FIORENZA ORLANDO;RAFFAELE ANTONELLI INCALZI;WALTER GIANNI;CARLO BERTONI–FREDDARI;MAURIZIO MARRA;MARTA BALIETTI","12;9;8;7;7;7;6;6;6;6;6;6;5;4;4;4;4;4;4;4","ANDREA CORSONELLO;FABRIZIA LATTANZIO;LAZZARO REPETTO;GABRIELLA BETTELLI;SERGIO GIUNTA;ROBERTO TESTA;FABIOLA OLIVIERI;EUGENIO MOCCHEGIANI;GIOVANNI LAMURA;A. FILENI;MARCO MALAVOLTA;RAFFAELE ANTONELLI INCALZI;ROBERTA PAPA;FRANCESCO PIACENZA;ANGELO SCUTERI;LIANA SPAZZAFUMO;CARLO BERTONI–FREDDARI;MARTA BALIETTI;PATRIZIA FATTORETTI;ANDREA PRINCIPI","2.01;1.16;1;1;1;0.99;0.81;0.73;0.67;0.67;0.63;0.62;0.61;0.56;0.54;0.53;0.5;0.5;0.5;0.5","ANGELO SCUTERI;FABRIZIA LATTANZIO;EDWARD G. LAKATTA;SAMER S. NAJJAR;ANDREA CORSONELLO;MANUELA UDA;DAVID SCHLESSINGER;CHRISTIAN GIEGER;SERENA SANNA;THOMAS MEITINGER;EUGENIO MOCCHEGIANI;ANDREW A. HICKS;ANNA KÖTTGEN;ARAVINDA CHAKRAVARTI;ARNE PFEUFER;BENNO PÜTZ;BERTRAM MÜLLER‐MYHSOK;CHRISTIAN FUCHSBERGER;CHRISTINE HAPPLE;CRISTIAN PATTARO","613;482;478;478;470;470;439;416;416;416;409;385;385;385;385;385;385;385;385;385","FABRIZIA LATTANZIO;ANDREA CORSONELLO;BENNO PÜTZ;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;ROBERTINA GIACCONI;LAURA COSTARELLI;CATIA CIPRIANO;SARA PIERPAOLI;SILVIA TESEI;MARIA LORENZI;ANGELO SCUTERI;ROBERTA PAPA;ROBERTA GALEAZZI;GIULIANO ENZI;WALTER GIANNI;ANDREA BASSO;FIORELLA MARCELLINI;SERGIO DI PIETRO;ELISA MUTI","482;469;385;384;365;362;332;307;307;307;259;228;217;213;173;171;170;162;153;151","FABRIZIA LATTANZIO;MARCO MALAVOLTA;EUGENIO MOCCHEGIANI;ROBERTINA GIACCONI;ANDREA CORSONELLO;LAURA COSTARELLI;ROBERTO TESTA;CATIA CIPRIANO;ROBERTA PAPA;SARA PIERPAOLI;SILVIA TESEI;ANGELO SCUTERI;CARLO BERTONI–FREDDARI;ELISA MUTI;FIORENZA ORLANDO;LIANA SPAZZAFUMO;MARTA BALIETTI;MAURIZIO MARRA;PATRIZIA FATTORETTI;WALTER GIANNI","12;8;8;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;SOCIOLOGY;GEOGRAPHY;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;ENGINEERING;HISTORY","74;35;11;10;7;5;4;4;4;3;3;3;2;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;GENETICS;GERONTOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;CELL BIOLOGY;PSYCHIATRY;SURGERY;NEUROSCIENCE;CLINICAL PSYCHOLOGY;ECOLOGY;ONCOLOGY;ORGANIC CHEMISTRY;PHYSICAL THERAPY;RADIOLOGY","54;22;18;14;12;11;11;10;9;9;7;6;6;5;4;4;4;4;4;4","GENE;DISEASE;POPULATION;DIABETES MELLITUS;OBESITY;FIBROSIS;ANEMIA;ASTHMA;BLOOD PRESSURE;CANCER;CHEMOTHERAPY;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;ZINC;ADVERSE EFFECT;AGEING;ANTIBODY;COGNITION;COHORT;COPD;IMMUNE SYSTEM;INFLAMMATION;MASS SPECTROMETRY;OLDER PEOPLE;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;RESPIRATORY SYSTEM;STEATOSIS","19;14;10;7;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GENOTYPE;DEMENTIA;HEPATIC FIBROSIS;SPIROMETRY;FATTY LIVER;HEPCIDIN;ALLELE;BASAL (MEDICINE);BREAST CANCER;CHROMOSOMAL TRANSLOCATION;CHRONIC LYMPHOCYTIC LEUKEMIA;COGNITIVE IMPAIRMENT;CYCLOPHOSPHAMIDE;HEART RATE;IMMUNOSENESCENCE;LIVER FIBROSIS;LOCUS (GENETICS);LUNG VOLUMES;METABOLIC SYNDROME;PHENOTYPE;RNA;SEMAPHORIN;SUCCINATE DEHYDROGENASE;TYPE 2 DIABETES;ZINC DEFICIENCY (PLANT DISORDER)","9;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","POLYMORPHISM (COMPUTER SCIENCE);SINGLE-NUCLEOTIDE POLYMORPHISM;BACTERIAL TRANSLOCATION;CAREGIVER BURDEN;HAPLOTYPE;ACUTE LYMPHOCYTIC LEUKEMIA;ADHERENS JUNCTION;AGGRESSIVE LYMPHOMA;ANTI-THYROID AUTOANTIBODIES;BRAIN-DERIVED NEUROTROPHIC FACTOR;CATENIN;CELLULAR AGING;CLASSIFICATION OF OBESITY;COGNITIVE DECLINE;D-LOOP;FEAR OF FALLING;FLUDARABINE;GENETICALLY MODIFIED MOUSE;HEART RATE VARIABILITY;IMPAIRED GLUCOSE TOLERANCE;LEFT VENTRICULAR NONCOMPACTION;LIVER STEATOSIS;MAMMARY GLAND;MAMMARY TUMOR;MAMMOGRAPHY;NEONATAL MORTALITY;NEVOID BASAL-CELL CARCINOMA SYNDROME;NUCLEOPLASM;PEANUT ALLERGY;PHARMACOGENETICS;PLEXIN;POLYADENYLATION;PON1;PROBAND;RESPIRATORY RATE;RNA SPLICING;SUBVENTRICULAR ZONE;THIOTEPA;TOTAL BODY IRRADIATION;UNTRANSLATED REGION;WAIST–HIP RATIO;X-INACTIVATION","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;;ITALY;AGED, 80 AND OVER;HYPERTENSION;ADULT;OBESITY;AGING;ZINC;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;CARDIOVASCULAR DISEASES;INFLAMMATION;ANIMALS;COGNITION DISORDERS;SURVEYS AND QUESTIONNAIRES;AGE FACTORS","47;42;40;33;27;25;22;19;16;15;15;12;12;11;10;10;9;9;8;7","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EFFECTS OF KETOGENIC DIET ON HEALTH;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MECHANISMS OF ALZHEIMER'S DISEASE;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;REGULATION OF IRON METABOLISM AND ANEMIA;STANDARDISATION AND MANAGEMENT OF COPD;ACUTE MYELOID LEUKEMIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANORECTAL SURGICAL PROCEDURES;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;APELIN SIGNALING AND PHYSIOLOGY;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER","5;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","HEPATIC FIBROSIS;LIVER FIBROSIS;AGING;CAREGIVER BURDEN;CELL SIGNALING;GENETIC ASSOCIATION;GENOME-WIDE ASSOCIATION STUDY;STEATOSIS;ZINC;BACTERIAL TRANSLOCATION;BASAL (MEDICINE);CAREGIVER STAFFING;CONTINUOUS GLUCOSE MONITORING;COPD;DIABETES;ELDERLY PATIENTS;HEART RATE VARIABILITY;HEPATIC STEATOSIS;HEPCIDIN;HOMEOSTASIS","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","HEPATIC FIBROSIS;ELDERLY PATIENTS;IRON OVERLOAD;MASS SPECTROMETRY;MUSCULAR DYSTROPHY;SPECTROMETRY METHOD;ALLOGENEIC TRANSPLANTATION;ALZHEIMERS DISEASE;BACTERIAL TRANSLOCATION;BLOOD PRESSURE;CHRONIC LIVER;COGNITIVE IMPAIRMENT;DUCHENNE MUSCULAR;ELDERLY HOSPITALIZED;HEALTH CARE;HEPATIC STEATOSIS;HOME CARE;HOSPITALIZED PATIENTS;LIVER DISEASE;LIVER INJURY;METABOLIC SYNDROME;MILD COGNITIVE;MITOCHONDRIAL DNA;MODULATES PROGRESSION;NUMERIC DENSITY;TRANSLOCATION MODULATES;ABDOMINAL CIRCULATORY;ABDOMINAL VOLUME;ABSTRACT HMGB;ACTIVATES VASCULAR","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","AD PATIENTS;POLYMERASE CHAIN;SERUM CORTISOL;MINIMAL RESIDUAL;ALLOGENEIC STEM;CELL TRANSPLANTATION;RESIDUAL DISEASE;STEM CELL;AIR POLLUTION;AUTOIMMUNE DIABETES;BLOOD PRESSURE;BODY VOLUME;CHAIN REACTION;INTENSITY CONDITIONING;METS COMPONENTS;NORMAL RANGE;PLASMA ACTH;REDUCED INTENSITY;RISK FACTOR;SERUM CHEMERIN;SERUM LEVELS;ASSOCIATION STUDIES;BDNF SERUM;CARDIOVASCULAR DISEASE;CENTRAL ADIPOSITY;CHAIN REACTION-NEGATIVE;CV RISK;HCRH TEST;HEALTHY SUBJECTS;HEPSF RATIO","7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3",13,0.17,7,2,1,1.5,1,1,1.75,1,1,3,0,1,5,1,1,0,0,5,0,0,0,80,99,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1751791,83418.62,3,21,12,1,0,288857.430721501,0.270029404489175,"ACADEMY OF FINLAND;AGE PLATFORM EUROPE;AUSTRIAN ACADEMY OF SCIENCES;BULGARIAN ACADEMY OF SCIENCES;HEIDELBERG UNIVERSITY;ISRAEL MINISTRY OF HEALTH;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;ISTITUTO SUPERIORE DI SANITÀ;LABORATORIO DI SCIENZE DELLA CITTADINANZA;LATVIAN COUNCIL OF SCIENCE;LUND UNIVERSITY;MINISTERUL SANATATII;MINISTRY OF ECONOMY, INDUSTRY AND COMPETITIVENESS;MINISTRY OF HEALTH;NEWCASTLE UNIVERSITY;SWEDISH RESEARCH COUNCIL FOR HEALTH WORKING LIFE AND WELFARE;TAMPERE UNIVERSITY;UNITATEA EXECUTIVA PENTRU FINANTAREA INVATAMANTULUI SUPERIOR A CERCETARII DEZVOLTARII SI INOVARII;UNIVERSITY OF LEICESTER;UNIVERSITY OF NAMUR","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CSA-CA - COORDINATION (OR NETWORKING) ACTIONS (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;46 INFORMATION AND COMPUTING SCIENCES","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"B12 ENGINEERING","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2010,78,8.62820512820513,2.34615384615385,0.358974358974359,0.307692307692308,0.397435897435897,1.88659793814433,1.27272727272727,1.5,1.29166666666667,0.256410256410256,3,26,23,9,16,0.33,0.29,0.12,0.21,40.47,0.895636806890883,NA,0.217948717948718,0.897435897435897,0.475,0.463,0.402,0.437,"FABRIZIA LATTANZIO;FELICE STROLLO;ANDREA CORSONELLO;ANGELA MARIE ABBATECOLA;WALTER GIANNI;ANGELO SCUTERI;CLAUDIO PEDONE;LIANA SPAZZAFUMO;MAURIZIO MARRA;CLAUDIO FRANCESCHI;MAURO PROVINCIALI;FIORENZA ORLANDO;ANTONIO CHERUBINI;RAFFAELE ANTONELLI INCALZI;GIUSEPPE PIPICELLI;PATRIZIA DI MAURO;PATRIZIO TATTI;ROBERTO TESTA;FABIOLA OLIVIERI;VINCENZO MARI","12;10;10;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","ANGELO SCUTERI;FELICE STROLLO;FABRIZIA LATTANZIO;ANDREA CORSONELLO;A. FILENI;MAURIZIO CARDELLI;MAURO PROVINCIALI;ANGELA MARIE ABBATECOLA;EUGENIO MOCCHEGIANI;GIUSEPPE PIPICELLI;PATRIZIA DI MAURO;PATRIZIO TATTI;CLAUDIO PEDONE;WALTER GIANNI;ANTONIO CHERUBINI;LIANA SPAZZAFUMO;MAURIZIO MARRA;RAFFAELE ANTONELLI INCALZI;ROBERTO ANTONICELLI;FIORENZA ORLANDO","1.95;1.7;1.42;1.27;1.27;1.08;1.08;0.98;0.89;0.8;0.8;0.8;0.77;0.63;0.6;0.57;0.56;0.55;0.52;0.5","FABRIZIA LATTANZIO;FELICE STROLLO;ANDREA CORSONELLO;ANGELA MARIE ABBATECOLA;WALTER GIANNI;ANGELO SCUTERI;LIANA SPAZZAFUMO;MAURIZIO MARRA;MAURO PROVINCIALI;FIORENZA ORLANDO;ANTONIO CHERUBINI;ROBERTO TESTA;FABIOLA OLIVIERI;VINCENZO MARI;EUGENIO MOCCHEGIANI;ANNA RITA BONFIGLI;MAURIZIO CARDELLI;SILVIA BUSTACCHINI;SABRINA GARASTO;ROBERTO ANTONICELLI","12;10;10;7;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3","ANGELO SCUTERI;FELICE STROLLO;FABRIZIA LATTANZIO;ANDREA CORSONELLO;A. FILENI;MAURIZIO CARDELLI;MAURO PROVINCIALI;ANGELA MARIE ABBATECOLA;EUGENIO MOCCHEGIANI;WALTER GIANNI;ANTONIO CHERUBINI;LIANA SPAZZAFUMO;MAURIZIO MARRA;ROBERTO ANTONICELLI;FIORENZA ORLANDO;ROBERTO TESTA;VINCENZO MARI;ANNA RITA BONFIGLI;ILARIA MAZZANTI;SILVIA BUSTACCHINI","1.95;1.7;1.42;1.27;1.27;1.08;1.08;0.98;0.89;0.63;0.6;0.57;0.56;0.52;0.5;0.49;0.42;0.4;0.38;0.33","LIANA SPAZZAFUMO;MAURIZIO C. CAPOGROSSI;STEFANIA STRAINO;ANNA DI CARLO;BARBARA MICHELI;FABIO MARTELLI;FEDERICA LIMANA;FELICE ACHILLI;GIANCARLO MARENZI;GIULIO POMPILIO;MARA RUBINO;MARCO DE SIMONE;MARIA CRISTINA CARENA;PAOLA BRAMBILLA;PAOLO BIGLIOLI;PAOLO DEVANNA;STEFANO MAGGIOLINI;YURI D’ALESSANDRA;WALTER GIANNI;FABRIZIA LATTANZIO","834;791;791;740;740;740;740;740;740;740;740;740;740;740;740;740;740;740;606;521","LIANA SPAZZAFUMO;WALTER GIANNI;FABRIZIA LATTANZIO;ANGELA MARIE ABBATECOLA;ANDREA CORSONELLO;SILVIA BUSTACCHINI;FRANCESCA MARCHEGIANI;ANGELO SCUTERI;MAURIZIO CARDELLI;FABIOLA OLIVIERI;FELICE STROLLO;FIORENZA ORLANDO;EUGENIO MOCCHEGIANI;ROBERTA PAPA;MAURO PROVINCIALI;ANDREA SANTARELLI;ELISA PIERPAOLI;VALENTINA VIOLA;LAZZARO REPETTO;ROBERTO ANTONICELLI","796;606;516;378;263;223;187;170;146;139;132;115;102;96;92;79;77;77;69;66","FABRIZIA LATTANZIO;FELICE STROLLO;ANDREA CORSONELLO;WALTER GIANNI;ANGELA MARIE ABBATECOLA;ANGELO SCUTERI;MAURIZIO MARRA;MAURO PROVINCIALI;FIORENZA ORLANDO;LIANA SPAZZAFUMO;ROBERTO TESTA;EUGENIO MOCCHEGIANI;SILVIA BUSTACCHINI;A. FILENI;ANNA RITA BONFIGLI;FABIOLA OLIVIERI;SABRINA GARASTO;VINCENZO MARI;FRANCESCA MARCHEGIANI;MAURIZIO CARDELLI","11;9;8;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS;SOCIOLOGY;COMPUTER SCIENCE;PHYSICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;GEOGRAPHY","72;23;12;9;6;6;6;5;5;5;4;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;GERONTOLOGY;PATHOLOGY;GENETICS;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;CARDIOLOGY;PHYSICAL THERAPY;CANCER RESEARCH;CELL BIOLOGY;IMMUNOLOGY;LAW;MACROECONOMICS;PHARMACOLOGY;RADIOLOGY;CLINICAL PSYCHOLOGY;DEMOGRAPHY;EMERGENCY MEDICINE;FAMILY MEDICINE;MICROBIOLOGY;PEDIATRICS","54;23;14;13;13;13;11;10;9;8;6;5;5;5;5;5;5;5;4;4;4;4;4;4","DISEASE;DIABETES MELLITUS;POPULATION;GENE;COGNITION;DEPRESSION (ECONOMICS);BODY MASS INDEX;OBESITY;ANXIETY;APOPTOSIS;CANCER;COMORBIDITY;CONFIDENCE INTERVAL;DISTRESS;EPIDEMIOLOGY;IMMUNE SYSTEM;INSULIN;ACTIVITIES OF DAILY LIVING;ADVERSE EFFECT;ANEMIA;ANTIBIOTICS;ANTIOXIDANT;BACTERIA;BASAL CELL;BLOOD PRESSURE;CELL;CHOLESTEROL;CLINICAL PRACTICE;CROSS-SECTIONAL STUDY;DNA;ENZYME;GERIATRICS;HEALTH CARE;HEART FAILURE;HORMONE;IMMUNOHISTOCHEMISTRY;IN VITRO;IN VIVO;INFLAMMATION;KIDNEY DISEASE;LONGEVITY;LONGITUDINAL STUDY;MEDICAL PRESCRIPTION;MENOPAUSE;MYOCARDIAL INFARCTION;ODDS RATIO;OXIDATIVE STRESS;PERSONALITY;PROCESS (COMPUTING);PSYCHOSOCIAL;RADIOLOGICAL WEAPON;RECEPTOR;RENAL FUNCTION;SEPSIS","15;14;11;10;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TYPE 2 DIABETES;ALZHEIMER'S DISEASE;DEMENTIA;TYPE 2 DIABETES MELLITUS;GENOTYPE;INSULIN RESISTANCE;PROGRAMMED CELL DEATH;ALLELE;APATHY;BIG FIVE PERSONALITY TRAITS;DEPRESSIVE SYMPTOMS;DOWNREGULATION AND UPREGULATION;EMBRYONIC STEM CELL;HAZARD RATIO;HYPOGLYCEMIA;LEPTIN;METABOLIC SYNDROME;POSTPRANDIAL;PSYCHOLOGICAL DISTRESS;SURVIVIN;TYPE 1 DIABETES;WAIST","7;6;6;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADIPOKINE;SINGLE-NUCLEOTIDE POLYMORPHISM;COGNITIVE DECLINE;CONTINUOUS GLUCOSE MONITORING;DNA FRAGMENTATION;EXTRAVERSION AND INTROVERSION;GERIATRIC DEPRESSION SCALE;HAPLOTYPE;ADIPONECTIN;ALLELE FREQUENCY;ALPHA (FINANCE);ANTIRETROVIRAL THERAPY;CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE;CONCENTRIC HYPERTROPHY;DNA VACCINATION;DONEPEZIL;GENETICALLY MODIFIED MOUSE;GLYCATED HEMOGLOBIN;HISTONE DEACETYLASE;HUMAN GENOME;INDUCED PLURIPOTENT STEM CELL;LEVODOPA;LYMPHOCYTE SUBSETS;MEMORY CLINIC;METHYLTRANSFERASE;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MOTOR SYMPTOMS;NEVOID BASAL-CELL CARCINOMA SYNDROME;ONCOGENE;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);POSACONAZOLE;PROPIDIUM IODIDE;REPEATED SEQUENCE;SEX HORMONE-BINDING GLOBULIN;STAPHYLOCOCCAL INFECTIONS;TACRINE;TRANSFERRIN SATURATION;TRANSPOSABLE ELEMENT;UNDERWEIGHT;VANCOMYCIN;ZYGOMYCOSIS","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;COGNITION DISORDERS;AGED, 80 AND OVER;ITALY;;ALZHEIMER DISEASE;MIDDLE AGED;AGING;BIOMARKERS;ADULT;ANIMALS;DEPRESSION;DIABETES COMPLICATIONS;KIDNEY FAILURE, CHRONIC;CARDIOVASCULAR DISEASES;DIABETES MELLITUS, TYPE 2;AMNESIA","51;37;37;35;23;22;21;20;18;18;17;13;12;11;9;9;9;8;8;7","DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;BODY COMPOSITION ASSESSMENT AND ANALYSIS;EFFECTS OF KETOGENIC DIET ON HEALTH;LONG-TERM EFFECTS OF TESTOSTERONE ON HEALTH;PHYSIOLOGICAL EFFECTS OF SPACE TRAVEL AND MICROGRAVITY;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ASTHMA;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF HEART FAILURE;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT","6;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CONTINUOUS GLUCOSE MONITORING;DIABETES;AGING;TYPE 1 DIABETES;TYPE 2 DIABETES;DEPRESSION (ECONOMICS);ALZHEIMER'S DISEASE;COGNITIVE DECLINE;HYPOGLYCEMIA;LOW-CARBOHYDRATE DIET;METABOLIC SYNDROME;NUTRITIONAL STATUS;APATHY;CELL DEATH;CLINICAL PRACTICE;CROSS-SECTIONAL STUDY;DEMENTIA;DIAGNOSIS;ELDERLY PATIENTS;GERIATRIC DEPRESSION SCALE","7;7;5;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","TYPE DIABETES;ALZHEIMERS DISEASE;DIABETES MELLITUS;COGNITIVE IMPAIRMENT;NUTRITIONAL FORMULA;ELDERLY PATIENTS;ACUTE CARE;BODY CELL;BRISIGHELLA HEART;CARE HOSPITALS;CELL CARCINOMA;CELL MASS;CHRONIC KIDNEY;CLINICAL RISK;COGNITIVE DECLINE;DAMAGES RELATED;DIABETES METABOLIC;DIABETES-SPECIFIC NUTRITIONAL;ELDERLY WOMEN;HEALTH CARE;HEALTHY PRE-MENOPAUSAL;HEART FAILURE;HEART STUDY;HYPOGLYCEMIC EVENTS;IDENTIFY VASCULAR;IL- POLYMORPHISMS;IMPAIRMENT SUBTYPES;KIDNEY DISEASE;LABORATORY PARAMETERS;MELLITUS REVERSAL","7;6;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEART FAILURE;CD CD;DDAVP TEST;JOB SATISFACTION;AD PATIENTS;ELDERLY WOMEN;FAT MASS;PSYCHOLOGICAL DISTRESS;WAIST CIRCUMFERENCE;ADIPOSITY PARAMETERS;AMNESTIC-MCI PATIENTS;CELLS CD;CLASS IIA;INTIMA-MEDIA THICKNESS;MEDITERRANEAN DIET;MODERATE VALUES;POLYTECHNIC UNIVERSITY;POST-MENOPAUSAL WOMEN;SATISFACTION PSYCHOLOGICAL;SE SP;SERUM CORTISOL;SEX HORMONES;SIGNIFICANTLY LOWER;TESTOSTERONEESTRONE RATIO;TOTAL FAT;WALKING SPEED;WC BETA;WHR BETA;ADULT HEALTHY;ADVANCING AGE","7;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2",15,0.19,3,1,1,1,0,1,3.25,0,1,2,0,1,3,0,1,2,2,1,1,0,0,129,129,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,1.16,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","44 HUMAN SOCIETY;31 BIOLOGICAL SCIENCES;4401 ANTHROPOLOGY;3105 GENETICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","7;6;5;1;1;1","ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BRAIN DISORDERS;DEMENTIA;GENETICS;NEURODEGENERATIVE;NEUROSCIENCES","1;1;1;1;1;1;1;1;1","NEUROLOGICAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"IRCCS_INRCA",2011,69,10.231884057971,2.88405797101449,0.347826086956522,0.260869565217391,0.463768115942029,2.12903225806452,1.2,1.05882352941176,1.14285714285714,0.478260869565217,1,29,15,10,9,0.42,0.22,0.14,0.13,52.12,1.22526897078461,NA,0.405797101449275,0.927536231884058,0.41,0.43,0.453,0.38,"FABRIZIA LATTANZIO;FIORENZA ORLANDO;LIANA SPAZZAFUMO;CARMELA SILVESTRI;MARIO GUERRIERI;LUCIA BRESCINI;ROBERTO GHISELLI;OSCAR CIRIONI;ANGELA MARIE ABBATECOLA;MAURO PROVINCIALI;GIOVANNI LAMURA;ROBERTO TESTA;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;ANDREA GIACOMETTI;ANTONIO DOMENICO PROCOPIO;RAFFAELE ANTONELLI INCALZI;C. SIROLLA;FABIOLA OLIVIERI;CLAUDIO PEDONE","11;10;9;8;8;8;8;8;7;7;6;6;6;6;6;5;5;5;5;5","FABRIZIA LATTANZIO;GIOVANNI LAMURA;GABRIELLA BETTELLI;FIORENZA ORLANDO;EUGENIO MOCCHEGIANI;ANDREA CORSONELLO;LIANA SPAZZAFUMO;ANGELA MARIE ABBATECOLA;RAFFAELE ANTONELLI INCALZI;CLAUDIO PEDONE;MAURO PROVINCIALI;CARMELA SILVESTRI;MARIO GUERRIERI;LUCIA BRESCINI;ROBERTO GHISELLI;OSCAR CIRIONI;C. SIROLLA;FIORELLA MARCELLINI;ANTONIO DOMENICO PROCOPIO;MARCO MALAVOLTA","1.2;1.07;1;0.93;0.89;0.84;0.76;0.69;0.68;0.68;0.67;0.66;0.66;0.66;0.66;0.66;0.59;0.58;0.55;0.51","FABRIZIA LATTANZIO;FIORENZA ORLANDO;LIANA SPAZZAFUMO;ANGELA MARIE ABBATECOLA;MAURO PROVINCIALI;GIOVANNI LAMURA;ROBERTO TESTA;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;ANTONIO DOMENICO PROCOPIO;C. SIROLLA;FABIOLA OLIVIERI;MARCO MALAVOLTA;ROBERTA GALEAZZI;ROBERTO ANTONICELLI;ANNA RITA BONFIGLI;SILVIA BUSTACCHINI;E. MARCHI;MASSIMO BOEMI;MAURIZIO MARRA","11;10;9;7;7;6;6;6;6;5;5;5;4;4;4;3;3;3;3;3","FABRIZIA LATTANZIO;GIOVANNI LAMURA;GABRIELLA BETTELLI;FIORENZA ORLANDO;EUGENIO MOCCHEGIANI;ANDREA CORSONELLO;LIANA SPAZZAFUMO;ANGELA MARIE ABBATECOLA;MAURO PROVINCIALI;C. SIROLLA;FIORELLA MARCELLINI;ANTONIO DOMENICO PROCOPIO;MARCO MALAVOLTA;ROBERTO TESTA;CARLOS CHIATTI;ROBERTINA GIACCONI;MASSIMO BOEMI;MARIA GABRIELLA MELCHIORRE;ROBERTO ANTONICELLI;MIRKO DI ROSA","1.2;1.07;1;0.93;0.89;0.84;0.76;0.69;0.67;0.59;0.58;0.55;0.51;0.5;0.45;0.43;0.42;0.39;0.38;0.38","ANGELA MARIE ABBATECOLA;TAMARA B. HARRIS;LUIGI FERRUCCI;AKIO INUI;ANDREW J.S. COATS;ANNE B. NEWMAN;BRIDGET‐ANNE KIRWAN;BRUNO VELLAS;FILIPPO ROSSI FANELLI;GERALD H. SOKOL;GIOVANNI MANTOVANI;GIUSEPPE ROSANO;JACK M. GURALNIK;JOHN E. MORLEY;JOSEP M. ARGILÉS;JÜRGEN BAUER;KAMYAR KALANTAR‐ZADEH;KENNETH C.H. FEARON;MAURIZIO MUSCARITOLI;MORRIS SCHAMBELAN","1441;1096;1010;986;986;986;986;986;986;986;986;986;986;986;986;986;986;986;986;986","ANGELA MARIE ABBATECOLA;FABRIZIA LATTANZIO;LIANA SPAZZAFUMO;ROBERTO TESTA;ANNA RITA BONFIGLI;MAURIZIO MARRA;FIORENZA ORLANDO;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;C. SIROLLA;I TESTA;MAURO PROVINCIALI;FABIO SALVI;VALERIA MORICHI;GIOVANNI LAMURA;LAZZARO REPETTO;SILVIA BUSTACCHINI;IRMA LAINO;FRANCO BUSCO;SABRINA GARASTO","1441;596;451;375;302;302;260;211;207;184;174;166;163;163;156;148;143;141;132;123","FABRIZIA LATTANZIO;FIORENZA ORLANDO;LIANA SPAZZAFUMO;ANGELA MARIE ABBATECOLA;MAURO PROVINCIALI;ANDREA CORSONELLO;GIOVANNI LAMURA;ROBERTO TESTA;EUGENIO MOCCHEGIANI;ANTONIO DOMENICO PROCOPIO;C. SIROLLA;MARCO MALAVOLTA;ROBERTA GALEAZZI;ROBERTINA GIACCONI;E. MARCHI;ELISA PIERPAOLI;IRMA LAINO;MASSIMO BOEMI;ROBERTO ANTONICELLI;SILVIA BUSTACCHINI","11;10;8;7;7;6;6;6;6;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;ENGINEERING;PHYSICS;BUSINESS;MATHEMATICS;MATERIALS SCIENCE;GEOLOGY;PHILOSOPHY","60;31;12;10;8;7;5;5;4;4;3;3;2;1;1","INTERNAL MEDICINE;GENETICS;ENDOCRINOLOGY;BIOCHEMISTRY;GERONTOLOGY;PSYCHIATRY;IMMUNOLOGY;MICROBIOLOGY;NURSING;PHYSICAL THERAPY;SURGERY;BIOTECHNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;CELL BIOLOGY;PATHOLOGY;DEMOGRAPHY;EMERGENCY MEDICINE;ARTIFICIAL INTELLIGENCE;INTENSIVE CARE MEDICINE;LAW;MACROECONOMICS;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;PHYSICAL MEDICINE AND REHABILITATION","40;19;13;10;9;9;8;8;8;8;8;7;7;7;7;6;6;5;5;4;4;4;4;4;4;4","GENE;IN VIVO;ANTIBIOTICS;BACTERIA;DISEASE;LOGISTIC REGRESSION;POPULATION;DIABETES MELLITUS;OBSERVATIONAL STUDY;GERIATRICS;IN VITRO;CANCER;CONFIDENCE INTERVAL;DEPRESSION (ECONOMICS);KIDNEY DISEASE;ODDS RATIO;RENAL FUNCTION;AGEING;ANTIMICROBIAL;BLOOD PRESSURE;DUCHENNE MUSCULAR DYSTROPHY;EPIDEMIOLOGY;IMMUNE SYSTEM;OBESITY;PATHOGENESIS;PROPORTIONAL HAZARDS MODEL;RESPIRATORY SYSTEM","11;9;8;8;7;7;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","STAPHYLOCOCCUS AUREUS;TYPE 2 DIABETES;GENOTYPE;INSULIN RESISTANCE;TIGECYCLINE;HAZARD RATIO;ANTIBACTERIAL AGENT;BIOFILM;ENTEROCOCCUS;HEALTHY AGEING;LEPTIN;LUNG FUNCTION;METABOLIC SYNDROME;NITRIC OXIDE SYNTHASE;PERIPHERAL BLOOD MONONUCLEAR CELL;PSEUDOMONAS AERUGINOSA;SPIROMETRY;TELOMERE;TYPE 2 DIABETES MELLITUS;ACTIVE AGEING;ACUTE CARE;AGE OF ONSET;ALBUMINURIA;ALLELE;ALZHEIMER'S DISEASE;AMIKACIN;ANAL CANAL;ANORECTAL MANOMETRY;ANOREXIA NERVOSA;ANTIOXIDANT CAPACITY;APOLIPOPROTEIN E;BECK DEPRESSION INVENTORY;BREAST CANCER;CACHEXIA;CANCER CELL;CARDIAC FUNCTION CURVE;CARDIAC MYOCYTE;CARDIOMYOPATHY;CARE WORK;CHROMATIN;CIVIL SOCIETY;CLARITHROMYCIN;CODE (SET THEORY);COLISTIN;CRONBACH'S ALPHA;DATA EXTRACTION;DEMENTIA;DETOXIFICATION (ALTERNATIVE MEDICINE);DEVELOPED COUNTRY;DIABETIC NEPHROPATHY;DIASTOLE;DYSTROPHIN;ELECTROCHEMISTRY;ELECTROPORATION;ENDOCYTOSIS;ESTRONE;ETHYLENEDIAMINETETRAACETIC ACID;EXPLORATORY FACTOR ANALYSIS;FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY;FRACTAL DIMENSION;GAIT ANALYSIS;GAIT TRAINING;GASTROCNEMIUS MUSCLE;GENE EXPRESSION;GENE SILENCING;GENETIC ENHANCEMENT;GENTAMICIN;GERIATRIC ONCOLOGY;GLUCAGON;GLYCEMIC;GLYCOPEPTIDE;GRAM;IMMUNITY;IMMUNIZATION;IMMUNOFLUORESCENCE;INDUCTIVELY COUPLED PLASMA;INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;INTERLEUKIN;IONIC LIQUID;LEAN BODY MASS;LEUKOENCEPHALOPATHY;LIPOPEPTIDE;LYAPUNOV EXPONENT;MAGMA;MARITAL STATUS;MESSENGER RNA;MICROALBUMINURIA;MINIMUM INHIBITORY CONCENTRATION;MITOCHONDRIAL DNA;MUTATION;NEUROMUSCULAR DISEASE;NIGHT WORK;NUCLEAR MEMBRANE;PHOTOCATALYSIS;PLASMA GLUCOSE;PLASMID;POPULATION AGEING;PROINFLAMMATORY CYTOKINE;PROSTATE CANCER;PSEUDOMONAS;PULSE (MUSIC);PULSE WAVE VELOCITY;RADAR IMAGING;RIFAMPICIN;RNA;SAPONIN;SIMILARITY (GEOMETRY);TELOMERASE;TIDAL VOLUME;TORONTO ALEXITHYMIA SCALE;TRANSGENE;TRANSPORTER;TRIMETHOPRIM;TROPONIN;TYPE 1 DIABETES;VITAMIN E;WAIST;ZINC DEFICIENCY (PLANT DISORDER)","6;5;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VANCOMYCIN;ENTEROCOCCUS FAECALIS;ADIPOKINE;ADIPONECTIN;DIFFUSING CAPACITY;HAPLOTYPE;SINGLE-NUCLEOTIDE POLYMORPHISM;CADASIL;CHROMATIN REMODELING;DNA METHYLATION;DNA VACCINATION;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;DYNAMIN;ENDOANAL ULTRASOUND;ENOS;ESTROGEN RECEPTOR;GLUCAGON-LIKE PEPTIDE-1;GRAM-POSITIVE COCCI;GSTP1;INCRETIN;INSULIN RESPONSE;INSULIN SENSITIVITY;INTERLEUKIN 1Β;INVERSE SYNTHETIC APERTURE RADAR;MDX MOUSE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROCOCCACEAE;NITROTYROSINE;POLYMORPHISM (COMPUTER SCIENCE);PROMOTER;RNA SPLICING;TROPONIN COMPLEX;VARIMAX ROTATION","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MALE;HUMANS;FEMALE;AGED;AGED, 80 AND OVER;AGING;;ANTI-BACTERIAL AGENTS;ANIMALS;MIDDLE AGED;MINOCYCLINE;ADULT;DAPTOMYCIN;ITALY;HOSPITALIZATION;DIABETES MELLITUS, TYPE 2;GRAM-POSITIVE BACTERIAL INFECTIONS;MICE;MUSCLE, SKELETAL;TREATMENT OUTCOME","41;40;37;30;22;20;16;16;14;14;14;12;12;12;11;10;9;9;9;9","FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;COPPER AND ZINC IN HEALTH AND DISEASE;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;IMMUNOBIOLOGY OF DENDRITIC CELLS;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY;CHRONIC CEREBRAL HYPOPERFUSION-RELATED NEURODEGENERATIVE DISEASES;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;EFFECTS OF KETOGENIC DIET ON HEALTH;EFFECTS OF PHYSICAL ACTIVITY ON HEALTH OUTCOMES;EFFECTS OF SLEEP DEPRIVATION AND FATIGUE ON PERFORMANCE;EMERGENCY DEPARTMENT CROWDING","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","AGING;DAPTOMYCIN;DEPRESSION (ECONOMICS);TIGECYCLINE;ANTIMICROBIAL SUSCEPTIBILITY TESTING;COMPREHENSIVE GERIATRIC ASSESSMENT;ENDOTHELIAL DYSFUNCTION;ENTEROCOCCUS FAECALIS;GERIATRIC ASSESSMENT;GLOMERULAR FILTRATION RATE;PATHOGENESIS;ADIPOKINES;ADVERSE DRUG EVENTS;DIABETES;EXERCISE;HEALTHY AGEING;IDENTIFICATION (BIOLOGY);INFORMAL CAREGIVING;METABOLIC SYNDROME;OBESITY","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ANIMAL MODEL;VIVO EFFICACY;ADVERSE DRUG;ANALYSE RÉTROSPECTIVE;ANS DACTIVITÉ;CHEZ LES;DASSISTANCE À;DE QUATRE;DOMICILE CHEZ;DRUG REACTIONS;DUCHENNE MUSCULAR;ELDERLY HOSPITALIZED;EMERGENCY DEPARTMENT;EN NUTRITION;ENDOTHELIAL NITRIC;ENTEROCOCCUS FAECALIS;ENTÉRALE NED;FILTRATION RATE;FRAGILES EN;GERIATRIC PATIENTS;GLOMERULAR FILTRATION;GLUCAGON-LIKE PEPTIDE;GRAM-POSITIVE COCCI;HOME RESIDENTS;HOSPITALIZED PATIENTS;LES PATIENTS;METABOLIC SYNDROME;MUSCULAR DYSTROPHY;NED ANALYSE;NITRIC OXIDE","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DIABETIC PATIENTS;FUNCTIONAL STATUS;LAUR-CKK-NH DIMER;BUYING PRESCRIBED;FUNCTIONAL DECLINE;HOME CARE;RENAL DISEASE;TYPE DIABETES;WORSENING DISABILITY;CHANNEL COMPLEX;CONTROL SUBJECTS;ENDOTHELIAL FUNCTION;HEALTHY AGEING;HYPERTENSIVE PATIENTS;LEPTINADIPONECTIN RATIO;MAIN OUTCOME;PRESCRIBED MEDICATIONS;ANTIMICROBIAL ACTIVITY;BIASP BID;CHRONIC KIDNEY;CLINICAL TRIALS;CREATININE CLEARANCE;DMD PATIENTS;DOPPLER VELOCITY;EXPLAINED VARIANCE;FOODBORNE DISEASES;GSTP SILENCING;IDENTIFY PATIENTS;INCREASED RISK;INSULIN SECRETION","6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3",24,0.35,5.06,4,1.5,1,0,1,4,0,1,4.25,0,1,3,1,1,1,1,1.75,1.75,0,0,93.25,93.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,14,2250,2.22,0,0,3,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,2,0,0,1,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","AGING;CLINICAL RESEARCH;PREVENTION","1;1;1","GENERIC HEALTH RELEVANCE","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,2,2860452,298808.5,4.5,10,5.5,1,18,280391.46968254,0.246084519183562,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;AALTO UNIVERSITY;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AUTONOMOUS UNIVERSITY OF BARCELONA;CETEMMSA TECHNOLOGICAL CENTRE (SPAIN);CULMINATUM INNOVATION (FINLAND);FLORALIS (FRANCE);FUNDACIÓ EURECAT;ISTANBUL METROPOLITAN MUNICIPALITY;LAUREA UNIVERSITY OF APPLIED SCIENCES;MARCHE POLYTECHNIC UNIVERSITY;RISE RESEARCH INSTITUTES OF SWEDEN;SABANCI UNIVERSITY;SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY;SOUTH EAST HEALTH TECHNOLOGIES ALLIANCE;SPRING TECHNO (GERMANY);TEL AVIV SOURASKY MEDICAL CENTER;UNIVERSITY OF CAMERINO;UNIVERSITY OF GALWAY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);CSA-CA - COORDINATION (OR NETWORKING) ACTIONS (FUNDING SCHEME);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2011-7 (CALL FOR PROPOSAL);FP7-REGIONS - SPECIFIC PROGRAMME ""CAPACITIES"": REGIONS OF KNOWLEDGE AND SUPPORT FOR REGIONAL RESEARCH-DRIVEN CLUSTERS (PROGRAMME);FP7-REGIONS-2010-1 (CALL FOR PROPOSAL)","1;1;1;1;1;1","42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4207 SPORTS SCIENCE AND EXERCISE","2;2;1;1","AGING;CLINICAL RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;HEALTH SERVICES;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);NEURODEGENERATIVE;PATIENT SAFETY","2;2;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;INJURIES AND ACCIDENTS","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS;C14 GEOGRAPHY AND ENVIRONMENTAL STUDIES","1;1",NA,NA,9,"PUBLIC LIBRARY OF SCIENCE","9","44 HUMAN SOCIETY;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;4401 ANTHROPOLOGY;3105 GENETICS;49 MATHEMATICAL SCIENCES;3109 ZOOLOGY;3202 CLINICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;4905 STATISTICS","9;6;6;4;3;2;1;1;1;1","CARDIOVASCULAR;DIABETES;HEART DISEASE;RARE DISEASES;BRAIN DISORDERS;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);KIDNEY DISEASE;MUSCULAR DYSTROPHY;NEUROSCIENCES;PEDIATRIC;PERIPHERAL NEUROPATHY","2;2;2;2;1;1;1;1;1;1;1;1;1","METABOLIC AND ENDOCRINE;CARDIOVASCULAR","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","3","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;1",NA,NA,NA,NA
"IRCCS_INRCA",2012,65,8.86153846153846,2.55384615384615,0.384615384615385,0.292307692307692,0.384615384615385,2.11538461538462,1.38888888888889,1.26666666666667,1.47058823529412,0.430769230769231,2,26,16,12,4,0.4,0.25,0.18,0.06,56.74,1.35840851147283,5.33836858006042,0.353846153846154,0.938461538461538,0.417,0.308,0.324,0.275,"LIANA SPAZZAFUMO;ROBERTO ANTONICELLI;FABRIZIA LATTANZIO;ROBERTO TESTA;CLAUDIO FRANCESCHI;ANTONIO CHERUBINI;ANTONIO DOMENICO PROCOPIO;FABIOLA OLIVIERI;ANGELA MARIE ABBATECOLA;MARIA GABRIELLA MELCHIORRE;C. SIROLLA;ANTONIO CERIELLO;ANDREA PRINCIPI;RAFFAELLA LAZZARINI;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;FRANCESCA MARCHEGIANI;ANNA RITA BONFIGLI;MAURIZIO CARDELLI;ROBERTA GALEAZZI","8;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3","MARIA GABRIELLA MELCHIORRE;MARINA GIAMPIERI;ANDREA PRINCIPI;ROBERTO ANTONICELLI;NICOLA MAGNAVITA;A. FILENI;LIANA SPAZZAFUMO;FABRIZIA LATTANZIO;ANDREA CORSONELLO;LAZZARO REPETTO;ROBERTO TESTA;FRANCESCA MARCHEGIANI;EUGENIO MOCCHEGIANI;CAROLA LOCATELLI;MARCELLA CICERCHIA;MAURO PROVINCIALI;MAURIZIO CARDELLI;ANTONIO CERIELLO;CLAUDIO FRANCESCHI;WALTER GIANNI","1.46;1;0.94;0.93;0.92;0.92;0.9;0.89;0.72;0.69;0.67;0.62;0.62;0.58;0.58;0.55;0.53;0.52;0.52;0.51","LIANA SPAZZAFUMO;ROBERTO ANTONICELLI;FABRIZIA LATTANZIO;ROBERTO TESTA;ANTONIO CHERUBINI;ANTONIO DOMENICO PROCOPIO;FABIOLA OLIVIERI;ANGELA MARIE ABBATECOLA;MARIA GABRIELLA MELCHIORRE;C. SIROLLA;ANDREA PRINCIPI;RAFFAELLA LAZZARINI;ANDREA CORSONELLO;EUGENIO MOCCHEGIANI;FRANCESCA MARCHEGIANI;ANNA RITA BONFIGLI;MAURIZIO CARDELLI;ROBERTA GALEAZZI;WALTER GIANNI;MASSIMO BOEMI","8;8;7;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3","MARIA GABRIELLA MELCHIORRE;MARINA GIAMPIERI;ANDREA PRINCIPI;ROBERTO ANTONICELLI;A. FILENI;LIANA SPAZZAFUMO;FABRIZIA LATTANZIO;ANDREA CORSONELLO;LAZZARO REPETTO;ROBERTO TESTA;FRANCESCA MARCHEGIANI;EUGENIO MOCCHEGIANI;CAROLA LOCATELLI;MARCELLA CICERCHIA;MAURO PROVINCIALI;MAURIZIO CARDELLI;WALTER GIANNI;ANGELA MARIE ABBATECOLA;GIOVANNI LAMURA;ANGELO SCUTERI","1.46;1;0.94;0.93;0.92;0.9;0.89;0.72;0.69;0.67;0.62;0.62;0.58;0.58;0.55;0.53;0.51;0.47;0.44;0.44","ANGELO SCUTERI;ALAN J. SINCLAIR;LUIGI FERRUCCI;CAROLINE NICHOLSON;CATHERINE FÉART;ENRIQUE VEGA;FERNANDO RODRÍGUEZ‐ARTALEJO;FRANÇOIS BÉLAND;GAETANO SERVIDDIO;GIOVANNI E. MANN;HOWARD BERGMAN;JEROME BICKENBACH;JOSÉ VIÑA;KENNETH ROCKWOOD;LAURE CARCAILLON‐BENTATA;LEOCADIO RODRÍGUEZ‐MAÑAS;LINDA P. FRIED;LUIS MIGUEL GUTIÉRREZ‐ROBLEDO;MAGALI GONZÁLEZ‐COLAÇO HARMAND;MARTHA PELÁEZ","1123;1097;1075;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048;1048","ANGELO SCUTERI;ROBERTO ANTONICELLI;ANTONIO DOMENICO PROCOPIO;LIANA SPAZZAFUMO;ANGELA MARIE ABBATECOLA;FABIOLA OLIVIERI;ROBERTA GALEAZZI;ROBERTO TESTA;RINA RECCHIONI;FIORELLA MARCHESELLI;FABRIZIA LATTANZIO;RAFFAELLA LAZZARINI;ANTONIO CHERUBINI;MARIA LORENZI;ROSAMARIA LISA;ANNA RITA BONFIGLI;SERENA MARIOTTI;EUGENIO MOCCHEGIANI;ROBERTINA GIACCONI;ANDREA BELLUIGI","1123;983;706;614;552;513;513;495;423;413;341;293;278;230;230;196;193;184;138;130","LIANA SPAZZAFUMO;ROBERTO ANTONICELLI;FABRIZIA LATTANZIO;ROBERTO TESTA;ANGELA MARIE ABBATECOLA;ANTONIO CHERUBINI;MARIA GABRIELLA MELCHIORRE;ANDREA CORSONELLO;ANDREA PRINCIPI;ANTONIO DOMENICO PROCOPIO;C. SIROLLA;EUGENIO MOCCHEGIANI;ANNA RITA BONFIGLI;MAURO PROVINCIALI;A. FILENI;FABIOLA OLIVIERI;FELICE STROLLO;FRANCESCA MARCHEGIANI;MASSIMO BOEMI;ROBERTA GALEAZZI","8;8;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;ECONOMICS;PSYCHOLOGY;POLITICAL SCIENCE;COMPUTER SCIENCE;SOCIOLOGY;BUSINESS;CHEMISTRY;ENGINEERING;PHYSICS;GEOGRAPHY;HISTORY;MATHEMATICS;PHILOSOPHY","62;21;14;14;9;7;7;6;5;5;4;1;1;1;1","INTERNAL MEDICINE;GERONTOLOGY;PATHOLOGY;ENDOCRINOLOGY;GENETICS;ENVIRONMENTAL HEALTH;PSYCHIATRY;CARDIOLOGY;NURSING;BIOCHEMISTRY;LAW;MACROECONOMICS;DEMOGRAPHY;IMMUNOLOGY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;SOCIAL PSYCHOLOGY;SURGERY;CANCER RESEARCH;CLINICAL PSYCHOLOGY;FAMILY MEDICINE","42;15;15;13;12;10;10;8;8;6;6;6;5;5;5;5;5;5;4;4;4","DISEASE;GENE;POPULATION;CONFIDENCE INTERVAL;DEPRESSION (ECONOMICS);DIABETES MELLITUS;MYOCARDIAL INFARCTION;COGNITION;COHORT;HEALTH CARE;KIDNEY DISEASE;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;ALTERNATIVE MEDICINE;BIOMARKER;BLOOD PRESSURE;CANCER;CLINICAL TRIAL;CROSS-SECTIONAL STUDY;INSULIN;LOGISTIC REGRESSION;ODDS RATIO;OLDER PEOPLE;OXIDATIVE STRESS;POISON CONTROL;STROKE (ENGINE)","11;10;10;7;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","DEMENTIA;TYPE 2 DIABETES;ACUTE CORONARY SYNDROME;INSULIN RESISTANCE;TROPONIN;ALZHEIMER'S DISEASE;HAZARD RATIO;ACTIVE AGEING;AMBULATORY BLOOD PRESSURE;DOWNREGULATION AND UPREGULATION;GENE EXPRESSION;GENOTYPE;METALLOTHIONEIN;MICRORNA;ORIGINALITY;ST ELEVATION;SUICIDE PREVENTION;TROPONIN T;WESTERN BLOT;ABSOLUTE RISK REDUCTION;ANTIDEPRESSANT;ARGININE;ARTERIAL STIFFNESS;BAYESIAN MULTIVARIATE LINEAR REGRESSION;BIOFILM;CD31;CENTENARIAN;CLINICAL ENDPOINT;DNA SEQUENCING;DULOXETINE;EFFECTS OF SLEEP DEPRIVATION ON COGNITIVE PERFORMANCE;EMBRYONIC STEM CELL;ESTRONE;EU COUNTRIES;EUTHYROID;FETUS;FINE-NEEDLE ASPIRATION;GENE ISOFORM;GENOME;GESTATION;GLUTAMATE RECEPTOR;GROWTH FACTOR;HEAD AND NECK CANCER;HEALTH ADMINISTRATION;HEALTH ECONOMICS;HEALTH TECHNOLOGY;HYPOGLYCEMIA;IMMUNITY;IMMUNOPHENOTYPING;INFORMED CONSENT;INJURY PREVENTION;ISCHAEMIC STROKE;JEJUNOSTOMY;LATE LIFE DEPRESSION;LDL CHOLESTEROL;LEPTIN;MARITAL STATUS;MEDICAL MALPRACTICE;MEMORY CONSOLIDATION;MESENCHYME;MESSENGER RNA;METABOLIC SYNDROME;MINIMUM DATA SET;MYCOSIS FUNGOIDES;NITRIC OXIDE SYNTHASE;ODDS;PARAOXONASE;PATIENT PARTICIPATION;PATIENT SAFETY;PHARMACODYNAMICS;PLASMA GLUCOSE;POSTERIOR POLE;PROMOTION (CHESS);PROTOCOL (SCIENCE);PSORALEN;PULSE WAVE VELOCITY;PUVA THERAPY;RADAR IMAGING;RECOGNITION MEMORY;REFRACTIVE ERROR;REVASCULARIZATION;SEMINOMA;SOCIOECONOMIC STATUS;SOMATIC CELL;STAPHYLOCOCCUS AUREUS;SUBFAMILY;SUPERIOR MESENTERIC ARTERY SYNDROME;SYNAPTIC PLASTICITY;TELEMEDICINE;TELOMERASE;TELOMERE;THYROID FUNCTION;TRANSFECTION;TRANSGENE;TRANSISTOR;TRIIODOTHYRONINE;TYPE 1 DIABETES;TYPE 2 DIABETES MELLITUS;UMBILICAL VEIN;UNSTABLE ANGINA;WAIST;WELFARE STATE;ZINC DEFICIENCY (PLANT DISORDER)","5;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COGNITIVE DECLINE;TROPONIN COMPLEX;WORKPLACE VIOLENCE;ADIPOKINE;ADIPONECTIN;AMNION;AMPA RECEPTOR;ASYMMETRIC DIMETHYLARGININE;COMPARATIVE GENOMIC HYBRIDIZATION;COPY-NUMBER VARIATION;DEFENSIVE MEDICINE;DIPPER;DNA MICROARRAY;DOMESTIC VIOLENCE;DONEPEZIL;ESCITALOPRAM;GENETICALLY MODIFIED MOUSE;GENOTYPING;GESTATIONAL DIABETES;GLUCOSE HOMEOSTASIS;GLYCATED HAEMOGLOBIN;GLYCATED HEMOGLOBIN;HUMAN GENOME;INDUCED PLURIPOTENT STEM CELL;INSULIN RECEPTOR;INSULIN-LIKE GROWTH FACTOR;INVERSE SYNTHETIC APERTURE RADAR;MICROARRAY ANALYSIS TECHNIQUES;PERIRHINAL CORTEX;POLYMORPHISM (COMPUTER SCIENCE);PON1;PRENATAL DIAGNOSIS;QUORUM SENSING;SEXUAL ABUSE;SUBTHRESHOLD CONDUCTION;VANCOMYCIN;VERBAL ABUSE;VITREOUS CHAMBER","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;ITALY;DIABETES MELLITUS, TYPE 2;MIDDLE AGED;;ALZHEIMER DISEASE;CARDIOVASCULAR DISEASES;AGED, 80 AND OVER;BIOMARKERS;ADULT;DEPRESSION;RISK FACTORS;AGING;MYOCARDIAL INFARCTION;ZINC;ACUTE CORONARY SYNDROME;COGNITION DISORDERS","47;34;33;31;21;17;17;15;15;15;14;12;10;9;9;8;8;8;7;7","DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MULTILEVEL PERSPECTIVES ON PROSOCIAL BEHAVIOR AND VOLUNTEERING;PREVALENCE AND CORRELATES OF ELDER ABUSE AND NEGLECT;COPPER AND ZINC IN HEALTH AND DISEASE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;SHARED DECISION MAKING IN HEALTHCARE;WORKPLACE BULLYING AND HARASSMENT IN PROFESSIONAL ENVIRONMENTS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;CHOLESTEROL-LOWERING TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DEVELOPMENTAL PERSPECTIVE ON MOTOR SKILL COMPETENCE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT;EMERGENCY DEPARTMENT CROWDING","3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","DEPRESSION (ECONOMICS);DIABETES;COGNITIVE DECLINE;CONTINUOUS GLUCOSE MONITORING;CROSS-SECTIONAL STUDY;STROKE (ENGINE);VOLUNTEERING;ACTIVE AGEING;ALZHEIMER'S DISEASE;BIOMARKERS;BLOOD PRESSURE;CANCER COMMUNICATION;ELDER MISTREATMENT;ENDOTHELIAL DYSFUNCTION;GLYCEMIC CONTROL;HYPERTENSION;METALLOTHIONEIN;PATHOGENESIS;PHYSICIAN BURNOUT;PHYSICIAN COMMUNICATION","5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ALZHEIMERS DISEASE;ELDERLY PATIENTS;MYOCARDIAL INFARCTION;ACUTE CORONARY;CANCER PATIENTS;CROSS-SECTIONAL STUDY;DIABETIC SUBJECTS;ELDERLY CANCER;ELDERLY PEOPLE;EUROPEAN COUNTRIES;GLYCATED HEMOGLOBIN;PROTON PUMP;PUMP INHIBITORS;SOMATIC COMPLAINTS;ST-ELEVATION MYOCARDIAL;TYPE DIABETES;TYPE DIABETIC;ABPM PARAMETER;AC DELEGATES;AC POLYMORPHISM;ACS STUDY;ACUTE CARE;ACUTE MYOCARDIAL;ADMA LEVELS;ADMINISTRATIVE DATA;ADRENAL MASSES;ADULT ELDERLY;ADULT MAMMALIAN;AGE-RELATED DIFFERENCES;AGED ANIMALS","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","LEFT EYE;PATIENTS AFFECTED;BLOOD PRESSURE;BUYING PRESCRIBED;CARDIOVASCULAR RISK;ELDERLY PATIENTS;HR CI;PHYSICAL PERFORMANCE;PRESCRIBED MEDICATIONS;SOMATIC COMPLAINTS;AIP AIP;CLINICAL TRIALS;CVDCARDIAC MORTALITY;DIETARY HABITS;ENDOTHELIAL CELLS;HOUR AMBULATORY;LEPTINADIPONECTIN RATIO;MYOCARDIAL INFARCTION;PERIRHINAL CORTEX;PLASMA LEVELS;PON POLYMORPHISM;RISK FACTOR;RISK FACTORS;SUBTHRESHOLD DEPRESSION;ADMA LEVELS;ALZHEIMERS DISEASE;ARTERIAL STIFFNESS;BP MONITORING;CARDIOVASCULAR DISEASE;CHRONIC KIDNEY","6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3",27,0.42,3.4,3,1,1.75,1,4,1,1,1,4,0,1,3,1,1,0,1,3.5,2,0,0,93,93,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,130,1.33,0,0,3,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","1;1;1;1","AGING;CHRONIC PAIN;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;PAIN RESEARCH","1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,4,4573864,503684.18,4.75,9.75,6.5,1,24.5,661859.70958153,0.0982081233515441,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;AGE PLATFORM EUROPE;UNIVERSITY OF EAST ANGLIA;AOK;ARTTIC (FRANCE);CLININFO (FRANCE);EUROCARERS;EUROHEALTHNET;FEDERAL CENTRE FOR HEALTH EDUCATION;GABO:MI;GHENT UNIVERSITY;HANZE UNIVERSITY OF APPLIED SCIENCES;HEIDELBERG UNIVERSITY;LATVIAN COUNCIL OF SCIENCE;LUND UNIVERSITY;MADRID HEALTH SERVICE;METRALABS (GERMANY);NATIONAL UNIVERSITY HOSPITAL OF ICELAND;NETHERLANDS ORGANISATION FOR APPLIED SCIENTIFIC RESEARCH;NEWCASTLE UNIVERSITY","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","4","COALITION S;EC & ERC - EUROPEAN UNION","4;4","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2012-INNOVATION-1 (CALL FOR PROPOSAL);CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2011-7 (CALL FOR PROPOSAL)","3;3;3;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;32 BIOMEDICAL AND CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4602 ARTIFICIAL INTELLIGENCE;4605 DATA MANAGEMENT AND DATA SCIENCE;4608 HUMAN-CENTRED COMPUTING","3;3;1;1;1;1;1","CLINICAL RESEARCH;AGING;BEHAVIORAL AND SOCIAL SCIENCE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEALTH SERVICES;PREVENTION","3;1;1;1;1;1","GENERIC HEALTH RELEVANCE","3","3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING","1","NOT SITE-SPECIFIC CANCER","1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS;C20 SOCIAL WORK AND SOCIAL POLICY;D32 ART AND DESIGN: HISTORY, PRACTICE AND THEORY","1;1;1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2013,79,10,2.59493670886076,0.278481012658228,0.316455696202532,0.354430379746835,1.95238095238095,1.15789473684211,1.78571428571429,1.27272727272727,0.455696202531646,1,25,37,5,8,0.32,0.47,0.06,0.1,36.16,1.03645453645614,5.56888888888889,0.392405063291139,0.974683544303797,0.51,0.346,0.364,0.319,"ANDREA CORSONELLO;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;MAURO PROVINCIALI;LUIGI FERRUCCI;STEFANIA BANDINELLI;GIAN PAOLO CEDA;LIANA SPAZZAFUMO;FULVIO LAURETANI;ELISA PIERPAOLI;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;MINDAUGAS STANKŪNAS;ANGELA MARIE ABBATECOLA;MARIA GABRIELLA MELCHIORRE;F. DE VITA;HENRIQUE BARROS;STEFANO VOLPATO;FIORENZA ORLANDO;O. SCARPINO","12;11;9;8;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4","EUGENIO MOCCHEGIANI;ANDREA CORSONELLO;MAURO PROVINCIALI;ANTONIO CHERUBINI;FABRIZIA LATTANZIO;ELISA PIERPAOLI;MAURIZIO CARDELLI;FELICE STROLLO;MARCELLO MAGGIO;MARCO MALAVOLTA;LIANA SPAZZAFUMO;O. SCARPINO;PATRIZIA FATTORETTI;LUIGI FERRUCCI;STEFANIA BANDINELLI;GIAN PAOLO CEDA;G. GHETTI;SANDRO FIORETTI;FRANCESCO PIACENZA;ROBERTINA GIACCONI","1.73;1.51;1.16;1.14;1.06;1.02;1;0.78;0.73;0.73;0.7;0.63;0.62;0.6;0.6;0.6;0.58;0.58;0.56;0.56","ANDREA CORSONELLO;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;MAURO PROVINCIALI;LIANA SPAZZAFUMO;ELISA PIERPAOLI;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;ANGELA MARIE ABBATECOLA;MARIA GABRIELLA MELCHIORRE;F. DE VITA;FIORENZA ORLANDO;O. SCARPINO;FRANCESCO PIACENZA;ROBERTO BERNABEI;ROBERTINA GIACCONI;FELICE STROLLO;LAURA COSTARELLI;TIZIANA CASOLI;PATRIZIA FATTORETTI","12;11;9;8;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","EUGENIO MOCCHEGIANI;ANDREA CORSONELLO;MAURO PROVINCIALI;ANTONIO CHERUBINI;FABRIZIA LATTANZIO;ELISA PIERPAOLI;MAURIZIO CARDELLI;FELICE STROLLO;MARCELLO MAGGIO;MARCO MALAVOLTA;LIANA SPAZZAFUMO;O. SCARPINO;PATRIZIA FATTORETTI;G. GHETTI;FRANCESCO PIACENZA;ROBERTINA GIACCONI;LAURA COSTARELLI;TIZIANA CASOLI;MARIA GABRIELLA MELCHIORRE;FRANCESCA MARCHEGIANI","1.73;1.51;1.16;1.14;1.06;1.02;1;0.78;0.73;0.73;0.7;0.63;0.62;0.58;0.56;0.56;0.56;0.54;0.53;0.5","ANTONIO CHERUBINI;GIAN PAOLO CEDA;LUIGI FERRUCCI;STEFANIA BANDINELLI;TIZIANA CASOLI;LIANA SPAZZAFUMO;STEFANO VOLPATO;FRANCO BUSCO;ANDREA CORSONELLO;FRANCESCO LANDI;ANA M. GONZALÉZ‐PARAMÁS;BRUNO MEZZETTI;CELESTINO SANTOS‐BUELGA;FRANCESCA GIAMPIERI;GIUSEPPINA DI STEFANO;JOSÉ L. QUILES;JOSÉ M. ÁLVAREZ-SUÁREZ;MARIO D. CORDERO;MAURIZIO BATTINO;SARA TULIPANI","518;447;447;447;409;402;363;354;350;339;336;336;336;336;336;336;336;336;336;336","ANTONIO CHERUBINI;TIZIANA CASOLI;LIANA SPAZZAFUMO;FRANCO BUSCO;ANDREA CORSONELLO;GIUSEPPINA DI STEFANO;FABRIZIA LATTANZIO;MAURO PROVINCIALI;ANGELA MARIE ABBATECOLA;ELISA PIERPAOLI;FIORENZA ORLANDO;ANTONIO DOMENICO PROCOPIO;RINA RECCHIONI;ANNA RITA BONFIGLI;ROBERTO TESTA;N. JUKIC-PELADIC;G. GHETTI;ANGELO SCUTERI;PATRIZIA FATTORETTI;ALESSANDRA BARUCCA","518;409;402;354;350;336;316;258;241;176;168;155;130;108;108;101;98;97;88;81","ANDREA CORSONELLO;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;MAURO PROVINCIALI;ELISA PIERPAOLI;LIANA SPAZZAFUMO;MARIA GABRIELLA MELCHIORRE;ANGELA MARIE ABBATECOLA;EUGENIO MOCCHEGIANI;FELICE STROLLO;FIORENZA ORLANDO;MARCO MALAVOLTA;PATRIZIA FATTORETTI;TIZIANA CASOLI;ANDREA SANTARELLI;MARTA BALIETTI;ANDREA BASSO;FRANCESCO PIACENZA;LAURA COSTARELLI;ROBERTINA GIACCONI","12;11;9;7;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;ECONOMICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;PHYSICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE","70;32;8;7;7;6;6;4;4;4;3;2;2","INTERNAL MEDICINE;ENDOCRINOLOGY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PATHOLOGY;PSYCHIATRY;BIOCHEMISTRY;GERONTOLOGY;CELL BIOLOGY;CANCER RESEARCH;PHYSICAL THERAPY;NEUROSCIENCE;SURGERY;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;DEMOGRAPHY;ECONOMIC GROWTH;PEDIATRICS;ANATOMY;CLINICAL PSYCHOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;LAW;NURSING","45;19;18;15;14;13;12;11;11;10;9;8;7;7;6;6;5;5;5;4;4;4;4;4;4","GENE;POPULATION;DISEASE;CANCER;SENESCENCE;DIABETES MELLITUS;IMMUNE SYSTEM;INFLAMMATION;RECEPTOR;GERIATRICS;HEALTH CARE;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;BODY MASS INDEX;CELL GROWTH;CONFIDENCE INTERVAL;IN VITRO;SARCOPENIA;AGEING;CELL;COGNITION;CONFOUNDING;CROSS-SECTIONAL STUDY;DNA;INSULIN;LONGEVITY;OLDER PEOPLE;OXIDATIVE STRESS;POISON CONTROL;STIMULATION","17;14;11;10;9;8;7;7;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","PHENOTYPE;DEMENTIA;GENOTYPE;INNATE IMMUNE SYSTEM;TYPE 2 DIABETES;CARCINOGENESIS;HAZARD RATIO;NEURODEGENERATION;SUICIDE PREVENTION;ACUTE CARE;ALZHEIMER'S DISEASE;BASAL (MEDICINE);BREAST CANCER;CANCER CELL;COGNITIVE IMPAIRMENT;DNA DAMAGE;EPIGENETICS;GROWTH FACTOR;INSULIN RESISTANCE;MICROGLIA;MICRORNA;PERIPHERAL BLOOD MONONUCLEAR CELL;PLACEBO;PROINFLAMMATORY CYTOKINE;STAPHYLOCOCCUS AUREUS;TOLERABILITY;TRANSGENE;VITAMIN E","6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CELLULAR SENESCENCE;SINGLE-NUCLEOTIDE POLYMORPHISM;ELDER ABUSE;GENETICALLY MODIFIED MOUSE;INSULIN-LIKE GROWTH FACTOR;SEXUAL ABUSE;TOLL-LIKE RECEPTOR;ANGIOTENSIN RECEPTOR BLOCKERS;BRAIN-DERIVED NEUROTROPHIC FACTOR;CAREGIVER BURDEN;CELL CYCLE CHECKPOINT;COGNITIVE DECLINE;DIABETIC FOOT ULCER;DNA METHYLATION;DOCOSAHEXAENOIC ACID;DOMESTIC VIOLENCE;EICOSAPENTAENOIC ACID;ELECTROCHEMOTHERAPY;FERRIC REDUCING ABILITY OF PLASMA;FRONTOTEMPORAL DEMENTIA;GENOME INSTABILITY;HAPLOTYPE;HOMEOSTATIC MODEL ASSESSMENT;MAMMARY GLAND;MAMMARY TUMOR;METABOTROPIC GLUTAMATE RECEPTOR;NEOPLASTIC TRANSFORMATION;NOS1;OSTEONECROSIS OF THE JAW;OXYGEN RADICAL ABSORBANCE CAPACITY;PATTERN RECOGNITION RECEPTOR;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);QUANTITATIVE COMPUTED TOMOGRAPHY;RESPIRATORY DISTURBANCE INDEX;REVERSE TRANSCRIPTASE;SEXUAL COERCION;SMALL HAIRPIN RNA;STAPHYLOCOCCAL INFECTIONS;TAQMAN;TLR2;TOCOPHEROL;VANCOMYCIN","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;ITALY;AGED, 80 AND OVER;AGING;;MIDDLE AGED;DIABETES MELLITUS, TYPE 2;ADULT;CARDIOVASCULAR DISEASES;ANIMALS;RISK FACTORS;CELLULAR SENESCENCE;MITOCHONDRIA;ALZHEIMER DISEASE;BIOMARKERS;CROSS-SECTIONAL STUDIES;MICE","58;41;37;30;22;20;20;17;16;15;12;11;10;10;9;9;8;8;8;8","CELLULAR SENESCENCE AND AGING-RELATED DISEASES;PREVALENCE AND CORRELATES OF ELDER ABUSE AND NEGLECT;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;EMERGENCY DEPARTMENT CROWDING;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;INNATE IMMUNE RECOGNITION AND SIGNALING PATHWAYS;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;NEUROIMMUNE INTERACTION IN PSYCHIATRIC DISORDERS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;ROLE OF MICROGLIA IN NEUROLOGICAL DISORDERS;ROLE OF OXIDATIVE STRESS IN HEALTH AND DISEASE;STANDARDISATION AND MANAGEMENT OF COPD;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ANTIOXIDANTS AND FREE RADICALS IN HEALTH AND DISEASE","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","SENESCENCE;AGING;DIABETES;CELLULAR SENESCENCE;CROSS-SECTIONAL STUDY;ELDER ABUSE;GERIATRIC ASSESSMENT;HEALTH CARE UTILIZATION;IGF-1;INSULIN-LIKE GROWTH FACTORS;ACUTE CARE;ADAPTIVE IMMUNITY REGULATION;BASAL (MEDICINE);BODY COMPOSITION;CANCER PROGRESSION;CONTINUOUS GLUCOSE MONITORING;COPD;DEPRESSION (ECONOMICS);FRAILTY;NEURODEGENERATION","9;7;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CELLULAR SENESCENCE;PROTON PUMP;PUMP INHIBITORS;TYPE DIABETES;ACUTE CARE;AGE-RELATED DISEASES;ALZHEIMER DISEASE;ALZHEIMERS DISEASE;ANIMAL MODEL;BIOACTIVITY PLAYS;CARDIOVASCULAR RISK;CELL CARCINOMA;CELL REJUVENATION;DISEASE PATIENTS;EUROPEAN STUDY;INSULIN-LIKE GROWTH;ITALIAN HEALTHCARE;LOWER TRABECULAR;MONONUCLEAR CELL;MOUSE MODEL;PERIPHERAL MONONUCLEAR;SENESCENCE SURVEILLANCE;TRABECULAR BONE;ACTIVATION MODALITIES;ACTIVE FACTORS;ACUTE CORONARY;ACUTE MEDICAL;ADENOCARCINOMA CELLS;ADMINISTRATION TECHNIQUES;ADULTS ADMITTED","5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","PPI USERS;ACUTE CARE;BODY COMPOSITION;UNMET CARE;AD PATIENTS;AGE SEX;GENE EXPRESSION;IMMUNE SYSTEM;MN FREQUENCY;MT DNA;UA PATIENTS;ACTING FACTORS;CARE SERVICES;GROWTH ARREST;HORMONALLY ACTING;IGF- LEVELS;ORAL CANCER;PATIENTS ADMITTED;SENESCENT-LIKE GROWTH;SOCIAL CARE;TLR SIGNALING;TLRPOS GENOTYPES;TYPE DIABETES;CANCER CELLS;CELL LINES;COGNITIVE PERFORMANCE;CVD RISK;DIABETIC PATIENTS;HEALTH CARE;HIGH-DOSE PPIS","7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3",40,0.51,4.5,3,3,2,44,6.25,2,0,1,4,2,0,3,2,2,1.25,7,2,1.75,0,0,103.25,103.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4,10564,1.01,1,1,977,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","ATHEROSCLEROSIS;CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY","1;1;1;1;1;1;1","CARDIOVASCULAR","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,3,6281700,258339.07,5,23,9.66666666666667,1,37.3333333333333,803122.594040639,0.0983660534346796,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;UNIVERSITÄT INNSBRUCK;AGE PLATFORM EUROPE;AMSTERDAM UMC LOCATION VUMC;ANGLIA RUSKIN UNIVERSITY;AUTONOMOUS UNIVERSITY OF MADRID;AZIENDA SANITARIA DI FIRENZE;AZIENDA UNITÀ SANITARIA LOCALE 11 DI EMPOLI;BIOMECHANICS INSTITUTE OF VALENCIA;CARDIFF METROPOLITAN UNIVERSITY;CENTER FOR SOCIAL AND ECONOMIC RESEARCH;CENTRE FOR EUROPEAN POLICY STUDIES;CENTRE FOR SOCIAL SCIENCES;CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE;CRANFIELD UNIVERSITY;DÉLÉGATION PARIS 11;EUROPEAN CENTRE FOR SOCIAL WELFARE POLICY AND RESEARCH;EVERCYTE (AUSTRIA);FRIEDRICH SCHILLER UNIVERSITY JENA;FUNDACIÓ SALUT I ENVELLIMENT UAB","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);CIP - COMPETITIVENESS AND INNOVATION FRAMEWORK PROGRAMME (CIP)(2007-2013) (PROGRAMME);CIP-ICT-PSP-2012-6 (CALL FOR PROPOSAL);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2012-INNOVATION-1 (CALL FOR PROPOSAL);FP7-SSH - SPECIFIC PROGRAMME ""COOPERATION"": SOCIO-ECONOMIC SCIENCES AND HUMANITIES (PROGRAMME);FP7-SSH-2012-1 (CALL FOR PROPOSAL);TN - THEMATIC NETWORK (FUNDING SCHEME)","2;1;1;1;1;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;32 BIOMEDICAL AND CLINICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION","2;2;1;1;1;1","AGING;PREVENTION;CLINICAL RESEARCH;PATIENT SAFETY","3;2;1;1","GENERIC HEALTH RELEVANCE","2","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C17 BUSINESS AND MANAGEMENT STUDIES","1;1;1",NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","42 HEALTH SCIENCES;38 ECONOMICS;3801 APPLIED ECONOMICS;32 BIOMEDICAL AND CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH;3202 CLINICAL SCIENCES;4202 EPIDEMIOLOGY","11;5;3;2;2;2;1;1","CARDIOVASCULAR;NUTRITION;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;CLINICAL RESEARCH;DIABETES","2;2;1;1;1;1","GENERIC HEALTH RELEVANCE","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","POPULATION & SOCIETY;CLINICAL;HEALTH SERVICES & SYSTEMS","2;1;1","PUBLIC HEALTH;HEALTH SERVICES RESEARCH","3;1",NA,NA,NA,NA
"IRCCS_INRCA",2014,63,8.85714285714286,2.6031746031746,0.365079365079365,0.349206349206349,0.428571428571429,1.76344086021505,1,1.375,1,0.507936507936508,0,23,16,5,7,0.37,0.25,0.08,0.11,31.95,0.845486708583018,5.57414965986395,0.412698412698413,0.936507936507937,0.42,0.438,0.403,0.386,"FABRIZIA LATTANZIO;ANDREA CORSONELLO;ANTONIO CHERUBINI;LIANA SPAZZAFUMO;ROBERTO BERNABEI;GRAZIANO ONDER;ROBERTO TESTA;STEFANO VOLPATO;DAVIDE LIBORIO VETRANO;CARLOS CHIATTI;FRANCESCO LANDI;ANTONIO CERIELLO;STEFANO GENOVESE;ANGELA MARIE ABBATECOLA;CLAUDIO FRANCESCHI;PAOLO FABBIETTI;EUGENIO MOCCHEGIANI;MAURIZIO RONDINELLI;MARCO MALAVOLTA;FRANCESCO PIACENZA","10;9;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3","FABRIZIA LATTANZIO;CARLOS CHIATTI;ANDREA CORSONELLO;LIANA SPAZZAFUMO;ANTONIO CHERUBINI;GRAZIANO ONDER;ROBERTO BERNABEI;ANGELA MARIE ABBATECOLA;ROBERTO TESTA;FRANCESCO DI NARDO;SANDRO FIORETTI;STEFANO VOLPATO;DAVIDE LIBORIO VETRANO;SARA SANTINI;ROBIN MILLER;SUSANNE IWARSSON;FRANCESCO LANDI;G. GHETTI;ALESSANDRO MENGARELLI;FIORENZO CONTI","1.28;1.23;1.07;0.8;0.79;0.71;0.69;0.66;0.65;0.65;0.65;0.6;0.58;0.5;0.5;0.5;0.49;0.45;0.45;0.44","FABRIZIA LATTANZIO;ANDREA CORSONELLO;ANTONIO CHERUBINI;LIANA SPAZZAFUMO;ROBERTO TESTA;CARLOS CHIATTI;ANGELA MARIE ABBATECOLA;PAOLO FABBIETTI;EUGENIO MOCCHEGIANI;MARCO MALAVOLTA;FRANCESCO PIACENZA;ANDREA BASSO;CRISTINA GAGLIARDI;RICCARDO SARZANI;ROBERTINA GIACCONI;FABIOLA OLIVIERI;PAOLO DESSÌ-FULGHERI;ANNA RITA BONFIGLI;FIORENZA ORLANDO;SILVIA BUSTACCHINI","10;9;8;7;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2","FABRIZIA LATTANZIO;CARLOS CHIATTI;ANDREA CORSONELLO;LIANA SPAZZAFUMO;ANTONIO CHERUBINI;ANGELA MARIE ABBATECOLA;ROBERTO TESTA;SARA SANTINI;G. GHETTI;FIORENZO CONTI;CRISTINA GAGLIARDI;PAOLO FABBIETTI;EUGENIO MOCCHEGIANI;ELVIRA MARANESI;RICCARDO SARZANI;PAOLO DESSÌ-FULGHERI;FELICE STROLLO;MARCELLO MELONE;MARCO MALAVOLTA;FRANCESCO PIACENZA","1.28;1.23;1.07;0.8;0.79;0.66;0.65;0.5;0.45;0.44;0.44;0.44;0.42;0.4;0.37;0.37;0.34;0.33;0.32;0.32","ANTONIO CHERUBINI;ANDREA CORSONELLO;ROBERTO BERNABEI;FRANCESCO LANDI;GRAZIANO ONDER;DAVIDE LIBORIO VETRANO;STEFANO VOLPATO;FABRIZIA LATTANZIO;STEFANIA BANDINELLI;CLAUDIO FRANCESCHI;ANNA MARIA MARTONE;GIOVANNI ZULIANI;LIANA SPAZZAFUMO;ROBERTO TESTA;ELEONORA MELONI;ANTONIO CERIELLO;STEFANO GENOVESE;BENEDETTA BARTALI;CRISTINA ANDRÉS‐LACUEVA;KAI SUN","609;527;500;491;473;361;360;335;241;238;222;193;185;182;181;162;162;158;158;158","ANTONIO CHERUBINI;ANDREA CORSONELLO;FABRIZIA LATTANZIO;LIANA SPAZZAFUMO;ROBERTO TESTA;FABIOLA OLIVIERI;CARLOS CHIATTI;PAOLO DESSÌ-FULGHERI;RICCARDO SARZANI;GIUSEPPINA DELL’AQUILA;ANTONIO DOMENICO PROCOPIO;LORENA ROSSI;EUGENIO MOCCHEGIANI;SILVIA BUSTACCHINI;ALESSANDRO CATALIOTTI;ALESSIA BUGLIONI;CHRISTOPHER G. SCOTT;DENISE M. HEUBLEIN;JOHN C. BURNETT;KENT R. BAILEY","609;516;324;174;171;122;118;114;114;110;104;95;87;86;83;83;83;83;83;83","FABRIZIA LATTANZIO;ANDREA CORSONELLO;ANTONIO CHERUBINI;LIANA SPAZZAFUMO;ROBERTO TESTA;CARLOS CHIATTI;EUGENIO MOCCHEGIANI;ANDREA BASSO;FABIOLA OLIVIERI;FRANCESCO PIACENZA;LAURA COSTARELLI;MARCO MALAVOLTA;PAOLO DESSÌ-FULGHERI;PAOLO FABBIETTI;RICCARDO SARZANI;ROBERTINA GIACCONI;ANGELA MARIE ABBATECOLA;ANDREA SANTARELLI;ANTONIO DOMENICO PROCOPIO;CRISTINA GAGLIARDI","9;8;8;6;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;ECONOMICS;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;CHEMISTRY;PHILOSOPHY;ENGINEERING;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY;MATERIALS SCIENCE","54;17;14;7;7;6;5;5;5;4;4;3;2;1;1;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ECONOMIC GROWTH;PATHOLOGY;PHYSICAL THERAPY;EMERGENCY MEDICINE;GERONTOLOGY;GENETICS;BIOCHEMISTRY;NURSING;SURGERY;LAW;PHYSIOLOGY;QUANTUM MECHANICS;GEOMETRY;IMMUNOLOGY;NEUROSCIENCE;PEDIATRICS;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION","33;14;14;12;9;9;9;8;8;7;6;6;6;5;5;5;4;4;4;4;4;4","POPULATION;HEALTH CARE;DIABETES MELLITUS;GENE;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;CANCER;CONFIDENCE INTERVAL;ODDS RATIO;PSYCHOLOGICAL INTERVENTION;DISEASE;IN VITRO;OBESITY;POLYPHARMACY;ANXIETY;DEPRESSION (ECONOMICS);INFLAMMATION;LOGISTIC REGRESSION;MEDICAL PRESCRIPTION;NITRIC OXIDE;OXIDATIVE STRESS;QUALITY OF LIFE (HEALTHCARE)","13;10;8;6;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","ACUTE CARE;INSULIN RESISTANCE;BREAST CANCER;NITRIC OXIDE SYNTHASE;TYPE 2 DIABETES;ACUTE CORONARY SYNDROME;CRONBACH'S ALPHA;DEMENTIA;GAIT ANALYSIS;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);LEFT VENTRICULAR HYPERTROPHY;MICRORNA;RELIABILITY (SEMICONDUCTOR);TELEMEDICINE;TYPE 2 DIABETES MELLITUS;ALLELE;ALZHEIMER'S DISEASE;ANKLE DORSIFLEXION;ANKLE SPRAIN;ANTIBIOTIC RESISTANCE;ANTICHOLINERGIC AGENTS;BARTHEL INDEX;BEERS CRITERIA;BIOSTATISTICS;BRAIN–COMPUTER INTERFACE;C-REACTIVE PROTEIN;CALCITRIOL RECEPTOR;CARCINOGENESIS;CELL CYCLE;CENTER OF PRESSURE (FLUID MECHANICS);CENTRE OF PRESSURE;COLISTIN;CONSTRUCT VALIDITY;CYTOKERATIN;DENTATE GYRUS;DENTIGEROUS CYST;DEPRESSIVE SYMPTOMS;DIASTOLE;EFFECTS OF SLEEP DEPRIVATION ON COGNITIVE PERFORMANCE;EJECTION FRACTION;ENTERAL ADMINISTRATION;GABAERGIC;GASTRECTOMY;GASTRITIS;GLYCATION;GROUND REACTION FORCE;HAND STRENGTH;HAZARD RATIO;HEALTH TECHNOLOGY;HOSPITAL ANXIETY AND DEPRESSION SCALE;IMMUNITY;IMMUNIZATION;IMMUNOTHERAPY;INCISIONAL HERNIA;INJURY PREVENTION;INTEGRATED CARE;INTERNAL CONSISTENCY;INTESTINAL METAPLASIA;INVESTMENT (MILITARY);ISCHEMIC STROKE;LEPTIN;MAMMARY CARCINOMA;MANDIBLE (ARTHROPOD MOUTHPART);METABOLIC SYNDROME;MINIMUM DATA SET;MINIMUM INHIBITORY CONCENTRATION;MITOCHONDRIAL DNA;MONOCLONAL ANTIBODY;MORRIS WATER NAVIGATION TASK;MOTOR CORTEX;MOTOR NEURON;MOTOR UNIT RECRUITMENT;MUCOEPIDERMOID CARCINOMA;NEOVASCULARIZATION;NEUROTROPHIC FACTORS;ODONTOGENIC CYST;OVERWEIGHT;PARATHYROID HORMONE;PERCUTANEOUS CORONARY INTERVENTION;PERIPHERAL BLOOD MONONUCLEAR CELL;PLACEBO;PLANTAR FLEXION;PLASMID;POPULATION AGEING;POSTPRANDIAL;PREFRONTAL CORTEX;PREHYPERTENSION;PREMOTOR CORTEX;PRESCRIPTION DRUG;PROBIOTIC;PROGRAMMED CELL DEATH;PSEUDOMONAS AERUGINOSA;PSPACE;PULSE PRESSURE;QUARTILE;RADICULAR CYST;RECOMBINANT DNA;REVASCULARIZATION;ST ELEVATION;STRATIFIED SQUAMOUS EPITHELIUM;TEMPERAMENT;TRANSGENE;URINARY CATHETERIZATION;VENTRAL HERNIA;VITAMIN D DEFICIENCY;WATER MAZE;WEIGHT LOSS;WESTERN BLOT","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NITROTYROSINE;ESTROGEN RECEPTOR;ADIPOKINE;ADIPONECTIN;BRAIN-DERIVED NEUROTROPHIC FACTOR;CAREGIVER BURDEN;COGNITIVE DECLINE;CROSSOVER STUDY;DNA VACCINATION;DORSOLATERAL PREFRONTAL CORTEX;EFFECT OF GAIT PARAMETERS ON ENERGETIC COST;FAS LIGAND;GABA TRANSPORTER;GASTRIC BYPASS;GENETICALLY MODIFIED MOUSE;GERIATRIC DEPRESSION SCALE;HYPERINSULINEMIA;IMIPENEM;MAMMARY GLAND;MODIFIED RANKIN SCALE;MOTOR IMAGERY;ONCOGENE;PANCREATIC HORMONE;SEXUAL ABUSE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;;AGED, 80 AND OVER;MIDDLE AGED;ITALY;DIABETES MELLITUS, TYPE 2;ADULT;INFLAMMATION;PROSPECTIVE STUDIES;AGING;BIOMARKERS;POSTMENOPAUSE;ACUTE CORONARY SYNDROME;HYPERGLYCEMIA;HYPOGLYCEMIC AGENTS;INSULIN;ACTIVITIES OF DAILY LIVING","38;34;32;27;24;19;18;14;12;11;9;9;8;8;8;7;7;7;7;6","POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;BIOMECHANICS OF RUNNING-RELATED INJURIES;BODY COMPOSITION ASSESSMENT AND ANALYSIS;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CHOLESTEROL-LOWERING TREATMENT;COMPUTATIONAL COMPLEXITY AND ALGORITHMIC INFORMATION THEORY;EFFECTS OF KETOGENIC DIET ON HEALTH;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;EUROPEAN INTEGRATION AND GOVERNANCE DYNAMICS;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE CARE;DEPRESSION (ECONOMICS);DIABETES;GAIT ANALYSIS;HEALTH CARE UTILIZATION;INAPPROPRIATE MEDICATION USE;MEDITERRANEAN DIET;ADVERSE DRUG EVENTS;AGING;CONTINUOUS GLUCOSE MONITORING;DIET QUALITY;DIETARY PATTERNS;GERIATRIC ASSESSMENT;HEALTH TECHNOLOGY;HEALTHY EATING INDEX;HYPERTENSION;INFORMAL CAREGIVING;NITROTYROSINE;POLYPHARMACY;TECHNOLOGY USE","5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE CARE;CRIME STUDY;TYPE DIABETES;ACUTE CORONARY;ADULTS RESULTS;ALZHEIMERS DISEASE;CHRONIC KIDNEY;CORONARY SYNDROME;DISEASE PATIENTS;ELDERLY PATIENTS;ENDOTHELIAL RESISTANCE;HORMONE REPLACEMENT;INFLAMMATORY MARKERS;KIDNEY DISEASE;MEDITERRANEAN DIET;MONOZYGOTIC TWIN;OBSERVATIONAL STUDY;PATIENTS DISCHARGED;PERCEIVED HEALTH;PHYSICAL PERFORMANCE;PRELIMINARY REPORT;PROTECTIVE EFFECT;REPLACEMENT THERAPY;TWIN PAIRS;ABUSE PSYCHOSOCIAL;ACUTELY ENHANCES;ADAPTATION INTERVENTIONS;ADMINISTRATION ACUTELY;ADMISSION HYPERGLYCEMIA;ADULT PARTICIPANTS","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","JYVÄSKYLÄ JYVÄSKYLÄ;HRT USERS;SKELETAL MUSCLE;DELLE MARCHE;HEALTH SCIENCES;MARCHE ANCONA;MEDITERRANEAN DIET;POLITECNICA DELLE;UNIVERSITÀ POLITECNICA;ENDOTHELIAL FUNCTION;JYVÄSKYLÄ FINLAND;MOLECULAR SCIENCES;PATHOLOGY UNIVERSITÀ;SCIENCES DIVISION;SCIENCES UNIVERSITY;ANCONA ITALYSEARCH;MCF- CELLS;PHYSICAL PERFORMANCE;ACUTE HYPERGLYCEMIA;CENTER UNIVERSITY;CONTRIBUTED EQUALLY;FUNCTION NITROTYROSINE;GERONTOLOGY RESEARCH;HOSPITAL STAY;ICAM- LEVELS;IGF-R FOXOA;ISO-PGFA IL-;NITROTYROSINE -ISO-PGFA;OLIVE OIL;PAIN COMPLAINTS","18;17;15;14;14;14;14;14;14;12;12;12;12;12;12;10;10;9;8;8;8;8;8;8;8;8;8;8;8;8",24,0.38,4.28,5,1,28,7,41.5,1,1,1,5.25,0,0,4,5.5,2,1,7,3,3,0,0,127.25,127.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,23999440,999976.67,7,24,12,1,17,866047.556897782,0.072744273103972,"ASTELLAS PHARMA (NETHERLANDS);ASTON UNIVERSITY;BOEHRINGER INGELHEIM (GERMANY);CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE;CHARLES UNIVERSITY;ELI LILLY (UNITED KINGDOM);GLAXOSMITHKLINE (UNITED KINGDOM);ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;JAGIELLONIAN UNIVERSITY;MAASTRICHT UNIVERSITY;MADRID HEALTH SERVICE;MEDICAL UNIVERSITY OF GRAZ;NOVARTIS (SWITZERLAND);ROESSINGH RESEARCH AND DEVELOPMENT;SANOFI (FRANCE);SERVIER (FRANCE);UNIVERSITY OF ERLANGEN-NUREMBERG;UNIVERSITY OF FLORENCE;UNIVERSITY OF GÖTTINGEN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP7-JTI - SPECIFIC PROGRAMME ""COOPERATION"": JOINT TECHNOLOGY INITIATIVES (PROGRAMME);IMI-JU-09-2013 (CALL FOR PROPOSAL);JTI-CP-IMI - JOINT TECHNOLOGY INITIATIVES - COLLABORATIVE PROJECT (IMI) (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","AGING;PREVENTION","1;1","MUSCULOSKELETAL","1","7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2015,96,8.77083333333333,3.10416666666667,0.427083333333333,0.375,0.489583333333333,2.14388489208633,1.28125,1.71428571428571,1.2051282051282,0.479166666666667,1,36,31,5,9,0.38,0.32,0.05,0.09,24.02,0.644539533904405,5.24710424710424,0.354166666666667,0.885416666666667,0.45,0.488,0.403,0.451,"ANTONIO CHERUBINI;FRANCESCO DI NARDO;SANDRO FIORETTI;ELVIRA MARANESI;LAURA BURATTINI;FABRIZIA LATTANZIO;ANNA RITA BONFIGLI;RICCARDO SARZANI;G. GHETTI;LIANA SPAZZAFUMO;GIOVANNI LAMURA;ROBERTO TESTA;ANDREA CORSONELLO;CARLOS CHIATTI;O. MERCANTE;PAOLO DESSÌ-FULGHERI;STEFANO VOLPATO;ALFONSO J. CRUZ‐JENTOFT;MARCELLO MAGGIO;MASSIMO BOEMI","16;10;10;10;10;9;7;7;7;6;6;6;6;6;6;6;5;5;5;5","ANTONIO CHERUBINI;FRANCESCO DI NARDO;SANDRO FIORETTI;ELVIRA MARANESI;LAURA BURATTINI;GIOVANNI LAMURA;G. GHETTI;GELSOMINA MALATESTA;O. MERCANTE;ANDREA CORSONELLO;FABRIZIA LATTANZIO;MARCELLO MAGGIO;CARLOS CHIATTI;RICCARDO SARZANI;ALESSANDRO MENGARELLI;ROBERTO TESTA;PAOLO DESSÌ-FULGHERI;ANNA RITA BONFIGLI;LIANA SPAZZAFUMO;MASSIMILIANO FEDECOSTANTE","1.91;1.71;1.71;1.71;1.71;1.38;1.11;1;0.99;0.99;0.97;0.92;0.91;0.79;0.77;0.73;0.68;0.68;0.64;0.63","ANTONIO CHERUBINI;ELVIRA MARANESI;FABRIZIA LATTANZIO;ANNA RITA BONFIGLI;RICCARDO SARZANI;G. GHETTI;LIANA SPAZZAFUMO;GIOVANNI LAMURA;ROBERTO TESTA;ANDREA CORSONELLO;CARLOS CHIATTI;O. MERCANTE;PAOLO DESSÌ-FULGHERI;MASSIMO BOEMI;MASSIMILIANO FEDECOSTANTE;FABIOLA OLIVIERI;ANGELA MARIE ABBATECOLA;FRANCESCO SPANNELLA;MAURO PROVINCIALI;JOSEPH M. RIMLAND","16;10;9;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;4","ANTONIO CHERUBINI;ELVIRA MARANESI;GIOVANNI LAMURA;G. GHETTI;GELSOMINA MALATESTA;O. MERCANTE;ANDREA CORSONELLO;FABRIZIA LATTANZIO;CARLOS CHIATTI;RICCARDO SARZANI;ROBERTO TESTA;PAOLO DESSÌ-FULGHERI;ANNA RITA BONFIGLI;LIANA SPAZZAFUMO;MASSIMILIANO FEDECOSTANTE;FIORENZO CONTI;FRANCESCO SPANNELLA;ANDREA PRINCIPI;FRANCESCO BARBABELLA;PAOLO FABBIETTI","1.91;1.71;1.38;1.11;1;0.99;0.99;0.97;0.91;0.79;0.73;0.68;0.68;0.64;0.63;0.62;0.59;0.53;0.51;0.49","ANGELA MARIE ABBATECOLA;ALFONSO J. CRUZ‐JENTOFT;ROBERTO TESTA;ANTONIO CHERUBINI;BRUNO VELLAS;ANNA RITA BONFIGLI;ANGELA M. SANFORD;ASHISH GOEL;BIRONG DONG;DEBBIE TOLSON;HIDENORI ARAI;HYUK GA;IVA HOLMEROVÁ;JEAN WOO;JOHN E. MORLEY;JÜRGEN M. BAUER;MARTIN ORRELL;PAUL R. KATZ;RAMZI R. HAJJAR;RAYMOND T.C.M. KOOPMANS","479;432;422;405;382;379;366;366;366;366;366;366;366;366;366;366;366;366;366;366","ANGELA MARIE ABBATECOLA;ROBERTO TESTA;ANTONIO CHERUBINI;ANNA RITA BONFIGLI;FABIOLA OLIVIERI;LIANA SPAZZAFUMO;MASSIMO BOEMI;ANTONIO DOMENICO PROCOPIO;MAURO PROVINCIALI;FABRIZIA LATTANZIO;ROBERTO ANTONICELLI;ANDREA CORSONELLO;FIORENZA ORLANDO;ELVIRA MARANESI;GIOVANNI LAMURA;EMANUELA MENSA’;FIORELLA MARCHESELLI;RAFFAELLA LAZZARINI;RINA RECCHIONI;PAOLO FABBIETTI","425;422;405;379;351;338;259;235;174;167;146;132;132;130;121;114;114;114;114;96","ANTONIO CHERUBINI;ELVIRA MARANESI;FABRIZIA LATTANZIO;ANNA RITA BONFIGLI;G. GHETTI;RICCARDO SARZANI;ROBERTO TESTA;ANDREA CORSONELLO;LIANA SPAZZAFUMO;O. MERCANTE;PAOLO DESSÌ-FULGHERI;CARLOS CHIATTI;MAURO PROVINCIALI;FABIOLA OLIVIERI;FRANCESCO SPANNELLA;MASSIMO BOEMI;GIOVANNI LAMURA;MASSIMILIANO FEDECOSTANTE;EMMA ESPINOSA;IOSIEF ABRAHA","16;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;4;3","MEDICINE;BIOLOGY;COMPUTER SCIENCE;SOCIOLOGY;CHEMISTRY;ECONOMICS;PSYCHOLOGY;PHYSICS;POLITICAL SCIENCE;BUSINESS;ENGINEERING;GEOGRAPHY;MATHEMATICS;PHILOSOPHY;HISTORY","90;26;13;12;10;10;10;8;8;7;4;4;4;4;1","INTERNAL MEDICINE;ENDOCRINOLOGY;GERONTOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;PHYSICAL THERAPY;BIOCHEMISTRY;PHYSICAL MEDICINE AND REHABILITATION;PSYCHIATRY;SURGERY;INTENSIVE CARE MEDICINE;NURSING;NEUROSCIENCE;CARDIOLOGY;DEMOGRAPHY;LAW;EMERGENCY MEDICINE;GENETICS;IMMUNOLOGY;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;ECONOMIC GROWTH;PALEONTOLOGY","57;21;20;14;14;14;12;12;12;11;10;10;9;8;8;7;6;6;6;5;5;5;5","DISEASE;POPULATION;DIABETES MELLITUS;CONFIDENCE INTERVAL;INFLAMMATION;GENE;BODY MASS INDEX;ELECTROMYOGRAPHY;GAIT;OBESITY;PSYCHOLOGICAL INTERVENTION;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;CONTEXT (ARCHAEOLOGY);INSULIN;LOGISTIC REGRESSION;PROSPECTIVE COHORT STUDY;RECEPTOR;BLOOD PRESSURE;CADENCE;CANCER;CHEMOTHERAPY;HEALTH CARE;HEART FAILURE;OBSERVATIONAL STUDY","18;12;11;9;9;8;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","DEMENTIA;HAZARD RATIO;TYPE 2 DIABETES;GAIT ANALYSIS;INSULIN RESISTANCE;ACUTE CORONARY SYNDROME;DOWNREGULATION AND UPREGULATION;MICRORNA;OVERWEIGHT;PROINFLAMMATORY CYTOKINE;RELIABILITY (SEMICONDUCTOR);ALZHEIMER'S DISEASE;GENE EXPRESSION;GLUTAMATE RECEPTOR;GROUND REACTION FORCE;HEMOFILTRATION;LEPTIN;MELPHALAN;MOTION CAPTURE;MUTATION;NITRIC OXIDE SYNTHASE;OZONE THERAPY;PI3K/AKT/MTOR PATHWAY;PROTOCOL (SCIENCE);SOCIOECONOMIC STATUS;ST ELEVATION;TIBIALIS ANTERIOR MUSCLE;TYPE 2 DIABETES MELLITUS;VASTUS MEDIALIS;WEIGHT LOSS","7;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COGNITIVE DECLINE;INSULIN RECEPTOR;ADIPOKINE;ADIPONECTIN;AFLIBERCEPT;BASDAI;CAREGIVER BURDEN;CETUXIMAB;DISEASE MANAGEMENT;DNA METHYLATION;ENOS;FOURNIER GANGRENE;FRONTOTEMPORAL DEMENTIA;GENETICALLY MODIFIED MOUSE;GERD;GLUCAGON-LIKE PEPTIDE-1;GLUCOSE HOMEOSTASIS;GLUTAMATERGIC;GLYCOME;HAPLOINSUFFICIENCY;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HEPARANASE;HER2/NEU;HETEROPLASMY;HUMAN MITOCHONDRIAL GENETICS;HYPERINSULINEMIA;IRINOTECAN;KRAS;LACTOBACILLUS RHAMNOSUS;MAMMARY TUMOR;MEDICATION THERAPY MANAGEMENT;METABOTROPIC GLUTAMATE RECEPTOR;METABOTROPIC RECEPTOR;MISSENSE MUTATION;N-LINKED GLYCOSYLATION;NPR2;ONCOGENE;POINT MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;WEIGHT CHANGE;WORTMANNIN;ZEAXANTHIN","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;AGED;AGED, 80 AND OVER;ITALY;MIDDLE AGED;BIOMARKERS;DIABETES MELLITUS, TYPE 2;AGING;ACUTE CORONARY SYNDROME;INFLAMMATION;FOLLOW-UP STUDIES;ADULT;ELECTROMYOGRAPHY;MUSCLE, SKELETAL;RISK FACTORS;C-REACTIVE PROTEIN;CARCINOMA, SQUAMOUS CELL","53;45;42;41;39;27;27;16;15;15;12;11;11;10;9;9;8;8;7;7","ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;MELANOMA;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;QUALITY AND PRACTICES IN NURSING HOME CARE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF PRIMARY ALDOSTERONISM;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE","6;6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1","HYPERTENSION;SENSORY FEEDBACK;CADENCE;GERIATRIC ASSESSMENT;MUSCULOSKELETAL MODELING;NUTRITIONAL STATUS;AGING;BLOOD PRESSURE;FRAILTY;HEALTH CARE UTILIZATION;PATIENT COMPLEXITY;PROINFLAMMATORY CYTOKINE;SURFACE EMG;ASSISTIVE TECHNOLOGY;B-TYPE NATRIURETIC PEPTIDE;CARDIOVASCULAR RISK ASSESSMENT;CAREGIVER BURDEN;COGNITIVE DECLINE;COMPREHENSIVE GERIATRIC ASSESSMENT;DEMOGRAPHICS","6;6;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","ALZHEIMERS DISEASE;ELDERLY PATIENTS;TYPE DIABETES;ACUTE CORONARY;CORONARY SYNDROME;INCHIANTI STUDY;NON-PHARMACOLOGICAL INTERVENTIONS;NURSING HOME;SURFACE ELECTROMYOGRAPHIC;ACTIVATION PATTERNS;BIOMECHANICAL MODEL;BLOOD PRESSURE;CELL CARCINOMA;ELDERLY SUBJECTS;ELECTROMYOGRAPHIC ACTIVITY;ELEVATION ACUTE;ENDOTHELIAL CELLS;FRAILTY PHENOTYPE;FUNCTIONAL REACH;GENDER DIFFERENCES;GRADE APPROACH;HEART FAILURE;HOME RESIDENTS;HOSPITALIZED PATIENTS;INFUSION CHEMOTHERAPY;ISOLATED LIMB;LIMB INFUSION;LIMB MELANOMA;MYOELECTRIC ACTIVITY;O- RECOMMENDATIONS","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PHYSICAL PERFORMANCE;MGLUR MGLUR;RISTOMED DIET;ANCONA ITALY;WEIGHT LOSS;ALZHEIMERS DISEASE;HEART FAILURE;TYPE DIABETES;Β SE;INRCA-IRCCS NATIONAL;INSTITUTE ANCONA;NATIONAL INSTITUTE;CARE ALLOWANCE;DISEASE AD;LIMB MELANOMA;MGLURΑ MGLUR;MIR--P LEVELS;MUSCLE MASS;RESPONSE RATE;ADVERSE EVENTS;AXON TERMINALS;BODY MASS;CSC-ENRICHED POPULATIONS;EDUCATIONAL LEVEL;EPIGENETIC MECHANISMS;FAMILY CAREGIVERS;GRIP STRENGTH;ISOLATED LIMB;LOGISTIC REGRESSION;LOW MUSCLE","11;10;10;8;8;7;7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",44,0.46,6.12,4,2,0,1,1,1.75,1,2,5,1,1,5,1,0,1.75,2.5,3,2,0,0,82.75,82.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,7,13980,0.73,1,1,705,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Japan","1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;PATIENT SAFETY","1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,1,2950000,327777.78,6,9,8,1,29,861929.186527412,0.111378059242628,"BEN-GURION UNIVERSITY OF THE NEGEV;ERASMUS MC;INSTITUT CATALÀ DE LA SALUT;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;MADRID HEALTH SERVICE;MEDICAL UNIVERSITY OF GRAZ;MEDICAL UNIVERSITY OF LODZ;UNIVERSITY OF ERLANGEN-NUREMBERG;UPPSALA UNIVERSITY","1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","AGING;CLINICAL RESEARCH;HEALTH SERVICES;KIDNEY DISEASE;PREVENTION","1;1;1;1;1","GENERIC HEALTH RELEVANCE;RENAL AND UROGENITAL","1;1",NA,NA,NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;38 ECONOMICS;3801 APPLIED ECONOMICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4202 EPIDEMIOLOGY","15;4;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;PREVENTION;MENTAL HEALTH;BRAIN DISORDERS;AGING;CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIABETES;NUTRITION;PATIENT SAFETY","5;4;4;4;3;2;1;1;1;1;1;1","MENTAL HEALTH;METABOLIC AND ENDOCRINE","5;1","7.3 MANAGEMENT AND DECISION MAKING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","2;1;1","CLINICAL","7","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","5;3","NOT SITE-SPECIFIC CANCER","1",NA,NA
"IRCCS_INRCA",2016,109,10.7155963302752,2.99082568807339,0.36697247706422,0.376146788990826,0.614678899082569,2.58730158730159,1.33333333333333,1.86363636363636,1.675,0.587155963302752,1,42,37,6,10,0.39,0.34,0.06,0.09,26.97,0.830356452810047,5.01125,0.422018348623853,0.908256880733945,0.468,0.4,0.448,0.382,"ANTONIO CHERUBINI;RICCARDO SARZANI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;MAURO PROVINCIALI;FRANCESCO SPANNELLA;ANNA RITA BONFIGLI;ROBERTO TESTA;PAOLO FABBIETTI;ANDREA CORSONELLO;ROBERTA PAPA;FRANCESCO PIACENZA;FABIOLA OLIVIERI;ANDREA PRINCIPI;EMMA ESPINOSA;STEFANO VOLPATO;AGNIESZKA SOWA;GIULIANO ENZI;ANDREA BASSO;GRAZIANO ONDER","14;14;11;11;10;8;7;7;7;7;6;6;6;6;6;5;5;5;5;5","RICCARDO SARZANI;ANTONIO CHERUBINI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;MAURO PROVINCIALI;FRANCESCO SPANNELLA;GIULIANO ENZI;DEMETRIO POSTACCHINI;ROBERTO TESTA;ANDREA CORSONELLO;PAOLO FABBIETTI;ROBERTA PAPA;ANNA RITA BONFIGLI;EMMA ESPINOSA;P. ORLANDONI;ANDREA PRINCIPI;FEDERICO GIULIETTI;CRISTINA GAGLIARDI;JOHN C. BURNETT;FRANCESCO PIACENZA","2.68;2.06;1.48;1.45;1.36;1.07;0.91;0.91;0.91;0.9;0.86;0.85;0.83;0.79;0.7;0.66;0.64;0.63;0.61;0.59","ANTONIO CHERUBINI;RICCARDO SARZANI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;MAURO PROVINCIALI;FRANCESCO SPANNELLA;ANNA RITA BONFIGLI;ROBERTO TESTA;PAOLO FABBIETTI;ANDREA CORSONELLO;ROBERTA PAPA;FRANCESCO PIACENZA;FABIOLA OLIVIERI;ANDREA PRINCIPI;EMMA ESPINOSA;GIULIANO ENZI;ANDREA BASSO;DEMETRIO POSTACCHINI;FEDERICO GIULIETTI;FIORENZA ORLANDO","14;14;11;11;10;8;7;7;7;7;6;6;6;6;6;5;5;5;5;4","RICCARDO SARZANI;ANTONIO CHERUBINI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;MAURO PROVINCIALI;FRANCESCO SPANNELLA;GIULIANO ENZI;DEMETRIO POSTACCHINI;ROBERTO TESTA;ANDREA CORSONELLO;PAOLO FABBIETTI;ROBERTA PAPA;ANNA RITA BONFIGLI;EMMA ESPINOSA;P. ORLANDONI;ANDREA PRINCIPI;FEDERICO GIULIETTI;CRISTINA GAGLIARDI;FRANCESCO PIACENZA;MARICA BORDICCHIA","2.68;2.06;1.48;1.45;1.36;1.07;0.91;0.91;0.91;0.9;0.86;0.85;0.83;0.79;0.7;0.66;0.64;0.63;0.59;0.55","ANTONIO CHERUBINI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;ROBERTO TESTA;ANDREA PRINCIPI;ANTONIO CERIELLO;FRANCESCO LANDI;ROBERTO BERNABEI;CLAUDIO FRANCESCHI;ALBERTO FERRARI;ALESSANDRO MORANDI;ANDREA MAZZONE;ANGELO BIANCHETTI;DANIELA MARI;ENRICO MOSSELLO;ERMELLINA ZANETTI;GIUSEPPE BELLELLI;MARCO TRABUCCHI;MASSIMO MUSICCO","618;333;301;262;259;253;243;240;240;237;228;228;228;228;228;228;228;228;228;228","ANTONIO CHERUBINI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;MARCO MALAVOLTA;ROBERTO TESTA;ANDREA PRINCIPI;ANNA RITA BONFIGLI;ROBERTA PAPA;MAURO PROVINCIALI;RINA RECCHIONI;MASSIMO BOEMI;CRISTINA GAGLIARDI;PAOLO FABBIETTI;FIORENZO CONTI;ANTONIO DOMENICO PROCOPIO;FRANCESCO PIACENZA;DEMETRIO POSTACCHINI;GIULIANO ENZI;LIANA SPAZZAFUMO;LUCA BRAGINA","595;333;300;262;259;253;223;214;207;151;150;148;147;142;130;129;125;125;125;124","RICCARDO SARZANI;ANTONIO CHERUBINI;MARCO MALAVOLTA;MAURO PROVINCIALI;FABRIZIA LATTANZIO;FRANCESCO SPANNELLA;ANDREA CORSONELLO;ANNA RITA BONFIGLI;ROBERTO TESTA;PAOLO FABBIETTI;ANDREA PRINCIPI;EMMA ESPINOSA;FABIOLA OLIVIERI;FRANCESCO PIACENZA;ROBERTA PAPA;ANDREA BASSO;FEDERICO GIULIETTI;CRISTINA GAGLIARDI;DEMETRIO POSTACCHINI;FIORENZA ORLANDO","15;13;11;10;10;8;7;7;7;7;6;6;6;6;6;5;5;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;PHYSICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;MATHEMATICS;ART","102;22;20;17;13;10;9;9;6;6;5;4;3;3;2","INTERNAL MEDICINE;ENDOCRINOLOGY;GERONTOLOGY;NURSING;ENVIRONMENTAL HEALTH;PSYCHIATRY;PATHOLOGY;GENETICS;PHYSICAL THERAPY;PHARMACOLOGY;BIOCHEMISTRY;SURGERY;FAMILY MEDICINE;IMMUNOLOGY;ECONOMIC GROWTH;INTENSIVE CARE MEDICINE;CARDIOLOGY;NEUROSCIENCE;PHYSICAL MEDICINE AND REHABILITATION;CHROMATOGRAPHY;DEMOGRAPHY;EMERGENCY MEDICINE;LAW;ORGANIC CHEMISTRY","64;26;26;23;18;17;16;13;12;11;10;9;8;8;7;7;6;6;6;5;5;5;5;5","POPULATION;DISEASE;DIABETES MELLITUS;GENE;QUALITY OF LIFE (HEALTHCARE);CANCER;LOGISTIC REGRESSION;BLOOD PRESSURE;INTERVENTION (COUNSELING);HEALTH CARE;MEDICAL PRESCRIPTION;COGNITION;CONFIDENCE INTERVAL;HEART FAILURE;OLDER PEOPLE;PUBLIC HEALTH;RANDOMIZED CONTROLLED TRIAL;ACTIVITIES OF DAILY LIVING;ADIPOSE TISSUE;ADVERSE EFFECT;ALTERNATIVE MEDICINE;COHORT;GERIATRICS;INSULIN;MEDLINE;OBSERVATIONAL STUDY","16;15;12;11;10;8;8;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","TYPE 2 DIABETES;DEMENTIA;BREAST CANCER;INSULIN RESISTANCE;LIPOLYSIS;ADIPOCYTE;COGNITIVE IMPAIRMENT;COGNITIVE TRAINING;GENE EXPRESSION;HAZARD RATIO;MICRORNA;NATRIURETIC PEPTIDE;ALZHEIMER'S DISEASE;CONVENTIONAL PCI;DYSLIPIDEMIA;EPIGENETICS;HEART RATE;METHYLATION;MICROWAVE IMAGING;MULTIMORBIDITY;PHENOTYPE;PROTOCOL (SCIENCE);RENIN–ANGIOTENSIN SYSTEM;STAPHYLOCOCCUS AUREUS;TELOMERE;TYPE 2 DIABETES MELLITUS","7;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGIOTENSIN RECEPTOR BLOCKERS;CELLULAR AGING;COGNITIVE DECLINE;DNA METHYLATION;HYPERINSULINEMIA;INSULIN RECEPTOR;MACE;PLASMA RENIN ACTIVITY;ANDROGEN DEPRIVATION THERAPY;AROMATASE;BREAST RECONSTRUCTION;CADASIL;CD117;CELLULAR SENESCENCE;CHEMOKINE RECEPTOR;CUTANEOUS T-CELL LYMPHOMA;CXCL10;CYSTATIN;DIPEPTIDYL PEPTIDASE-4;DIPEPTIDYL PEPTIDASE-4 INHIBITOR;DOUBLE BLIND;EARLY-ONSET ALZHEIMER'S DISEASE;ENDOTHELIAL PROGENITOR CELL;EXOME SEQUENCING;FALLS IN OLDER ADULTS;FRONTOTEMPORAL DEMENTIA;GLUCAGON-LIKE PEPTIDE-1;GLUCOSE HOMEOSTASIS;GLUTATHIONE PEROXIDASE;HEART RATE VARIABILITY;MASTECTOMY;MEAN ARTERIAL PRESSURE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;METHYLTRANSFERASE;MICRONUCLEUS;MICROVESICLES;NPR1;NPR2;NUCLEAR RECEPTOR;OMALIZUMAB;OXALIPLATIN;PERILIPIN;PERIPHERAL T-CELL LYMPHOMA;PRESENILIN;PROGENITOR;QUORUM SENSING;SCANNING ION-CONDUCTANCE MICROSCOPY;SEXUAL ABUSE;TRANSCRIPTOME;TRASTUZUMAB;TREPONEMA DENTICOLA;VANCOMYCIN;VASCULAR DEMENTIA","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;AGED;FEMALE;MIDDLE AGED;AGED, 80 AND OVER;ITALY;AGING;DIABETES MELLITUS, TYPE 2;ADULT;PROSPECTIVE STUDIES;BIOMARKERS;RISK FACTORS;ANIMALS;ANTI-BACTERIAL AGENTS;BLOOD GLUCOSE;CARDIOVASCULAR DISEASES;ENDOTHELIAL CELLS;HEART FAILURE","56;49;45;39;39;23;21;19;18;17;14;9;8;8;7;7;7;7;7;7","DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;MANAGEMENT OF PRIMARY ALDOSTERONISM;PHOTONIC NANOJET ENHANCEMENT AND APPLICATIONS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DYSPHAGIA AND SWALLOWING DISORDERS;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEALTH LOCUS OF CONTROL AND PROMOTING BEHAVIORS;IMPACT OF RELIGION AND SPIRITUALITY ON HEALTH OUTCOMES;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;PREVALENCE AND CORRELATES OF ELDER ABUSE AND NEGLECT","7;6;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","AGING;HYPERTENSION;B-TYPE NATRIURETIC PEPTIDE;COGNITIVE DECLINE;MULTIMORBIDITY;TREATMENT;TYPE 2 DIABETES;ADRENAL VEIN SAMPLING;AGING SOCIETIES;ANGIOTENSIN RECEPTOR BLOCKERS;COGNITIVE TRAINING;CONTINUOUS GLUCOSE MONITORING;FRAILTY;INFORMAL CAREGIVING;SCANNING PROBE MICROSCOPY;SENESCENCE;VASCULAR AGING;ASSOCIATION (PSYCHOLOGY);ATRIAL NATRIURETIC PEPTIDE;BLOOD PRESSURE","8;7;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","NATRIURETIC PEPTIDE;TYPE DIABETES;CLEARANCE RECEPTOR;ENDOTHELIAL CELLS;PEPTIDE CLEARANCE;ACTIVITYPLASMA ALDOSTERONE;ALDOSTERONE CONCENTRATION;BREAST CANCER;CARDIOVASCULAR RISK;CLINICAL PRACTICE;CONCENTRATION RATIO;EUROPEAN COUNTRIES;FAMILY CAREGIVERS;HEART FAILURE;HUMAN ADIPOCYTES;MICROWAVE MICROSCOPY;PLASMA RENIN;RENIN ACTIVITYPLASMA;RISK FACTORS;SCANNING MICROWAVE;ALZHEIMERS DISEASE;CANCER CELLS;CARDIAC NATRIURETIC;CLINICAL EFFECTIVENESS;COGNITIVE IMPAIRMENT;COGNITIVE TRAINING;CRIME STUDY;DRUG THERAPY;ELDERLY POPULATION;FULLERENE EXPOSURE","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","Α NKA;ANCONA ITALY;ITALY SEARCH;CORTICAL ASTROCYTES;DELLE MARCHE;FHM-KI MICE;MARCHE ANCONA;POLITECNICA DELLE;Τ HZ;PADOVA ITALY;STC ELICITED;KI MICE;WT MICE;GLU CLEARANCE;UNIVERSITÀ POLITECNICA;Τ DECAY;BIOMEDICAL SCIENCES;BLOOD PRESSURE;COGNITIVE DECLINE;PADOVA PADOVA;SCIENCES UNIVERSITY;SINGLE PULSE;SOCIAL SUPPORT;AGING INRCA;ASTROCYTIC PROCESSES;ENDOTHELIAL CELLS;EUROPEAN COUNTRIES;GLT-A PUNCTA;GLUTAMATERGIC SYNAPSES;ITALY CENTER","26;21;16;13;13;13;13;13;13;12;12;11;11;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;8",55,0.5,8.41,4,2,1,1,1,1,0,1,4.5,1,0,4,0,0,1,5.5,3,1.75,0,0,116,116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3,1558.5,1.64,0,0,29.5,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Spain;Germany;Israel;Netherlands;Poland;Sweden","2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","2;2;2","CLINICAL RESEARCH;HEALTH SERVICES;AGING;BEHAVIORAL AND SOCIAL SCIENCE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;KIDNEY DISEASE;LUNG;PREVENTION","2;2;1;1;1;1;1;1","RENAL AND UROGENITAL;RESPIRATORY","1;1",NA,NA,NA,NA,NA,NA,1,3759345,187967.25,4,20,11,1,50,456439.886112549,0.238804721752829,"AGE PLATFORM EUROPE;AUSTRIAN INSTITUTE OF TECHNOLOGY;DE MONTFORT UNIVERSITY;DUNDALK INSTITUTE OF TECHNOLOGY;EUROPEAN ALLIANCE AGAINST DEPRESSION;INGENIERÍA Y SOLUCIONES INFORMÁTICAS (SPAIN);ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;LULEÅ UNIVERSITY OF TECHNOLOGY;METRALABS (GERMANY);NATIONAL RESEARCH COUNCIL;NOLDUS INFORMATION TECHNOLOGY;NORTHWESTERN POLYTECHNICAL UNIVERSITY;PHILIPS (NETHERLANDS);PHILIPS (UNITED KINGDOM);REHA RHEINFELDEN;TECHNICAL UNIVERSITY OF MADRID;TU WIEN;UNIVERSITY OF ERLANGEN-NUREMBERG;UNIVERSITY OF PASSAU;UNIVERSITY OF ULSTER","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-MSCA-ITN-2015 (CALL FOR PROPOSAL);MSCA-ITN-ETN - EUROPEAN TRAINING NETWORKS (FUNDING SCHEME)","1;1;1","46 INFORMATION AND COMPUTING SCIENCES;4608 HUMAN-CENTRED COMPUTING","1;1",NA,NA,"GENERIC HEALTH RELEVANCE","1",NA,NA,NA,NA,NA,NA,"C17 BUSINESS AND MANAGEMENT STUDIES","1","9 INDUSTRY, INNOVATION AND INFRASTRUCTURE","1",2,"KARGER PUBLISHERS;PUBLIC LIBRARY OF SCIENCE","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","4;2;1","AGING;BEHAVIORAL AND SOCIAL SCIENCE;BREAST CANCER;CANCER;CLINICAL RESEARCH;PREVENTION","1;1;1;1;1;1","CANCER","1","6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","1;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"IRCCS_INRCA",2017,104,10.625,2.83653846153846,0.442307692307692,0.423076923076923,0.528846153846154,2.25190839694656,1.48387096774194,1.76,1.52777777777778,0.653846153846154,3,32,35,7,6,0.31,0.34,0.07,0.06,25.88,0.878188009719251,4.97235023041475,0.394230769230769,0.923076923076923,0.522,0.422,0.386,0.44,"ANTONIO CHERUBINI;GIOVANNI LAMURA;FRANCESCO BARBABELLA;RICCARDO SARZANI;ANDREA CORSONELLO;MAURO PROVINCIALI;MIRKO DI ROSA;FABRIZIA LATTANZIO;ROBERTA PAPA;GUIDO COCCI;FIORENZA ORLANDO;FRANCESCO LANDI;PAOLO BALIETTI;FABIOLA OLIVIERI;FRANCESCO SPANNELLA;MARIA GABRIELLA MELCHIORRE;MARCO MALAVOLTA;ANTONIO DOMENICO PROCOPIO;CARLOS CHIATTI;FIORENZO CONTI","12;10;10;9;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5","FRANCESCO BARBABELLA;GIOVANNI LAMURA;SANTE CAPITANO;ROBERTA PAPA;RICCARDO SARZANI;LUCA COLLEBRUSCO;G CENSI;RITA LOMBARDINI;MARIA GABRIELLA MELCHIORRE;MAURO PROVINCIALI;ANTONIO CHERUBINI;GUIDO COCCI;CARLOS CHIATTI;ANDREA CORSONELLO;FIORENZO CONTI;FIORENZA ORLANDO;ROBERTO ANTONICELLI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;PAOLO BALIETTI","2.75;2.33;2;1.44;1.43;1.25;1.25;1.25;1.13;1.03;1.02;1.01;0.99;0.97;0.9;0.83;0.81;0.81;0.8;0.76","ANTONIO CHERUBINI;GIOVANNI LAMURA;FRANCESCO BARBABELLA;RICCARDO SARZANI;ANDREA CORSONELLO;MAURO PROVINCIALI;MIRKO DI ROSA;FABRIZIA LATTANZIO;ROBERTA PAPA;GUIDO COCCI;FIORENZA ORLANDO;PAOLO BALIETTI;FABIOLA OLIVIERI;FRANCESCO SPANNELLA;MARIA GABRIELLA MELCHIORRE;MARCO MALAVOLTA;ANTONIO DOMENICO PROCOPIO;CARLOS CHIATTI;FIORENZO CONTI;ALFONSO J. CRUZ‐JENTOFT","12;10;10;9;8;8;7;7;7;7;6;6;6;6;6;5;5;5;5;4","FRANCESCO BARBABELLA;GIOVANNI LAMURA;SANTE CAPITANO;ROBERTA PAPA;RICCARDO SARZANI;G CENSI;MARIA GABRIELLA MELCHIORRE;MAURO PROVINCIALI;ANTONIO CHERUBINI;GUIDO COCCI;CARLOS CHIATTI;ANDREA CORSONELLO;FIORENZO CONTI;FIORENZA ORLANDO;ROBERTO ANTONICELLI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;PAOLO BALIETTI;FRANCESCO SPANNELLA;MIRKO DI ROSA","2.75;2.33;2;1.44;1.43;1.25;1.13;1.03;1.02;1.01;0.99;0.97;0.9;0.83;0.81;0.81;0.8;0.76;0.76;0.73","ANTONIO CHERUBINI;FRANCESCO LANDI;MASSIMO BOEMI;ANTONIO NICOLUCCI;MAURO DI BARI;ALDO P. MAGGIONI;CRISTIANA SCARANNA;FABRIZIO CAPPELLINI;FRANCESCO GIORGINO;GABRIELE RICCARDI;GIORGIO SESTI;GIUSEPPE LUCISANO;LUCIA RICCI‐VITIANI;MARIA MASULLI;MICHELE SACCO;OLGA VACCARO;PAOLO MOCARELLI;STEFANO SIGNORINI;EMANUELE MARZETTI;BRUNO VELLAS","772;616;555;530;513;510;510;510;510;510;510;510;510;510;510;510;510;510;437;343","ANTONIO CHERUBINI;MASSIMO BOEMI;FABIOLA OLIVIERI;ANTONIO DOMENICO PROCOPIO;FABRIZIA LATTANZIO;MARIA GABRIELLA MELCHIORRE;MIRKO DI ROSA;P. ORLANDONI;ROBERTO TESTA;ANDREA CORSONELLO;ROBERTA PAPA;FIORELLA MARCHESELLI;RINA RECCHIONI;MAURO PROVINCIALI;FIORENZO CONTI;FRANCESCO BARBABELLA;EMANUELA MENSA’;ELISA PIERPAOLI;PAOLO FABBIETTI;FIORENZA ORLANDO","763;555;263;249;236;198;185;168;160;153;149;140;140;117;106;105;97;95;89;85","ANTONIO CHERUBINI;FRANCESCO BARBABELLA;GIOVANNI LAMURA;RICCARDO SARZANI;MAURO PROVINCIALI;ROBERTA PAPA;ANDREA CORSONELLO;MIRKO DI ROSA;FABIOLA OLIVIERI;GUIDO COCCI;MARIA GABRIELLA MELCHIORRE;FABRIZIA LATTANZIO;FIORENZA ORLANDO;ANTONIO DOMENICO PROCOPIO;FIORENZO CONTI;FRANCESCO SPANNELLA;MARCO MALAVOLTA;PAOLO BALIETTI;CARLOS CHIATTI;DEMETRIO POSTACCHINI","11;9;9;9;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;4","MEDICINE;BIOLOGY;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;ECONOMICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;PHYSICS;CHEMISTRY;ENGINEERING;GEOGRAPHY;PHILOSOPHY","94;33;18;16;10;10;9;8;6;6;5;5;2;2","INTERNAL MEDICINE;PSYCHIATRY;GERONTOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;SURGERY;LAW;PHYSICAL THERAPY;BIOCHEMISTRY;GENETICS;NURSING;PATHOLOGY;PHARMACOLOGY;ECONOMIC GROWTH;PALEONTOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;PHYSICAL MEDICINE AND REHABILITATION;EMERGENCY MEDICINE;FAMILY MEDICINE;IMMUNOLOGY;NEUROSCIENCE;PEDIATRICS;RADIOLOGY","53;20;17;16;15;14;13;13;12;12;11;10;10;9;9;7;7;7;6;6;6;6;6;6","DISEASE;POPULATION;GENE;HEALTH CARE;RANDOMIZED CONTROLLED TRIAL;OBSERVATIONAL STUDY;GERIATRICS;CANCER;CONTEXT (ARCHAEOLOGY);SARCOPENIA;BLOOD PRESSURE;DIABETES MELLITUS;HEART FAILURE;ACTIVITIES OF DAILY LIVING;ADVERSE EFFECT;BODY MASS INDEX;CHOLESTEROL;CONFIDENCE INTERVAL;IN VITRO;IN VIVO;INCIDENCE (GEOMETRY);INSULIN;INTERVENTION (COUNSELING);OLDER PEOPLE;POISON CONTROL;RECEPTOR","14;13;12;10;10;9;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","AMBULATORY BLOOD PRESSURE;DEMENTIA;MULTIMORBIDITY;ANGIOTENSIN-CONVERTING ENZYME;EHEALTH;INJURY PREVENTION;MULTICENTER STUDY;STAPHYLOCOCCUS AUREUS;TYPE 2 DIABETES;ACTIVE AGEING;ACUTE CARE;ADIPOCYTE;ANTIHYPERTENSIVE DRUG;BEERS CRITERIA;CLINICAL ENDPOINT;DYSLIPIDEMIA;ENDOTHELIAL STEM CELL;EPIGENETICS;ESSENTIAL HYPERTENSION;FRACTAL DIMENSION;GENE EXPRESSION;GLUTAMATE RECEPTOR;HAZARD RATIO;INTEGRATED CARE;LIPID PROFILE;LIPOPROTEIN;METHYLATION;MUTATION;NITRIC OXIDE SYNTHASE;OFFSPRING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHARMACOVIGILANCE;PHENOTYPE;PULSE PRESSURE;RENIN–ANGIOTENSIN SYSTEM","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VANCOMYCIN;CAREGIVER BURDEN;DNA METHYLATION;ELDER ABUSE;FALL PREVENTION;LACUNARITY;LDL RECEPTOR;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;PLASMA RENIN ACTIVITY;ACE INHIBITOR;ACTIVE CITIZENSHIP;ANDROGEN RECEPTOR;ANGIOTENSIN II RECEPTOR TYPE 1;ANGIOTENSIN RECEPTOR BLOCKERS;ANTIANDROGEN;BOOSTER DOSE;BREAST SURGERY;CETUXIMAB;DNA VACCINATION;ENOS;ENTEROCOCCUS FAECALIS;EXCITOTOXICITY;FALLS IN OLDER ADULTS;FEAR OF FALLING;FRAGILITY FRACTURE;FUSIDIC ACID;GABA TRANSPORTER;GENETICALLY MODIFIED MOUSE;GERD;GLIMEPIRIDE;GLUTAMATERGIC;GLYCATED HEMOGLOBIN;HEARTBURN;HEMATOPOIETIC STEM CELL;HETEROPLASMY;IRINOTECAN;KRAS;LIRAGLUTIDE;MASTECTOMY;METABOTROPIC GLUTAMATE RECEPTOR;METABOTROPIC RECEPTOR;METHYLTRANSFERASE;NPR1;NPR2;OLIGODENDROCYTE;OSTEOPENIA;OSTEOPOROTIC FRACTURE;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA;PEROXYNITRITE;PIOGLITAZONE;POLYCYSTIC OVARY;PROMOTER;QUANTITATIVE COMPUTED TOMOGRAPHY;RILUZOLE;SINGLE-NUCLEOTIDE POLYMORPHISM;SOCIAL CITIZENSHIP;SOD1;SYNAPTIC VESICLE;TIAGABINE;VASCULAR DEMENTIA","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;AGED;AGED, 80 AND OVER;MIDDLE AGED;ITALY;ADULT;AGING;DELIRIUM;SARCOPENIA;HOSPITALIZATION;ANIMALS;DIABETES MELLITUS, TYPE 2;TREATMENT OUTCOME;CARDIOVASCULAR DISEASES;DEMENTIA;SURVEYS AND QUESTIONNAIRES;ANGIOTENSIN-CONVERTING ENZYME INHIBITORS","50;49;36;35;30;20;19;18;12;12;12;12;10;9;9;9;8;8;8;7","EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;TECHNOLOGY ADOPTION AND AGING POPULATION;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;LIFESTYLE MIGRATION AND RETIREMENT MOBILITY;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHOLESTEROL-LOWERING TREATMENT;COPPER AND ZINC IN HEALTH AND DISEASE;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;HERNIA REPAIR TECHNIQUES AND MATERIALS;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;PREVALENCE AND CORRELATES OF ELDER ABUSE AND NEGLECT;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS","6;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1","HYPERTENSION;AGING;DIABETES;GERIATRIC ASSESSMENT;FRAILTY;MULTIMORBIDITY;ADRENAL VEIN SAMPLING;COMPREHENSIVE GERIATRIC ASSESSMENT;EHEALTH;ELDER ABUSE;SENESCENCE;TECHNOLOGY USE;ABDOMINAL WALL RECONSTRUCTION;ACTIVE AGEING;ACUTE CARE;ANTIHYPERTENSIVE DRUG;BEERS CRITERIA;BLOOD PRESSURE;CAREGIVER BURDEN;CLINICAL ENDPOINT","6;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","HYPERTENSIVE PATIENTS;ACUTE CARE;ALZHEIMERS DISEASE;ANGIOTENSIN-CONVERTING ENZYME;ENDOTHELIAL CELLS;INTEGRATED CARE;MOUSE MODEL;TYPE DIABETES;AMBULATORY BLOOD;BLOOD PRESSURE;CARE HOSPITAL;CARE PROGRAMS;CLINICAL PRACTICE;COLORECTAL CANCER;CONTROLLED TRIAL;DISEASE PROGRESSION;ELDERLY HYPERTENSIVES;ESSENTIAL HYPERTENSIVE;FALL RISK;FOLFIRI CETUXIMAB;GLISTEN STUDY;ICAREEU PROJECT;IN-HOSPITAL MORTALITY;INFORMAL CAREGIVERS;INTERNATIONAL SUMMER;MARK-AGE PROJECT;METASTATIC COLORECTAL;METHICILLIN-RESISTANT STAPHYLOCOCCUS;MULTICENTER STUDY;NATIONAL SURVEY","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EUROPEAN COUNTRIES;CLINICAL PRACTICE;INTEGRATED CARE;ENDOTHELIAL CELLS;Β-GAL ACTIVITY;INTESTINAL FAILURE;RISK FACTORS;ACTIVE AGEING;ACUTE CARE;FUNCTIONAL DECLINE;HEALTH LITERACY;HOSPITAL STAY;HR CI;MASS INDEX;BODY COMPOSITION;BODY MASS;CELLULAR SENESCENCE;CHRONIC DISEASES;ELDER ABUSE;EMERGENCY DEPARTMENT;FRACTAL LACUNARITY;FRACTURE RISK;HEALTH PROFESSIONALS;HOSPITAL ADMISSION;INFORMAL CAREGIVERS;STRONGLY RECOMMENDED;ACE INHIBITORS;ACE RS;ACTIVE CITIZENSHIP;CAREGIVER BURDEN","13;9;9;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4",51,0.49,7.47,8,1.5,1,0,1,2,0,1,9,0,0,6.25,0,0,1,3,5,4,0,0,102,102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3816877.5,273314.17,4.5,18.5,13,1,18,550972.901985565,0.18875701441071,"MINISTRY OF HEALTH;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;AGÈNCIA DE QUALITAT I AVALUACIÓ SANITÀRIES DE CATALUNYA;ANDALUSIAN HEALTH SERVICE;BABEȘ-BOLYAI UNIVERSITY;CATHOLIC UNIVERSITY OF THE SACRED HEART;CONSEJERÍA DE SALUD Y FAMILIAS;FINNISH INSTITUTE FOR HEALTH AND WELFARE;HANNOVER MEDICAL SCHOOL;HEALTH SERVICE EXECUTIVE;HOSPITAL SANT JOAN DE DÉU BARCELONA;HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO;INSTITUTE OF RESEARCH AND INNOVATION PARC TAULI;ISTITUTO SUPERIORE DI SANITÀ;LAUREA UNIVERSITY OF APPLIED SCIENCES;LITHUANIAN UNIVERSITY OF HEALTH SCIENCES;MAASTRICHT UNIVERSITY;MAASTRICHT UNIVERSITY MEDICAL CENTRE;MADRID HEALTH SERVICE;MEDICAL UNIVERSITY OF GRAZ","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","3RD HEALTH PROGRAMME (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-SC1-2016-CNECT (CALL FOR PROPOSAL);PCP - PRE-COMMERCIAL PROCUREMENT (FUNDING SCHEME)","1;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","2;2;1","AGING","1","MENTAL HEALTH","1","7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","2","4 QUALITY EDUCATION","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2018,98,12.1020408163265,3.36734693877551,0.418367346938776,0.397959183673469,0.561224489795918,2.44444444444444,1.32258064516129,1.85714285714286,1.34146341463415,0.530612244897959,0,38,38,11,4,0.39,0.39,0.11,0.04,127.05,4.16448018482251,5.13758389261745,0.377551020408163,0.959183673469388,0.454,0.446,0.419,0.458,"ANTONIO CHERUBINI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;FABIOLA OLIVIERI;PAOLO FABBIETTI;ANDREA CORSONELLO;MIRKO DI ROSA;MARCO MALAVOLTA;FRANCESCO PIACENZA;FRANCESCO LANDI;RICCARDO SARZANI;STEFANO VOLPATO;GRAZIANO ONDER;FRANCESCO SPANNELLA;DANIELE CASTELLANI;MARIA CRISTINA ALBERTINI;FIORENZA ORLANDO;MARCELLO MAGGIO;ROBERTA GALEAZZI;GIULIA ROSETTANI","15;13;12;9;8;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5","ANTONIO CHERUBINI;DANIELE CASTELLANI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;FIORENZO CONTI;SARA SANTINI;MIRKO DI ROSA;MARCO MASCITTI;ANDREA SANTARELLI;PAOLO FABBIETTI;FABIOLA OLIVIERI;RICCARDO SARZANI;ANDREA CORSONELLO;MARCO DELLABELLA;LUCA BRAGINA;FRANCESCO SPANNELLA;FRANCESCO PIACENZA;ANDREA PRINCIPI;DEBORAH SMEATON;BARBARA BASCHIERA","1.27;1.18;1.11;1.07;1.03;0.95;0.94;0.9;0.9;0.87;0.84;0.77;0.73;0.68;0.67;0.66;0.64;0.62;0.62;0.58","ANTONIO CHERUBINI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;FABIOLA OLIVIERI;PAOLO FABBIETTI;ANDREA CORSONELLO;MIRKO DI ROSA;MARCO MALAVOLTA;FRANCESCO PIACENZA;RICCARDO SARZANI;FRANCESCO SPANNELLA;DANIELE CASTELLANI;FIORENZA ORLANDO;ROBERTA GALEAZZI;GIULIA ROSETTANI;BEATRICE BERNARDI;ROBERTINA GIACCONI;ROBERTO TESTA;GUIDO COCCI;MARCO DELLABELLA","15;13;12;9;8;8;7;7;7;7;6;6;5;5;5;5;5;5;5;5","ANTONIO CHERUBINI;DANIELE CASTELLANI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;FIORENZO CONTI;SARA SANTINI;MIRKO DI ROSA;ANDREA SANTARELLI;PAOLO FABBIETTI;FABIOLA OLIVIERI;RICCARDO SARZANI;ANDREA CORSONELLO;MARCO DELLABELLA;LUCA BRAGINA;FRANCESCO SPANNELLA;FRANCESCO PIACENZA;ANDREA PRINCIPI;BARBARA BASCHIERA;GIOVANNI LAMURA;MARCO MALAVOLTA","1.27;1.18;1.11;1.07;1.03;0.95;0.94;0.9;0.87;0.84;0.77;0.73;0.68;0.67;0.66;0.64;0.62;0.58;0.58;0.55","ANTONIO CHERUBINI;FRANCESCO LANDI;MATTEO CESARI;JÜRGEN M. BAUER;CYRUS COOPER;IVAN BAUTMANS;JEAN‐YVES REGINSTER;JOHN А. KANIS;MARJOLEIN VISSER;OLIVIER BRUYÈRE;RENÉ RIZZOLI;TOMMY CEDERHOLM;YVES ROLLAND;MARCELLO MAGGIO;EVA TOPINKOVÁ;ALFONSO J. CRUZ‐JENTOFT;CORNEL SIEBER;JOS M. G. A. SCHOLS;FINBARR C. MARTIN;AVAN AIHIE SAYER","10424;10146;9981;9921;9917;9917;9917;9917;9917;9917;9917;9917;9917;9501;9498;9402;9402;9402;9342;9338","ANTONIO CHERUBINI;FABRIZIA LATTANZIO;ANDREA CORSONELLO;FABIOLA OLIVIERI;ROBERTO TESTA;ROBERTO ANTONICELLI;MAURO PROVINCIALI;PAOLO FABBIETTI;MIRKO DI ROSA;FRANCESCO PIACENZA;ANTONIO DOMENICO PROCOPIO;MARCO MALAVOLTA;FIORENZO CONTI;ROBERTA GALEAZZI;ELISA FELICI;ROBERTA BEVILACQUA;SARA SANTINI;MARCELLO MELONE;GIOVANNI LAMURA;ANDREA SANTARELLI","10424;482;262;245;225;222;202;201;170;144;135;128;122;121;114;114;107;104;88;82","ANTONIO CHERUBINI;FABRIZIA LATTANZIO;MAURO PROVINCIALI;ANDREA CORSONELLO;FABIOLA OLIVIERI;PAOLO FABBIETTI;MIRKO DI ROSA;MARCO MALAVOLTA;FRANCESCO PIACENZA;FRANCESCO SPANNELLA;RICCARDO SARZANI;DANIELE CASTELLANI;ROBERTO TESTA;BEATRICE BERNARDI;GIULIA ROSETTANI;MARCO DELLABELLA;ROBERTA GALEAZZI;ROBERTINA GIACCONI;GUIDO COCCI;LUCA GASPARRI","15;13;11;8;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;SOCIOLOGY;ENGINEERING;PHYSICS;GEOGRAPHY;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;ART","87;28;21;15;14;11;10;7;7;5;5;3;3;3;2;1","INTERNAL MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;GERONTOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;PATHOLOGY;CELL BIOLOGY;GENETICS;LAW;CARDIOLOGY;NURSING;PHYSICAL THERAPY;IMMUNOLOGY;SURGERY;INTENSIVE CARE MEDICINE;NEUROSCIENCE;ONCOLOGY;ANATOMY;CANCER RESEARCH;ECONOMIC GROWTH;EMERGENCY MEDICINE;MECHANICAL ENGINEERING;PUBLIC RELATIONS;SOCIAL PSYCHOLOGY","64;17;17;16;15;14;13;10;10;10;9;9;9;8;8;7;7;6;5;5;5;5;5;5;5","POPULATION;GENE;CONFOUNDING;DISEASE;CANCER;LOGISTIC REGRESSION;OBSERVATIONAL STUDY;DIABETES MELLITUS;COGNITION;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;BLOOD PRESSURE;CONFIDENCE INTERVAL;HEALTH CARE;RANDOMIZED CONTROLLED TRIAL;SARCOPENIA;ALTERNATIVE MEDICINE;ANTICHOLINERGIC;APOPTOSIS;COHORT;COHORT STUDY;OBESITY;ODDS RATIO;OXIDATIVE STRESS","13;12;9;9;8;8;8;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","DEMENTIA;MICRORNA;PROSTATE;TYPE 2 DIABETES;GENOTYPE;HAZARD RATIO;SYNAPTIC PLASTICITY;ACUTE CARE;ACUTE CORONARY SYNDROME;AMBULATORY BLOOD PRESSURE;AUTOPHAGY;CLINICAL ENDPOINT;CLOPIDOGREL;CONTINUOUS POSITIVE AIRWAY PRESSURE;CYTOCHROME C;FETUS;GLUTAMATE RECEPTOR;LIPID PROFILE;MULTICENTER STUDY;NATRIURETIC PEPTIDE;OVERWEIGHT;PERCUTANEOUS CORONARY INTERVENTION;POPULATION AGEING;ROBOTICS;WARFARIN;WEB USABILITY","7;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COENZYME Q – CYTOCHROME C REDUCTASE;DABIGATRAN;RIVAROXABAN;SYSTEM USABILITY SCALE;ADVANCED LIFE SUPPORT;AMNION;ANTIPLATELET DRUG;BASIC LIFE SUPPORT;BLADDER OUTLET OBSTRUCTION;BROTH MICRODILUTION;CAREGIVER BURDEN;CELL CYCLE CHECKPOINT;CERTOLIZUMAB PEGOL;COGNITIVE DECLINE;CYP2C19;CYSTECTOMY;FORAMEN OVALE (HEART);GENETICALLY MODIFIED MOUSE;GENOTYPING;GERIATRIC DEPRESSION SCALE;GLUCOSE HOMEOSTASIS;GLUTAMATERGIC;GLYCINE RECEPTOR;GOLIMUMAB;GUANOSINE TRIPHOSPHATE;HUMAN BREAST;INDACATEROL;LIRAGLUTIDE;MEMBER STATE;MICROVESICLES;MUSCARINIC ANTAGONIST;PLACENTA;PRASUGREL;SEVERE DEMENTIA;SINGLE-NUCLEOTIDE POLYMORPHISM;THROMBIN GENERATION;TICAGRELOR;TORQUE TENO VIRUS;TRANSURETHRAL RESECTION OF THE PROSTATE;TROUGH LEVEL;UNDERWEIGHT;USTEKINUMAB;WHITE COAT HYPERTENSION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;AGED;FEMALE;AGED, 80 AND OVER;;ITALY;MIDDLE AGED;BIOMARKERS;MICRORNAS;PROSTATIC HYPERPLASIA;CELL PROLIFERATION;COGNITIVE DYSFUNCTION;QUALITY OF LIFE;UBIQUINONE;AGING;ANIMALS;DEMENTIA;OXIDATIVE STRESS;PROSPECTIVE STUDIES","68;50;47;44;30;25;25;19;17;15;12;11;10;10;10;9;9;9;9;9","POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;TECHNOLOGY ADOPTION AND AGING POPULATION;IMPACT OF RETIREMENT ON AGING WORKFORCE;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DYSPHAGIA AND SWALLOWING DISORDERS;IMPACT OF RELIGION AND SPIRITUALITY ON HEALTH OUTCOMES;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ALARM FATIGUE IN CLINICAL MONITORING SYSTEMS;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ANTIMICROBIAL PROPERTIES OF ESSENTIAL OILS IN FOODS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH","5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1","AGING;ANTICHOLINERGIC BURDEN;HYPERTENSION;PROSTATE CANCER;TECHNOLOGY USE;DELIRIUM;ACUTE CARE;AFFECT (LINGUISTICS);ANTICOAGULANT THERAPY;APIXABAN;BLOOD PRESSURE;CARDIOVASCULAR RISK ASSESSMENT;CAREGIVER BURDEN;CHOLANGIOCYTE;CLINICAL ENDPOINT;CLOPIDOGREL;COLOCALIZATION;CONTINUOUS GLUCOSE MONITORING;DEPRESSION (ECONOMICS);DIABETES","4;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE CARE;ACUTE CORONARY;ANTICHOLINERGIC BURDEN;ELDERLY PATIENTS;OXIDATIVE STRESS;PATIENTS DISCHARGED;PHYSICAL ACTIVITY;TYPE DIABETES;AIRWAY PRESSURE;BIOLOGICAL RESPONSE;BLOOD PRESSURE;BREAST CANCER;CANCER CELLS;CANCER PATIENTS;CARE HOSPITAL;CHOLANGIOCYTE BIOLOGICAL;CONTROLLED TRIAL;CORONARY SYNDROME;DELIRIUM DAY;DIRECT ORAL;FAMILY CAREGIVERS;FUNCTIONAL DECLINE;HOME RESIDENTS;HOSPITALIZED PATIENTS;INVERSELY CORRELATED;LASER ENUCLEATION;LIPOPROTEIN CHOLESTEROL;MOUSE MODEL;NATRIURETIC PEPTIDE;NURSING HOME","3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","OXIDATIVE STRESS;ALDOSTERONE LEVELS;PHYSICAL ACTIVITY;PHYSICAL EXERCISE;MUSCLE MASS;ROBOT-ERA SYSTEM;UBIQUINOL SUPPLEMENTATION;WALKING SUPPORT;ACUTE CORONARY;BLOOD PRESSURE;CANCER CELLS;CONFIDENCE INTERVAL;ELDERLY PATIENTS;ELDERLY PEOPLE;HOUR PP;HR CI;OBESE PATIENTS;PHYSICAL PERFORMANCE;ROBOTIC SERVICES;TELOMERE LENGTH;BASELINE HBAC;BP CONTROL;BREAST CANCER;CORONARY SYNDROME;CTROUGH LEVELS;DNA DAMAGE;EUROPEAN COUNTRIES;FRAILTY PREVENTION;GERIATRIC MEDICINE;INCREASED RISK","13;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",66,0.67,7.39,10,2.25,3,1,1,4,0,2.5,11.5,1,0,10,5,1,1,4,5,4,0,0,80.5,80.5,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,29,8.79,22,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ASPINALL RICHARD;BERNHARDT JÜRGEN;BERTHOLD MICHAEL;BLASCO MARÍA;BREUSING NICOLLE;BÜRKLE ALEXANDER;CAIAFA PAOLA;COLLINO SEBASTIANO;DOLLÉ MARTIJN;FRANCESCHI CLAUDIO","1;1;1;1;1;1;1;1;1;1","AARHUS UNIVERSITET;ASTON UNIVERSITY;BIOTESYS GMBH;CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CNIO;CRANFIELD UNIVERSITY;ERASMUS UNIVERSITY MEDICAL CENTER;INSTITUTUL NATIONAL DE GERONTOLOGIE SI GERIATRIE ANA ASLAN;INSTYTUT BIOLOGII DOSWIADCZALNEJ IM M NECKIEGO PAN (NENCKI INSTITUTE);ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI (INCRA);MARTIN LUTHER UNIVERSITAET HALLE WITTENBERG","1;1;1;1;1;1;1;1;1;1",NA,NA,NA,NA,NA,NA,"C12Q1/68;G06F19/00","1;1","C12Q1/6876;C12Q1/6881;C12Q2600/154","1;1;1",1,5,60,0.75,1,1,18,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;PATIENT SAFETY","1;1;1;1","CARDIOVASCULAR","1",NA,NA,NA,NA,NA,NA,2,4045889.5,352290.16,5,14,5.5,1,44.5,673151.193652231,0.145583935561777,"ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;MINISTRY OF HEALTH WELFARE AND SPORT;BANGOR UNIVERSITY;BAR-ILAN UNIVERSITY;CAREGIVERS (ISRAEL);CARERS TRUST;CATHOLIC UNIVERSITY OF THE SACRED HEART;CLALIT HEALTH SERVICES;CONSEQUENTIAL ROBOTICS (UNITED KINGDOM);HOMELIFE SUPPORTED ACCOMMODATION (UNITED KINGDOM);ISTITUTO AUXOLOGICO ITALIANO;KALAIDOS UNIVERSITY OF APPLIED SCIENCES;LINKÖPING UNIVERSITY;LINNAEUS UNIVERSITY;REICHMAN UNIVERSITY;SHEBA MEDICAL CENTER;TTOPSTART (NETHERLANDS);UNIVERSITY MEDICAL CENTER GRONINGEN;UNIVERSITY OF GLASGOW;UNIVERSITY OF GRONINGEN","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-MSCA-ITN-2018 (CALL FOR PROPOSAL);MSCA-ITN - MARIE SKŁODOWSKA-CURIE INNOVATIVE TRAINING NETWORKS (ITN) (FUNDING SCHEME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;2","BEHAVIORAL AND SOCIAL SCIENCE;AGING;CLINICAL RESEARCH;HEALTH SERVICES;MENTAL HEALTH;PEDIATRIC;PREVENTION","2;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;MENTAL HEALTH","1;1","7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C20 SOCIAL WORK AND SOCIAL POLICY","1;1","4 QUALITY EDUCATION","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2019,93,11.1720430107527,3.09677419354839,0.43010752688172,0.451612903225806,0.451612903225806,2.21538461538462,1.53846153846154,1.90909090909091,1.55555555555556,0.53763440860215,0,34,26,8,9,0.37,0.28,0.09,0.1,19.03,0.782676576310162,5.68972533062054,0.419354838709677,0.978494623655914,0.493,0.36,0.438,0.424,"ANTONIO CHERUBINI;FRANCESCO SPANNELLA;FABRIZIA LATTANZIO;RICCARDO SARZANI;FABIOLA OLIVIERI;PAOLO FABBIETTI;MIRKO DI ROSA;MAURO PROVINCIALI;ANNA RITA BONFIGLI;GIOVANNI LAMURA;ANDREA CORSONELLO;STEFANO VOLPATO;MARCO MALAVOLTA;CHIARA DI PENTIMA;ROBERTINA GIACCONI;GRAZIANO ONDER;DANIELE CASTELLANI;MARCO DELLABELLA;FIORENZO CONTI;ROBERTA GALEAZZI","15;10;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5;5;5;4","GIOVANNI LAMURA;FRANCESCO SPANNELLA;ANTONIO CHERUBINI;PAOLO FABBIETTI;RICCARDO SARZANI;ANDREA SAGGINI;ROBERTA PAPA;SARA SANTINI;MIRKO DI ROSA;CHIARA DI PENTIMA;FIORENZO CONTI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;CARLO COTA;GEORGIA CASANOVA;AVIAD TUR‐SINAI;DANIELE CASTELLANI;MARCO DELLABELLA;ANDREA CORSONELLO;LORENZO CERRONI","1.8;1.27;1.25;1.2;1.08;1.03;1.02;1;0.98;0.81;0.81;0.8;0.77;0.7;0.67;0.67;0.58;0.54;0.54;0.53","ANTONIO CHERUBINI;FRANCESCO SPANNELLA;FABRIZIA LATTANZIO;RICCARDO SARZANI;FABIOLA OLIVIERI;PAOLO FABBIETTI;MIRKO DI ROSA;MAURO PROVINCIALI;ANNA RITA BONFIGLI;GIOVANNI LAMURA;ANDREA CORSONELLO;MARCO MALAVOLTA;CHIARA DI PENTIMA;ROBERTINA GIACCONI;DANIELE CASTELLANI;MARCO DELLABELLA;FIORENZO CONTI;ROBERTA GALEAZZI;ROBERTA PAPA;FRANCESCO PIACENZA","15;10;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5;4;4;4","GIOVANNI LAMURA;FRANCESCO SPANNELLA;ANTONIO CHERUBINI;PAOLO FABBIETTI;RICCARDO SARZANI;ROBERTA PAPA;SARA SANTINI;MIRKO DI ROSA;CHIARA DI PENTIMA;FIORENZO CONTI;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;CARLO COTA;GEORGIA CASANOVA;DANIELE CASTELLANI;MARCO DELLABELLA;ANDREA CORSONELLO;FEDERICO GIULIETTI;CLAUDIA DI MATTEO;CRISTINA GAGLIARDI","1.8;1.27;1.25;1.2;1.08;1.02;1;0.98;0.81;0.81;0.8;0.77;0.7;0.67;0.58;0.54;0.54;0.5;0.5;0.48","ANTONIO CHERUBINI;FABIOLA OLIVIERI;ANNA RITA BONFIGLI;EMANUELA MENSA’;FRANCESCO SPANNELLA;FRANCESCO LANDI;RICCARDO SARZANI;JACOPO SABBATINELLI;FIORENZO CONTI;FEDERICO GIULIETTI;GIUSEPPE BELLELLI;ANGELICA GIULIANI;MARÍA DE LUCA;ROBERTO TESTA;FRANCESCO PRATTICHIZZO;MAURO PROVINCIALI;PAOLO FABBIETTI;MARCELLO MELONE;ADAM GORDON;ANDREAS E. STUCK","400;280;212;208;205;185;172;171;121;120;113;110;108;107;101;99;98;97;96;96","ANTONIO CHERUBINI;FABIOLA OLIVIERI;ANNA RITA BONFIGLI;FRANCESCO SPANNELLA;RICCARDO SARZANI;FEDERICO GIULIETTI;FIORENZO CONTI;ROBERTO TESTA;MAURO PROVINCIALI;PAOLO FABBIETTI;MARCELLO MELONE;FABRIZIA LATTANZIO;FABIO ROMAGNOLI;MARCO MALAVOLTA;ANTONIO DOMENICO PROCOPIO;ROBERTINA GIACCONI;CHIARA DI PENTIMA;ROBERTA GALEAZZI;FRANCESCO PIACENZA;MIRKO DI ROSA","400;244;212;191;122;120;116;107;99;98;97;92;91;87;81;80;77;77;75;74","ANTONIO CHERUBINI;FRANCESCO SPANNELLA;FABRIZIA LATTANZIO;PAOLO FABBIETTI;RICCARDO SARZANI;MIRKO DI ROSA;MAURO PROVINCIALI;ANDREA CORSONELLO;ANNA RITA BONFIGLI;FABIOLA OLIVIERI;GIOVANNI LAMURA;CHIARA DI PENTIMA;DANIELE CASTELLANI;MARCO DELLABELLA;MARCO MALAVOLTA;ROBERTINA GIACCONI;FRANCESCO PIACENZA;FIORENZO CONTI;ROBERTA GALEAZZI;TIZIANA CASOLI","16;9;8;8;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;ENGINEERING;MATHEMATICS;CHEMISTRY;PHYSICS;BUSINESS;PHILOSOPHY;ART;GEOGRAPHY;MATERIALS SCIENCE","85;27;15;11;10;10;10;9;9;8;7;6;5;2;1;1","INTERNAL MEDICINE;PSYCHIATRY;GERONTOLOGY;PATHOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;NURSING;PHYSICAL THERAPY;BIOCHEMISTRY;CARDIOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;LAW;NEUROSCIENCE;SURGERY;GENETICS;PHARMACOLOGY;ECONOMIC GROWTH;STATISTICS;BIOINFORMATICS;IMMUNOLOGY;MECHANICAL ENGINEERING","59;21;20;16;14;12;12;12;9;9;9;9;9;9;9;8;8;7;7;6;6;6","DISEASE;GENE;POPULATION;BLOOD PRESSURE;DIABETES MELLITUS;CANCER;COGNITION;GERIATRICS;HEALTH CARE;OBSERVATIONAL STUDY;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;ACTIVITIES OF DAILY LIVING;CHOLESTEROL;COHORT;EMERGENCY DEPARTMENT;KIDNEY DISEASE;MEDICAL PRESCRIPTION;POLYPHARMACY;REFERRAL;REHABILITATION;RENAL FUNCTION;WORK (PHYSICS)","15;10;10;9;7;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","DEMENTIA;TYPE 2 DIABETES;ALLELE;AMBULATORY BLOOD PRESSURE;COGNITIVE IMPAIRMENT;LIPID PROFILE;OVERWEIGHT;ALZHEIMER'S DISEASE;BLEOMYCIN;EJECTION FRACTION;EXCITATORY POSTSYNAPTIC POTENTIAL;HEART RATE;METABOLIC SYNDROME;MICRORNA;POPULATION AGEING;POSTSYNAPTIC POTENTIAL;PROSTATE;PULMONARY FIBROSIS;SYSTEMIC ADMINISTRATION;VALSARTAN;WAIST;WELFARE STATE","9;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COGNITIVE DECLINE;HAPLOTYPE;SACUBITRIL;SACUBITRIL, VALSARTAN;ACANTHOLYSIS;ACUTE MIGRAINE;ADVANCED GLYCATION END-PRODUCT;AMPA RECEPTOR;BEHAVIOURAL DESPAIR TEST;BRADYCARDIA;CALCIFEDIOL;CAREGIVER BURDEN;CONVENTIONAL TRANSMISSION ELECTRON MICROSCOPE;CYSTECTOMY;DABIGATRAN;DNA METHYLATION;FKBP5;FRONTOTEMPORAL DEMENTIA;GABA TRANSPORTER;GENOME INSTABILITY;GERIATRIC DEPRESSION SCALE;GLUTAMATERGIC;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HETEROPLASMY;HUMAN GENOME;IONOTROPIC EFFECT;LDL RECEPTOR;MEDDRA;MICROVESICLES;MINI–MENTAL STATE EXAMINATION;NEURAL FACILITATION;ORAL ANTICOAGULANT;POSTSYNAPTIC CURRENT;POSTSYNAPTIC DENSITY;RIVAROXABAN;SCANNING ION-CONDUCTANCE MICROSCOPY;SEXUAL ABUSE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAPENTADOL;TRANSLATION (BIOLOGY);UNTRANSLATED REGION;VASCULAR DEMENTIA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;AGED, 80 AND OVER;;MIDDLE AGED;ITALY;COGNITIVE DYSFUNCTION;ALZHEIMER DISEASE;BIOMARKERS;DIABETES MELLITUS, TYPE 2;ADULT;AGING;RISK FACTORS;EUROPE;CROSS-SECTIONAL STUDIES;DEMENTIA;PROSPECTIVE STUDIES;ANIMALS","57;52;46;41;34;30;24;20;18;17;16;14;12;11;10;9;8;8;8;7","DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;STANDARDISATION AND MANAGEMENT OF COPD;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFECTS OF STRESS ON BRAIN FUNCTION AND HEALTH;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MECHANISMS OF ALZHEIMER'S DISEASE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;PROSTATE CANCER RESEARCH AND TREATMENT;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;ADVANCES IN METABOLOMICS RESEARCH;ATRIAL FIBRILLATION;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CANCER SURVIVORSHIP AND QUALITY OF LIFE","5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1","AGING;HYPERTENSION;INFORMAL CAREGIVING;PULMONARY DISEASE;BLOOD PRESSURE;CAREGIVER BURDEN;COMPREHENSIVE GERIATRIC ASSESSMENT;COPD;DEMENTIA;DEPRESCRIBING;GERIATRIC ASSESSMENT;LIPID PROFILE;LONGITUDINAL STUDY;SARCOPENIA;ADVERSE DRUG EVENTS;CAREGIVING;COGNITIVE DECLINE;DELIRIUM;DEPRESSION (ECONOMICS);DIABETES","7;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ALZHEIMERS DISEASE;BLOOD PRESSURE;COGNITIVE IMPAIRMENT;CHRONIC OBSTRUCTIVE;FAMILY CAREGIVERS;LIPID PROFILE;OBSTRUCTIVE PULMONARY;PULMONARY DISEASE;TYPE DIABETES;AMBULATORY BLOOD;ATHEROGENIC LIPID;COGNITIVE DECLINE;COGNITIVE STATUS;DOUBLE-TROUBLE ATHEROGENIC;EJECTION FRACTION;ENDOTRACHEAL INJECTION;GEAR GESTIONE;GESTIONE DELLEMERGENZA;GLISTEN STUDY;GLOMERULAR FILTRATION;HEALTHY AGING;HEART FAILURE;HOUR AMBULATORY;HYPERTENSIVE EMERGENCIES;INCHIANTI STUDY;INCIDENT ADVERSE;ITALIAN PATIENTS;LONGITUDINAL STUDY;LUNG INJURY;MARCHE REGION","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HR CI;URIC ACID;HEALTH LITERACY;SOMATIC SYMPTOMS;BLOOD PRESSURE;COGNITIVE DECLINE;MIXED SYNAPSES;FAMILY CAREGIVERS;INFORMAL CARERS;INTESTINAL PERMEABILITY;LIPID PROFILE;COGNITIVE IMPAIRMENT;DEMENTIA DIAGNOSIS;EUROPEAN COUNTRIES;GERIATRIC REHABILITATION;HASHTAG UROSOME;LIPOPROTEIN CHOLESTEROL;PHYSICAL ACTIVITY;SERUM LEVELS;SOCIAL MEDIA;TDM PATIENTS;ALZHEIMERS DISEASE;CARDIOVASCULAR MORTALITY;CARDIOVASCULAR RISK;DEL BO;DIETARY PATTERN;DISEASE AD;GERIATRIC MEDICINE;INCREASED RISK;INVERSE CORRELATION","10;10;9;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",50,0.54,9.14,7,1.5,1,0,1,0,0,0,8,0,1,7,1,0,1.5,4,5,6.5,0,0,79.25,79.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,2.67,210,2.34,0,0,10,0,1,0,0,0,0,0,2,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Netherlands;Spain;Sweden;United Kingdom","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;3213 PAEDIATRICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH","3;3;2;1;1;1;1","CLINICAL RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;PREVENTION;AGING;BIOENGINEERING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEALTH SERVICES;KIDNEY DISEASE;MENTAL HEALTH;MIND AND BODY;OSTEOPOROSIS;PATIENT SAFETY;PEDIATRIC;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;PHYSICAL REHABILITATION;REHABILITATION","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INJURIES AND ACCIDENTS;MENTAL HEALTH;RENAL AND UROGENITAL","1;1;1","6.6 PSYCHOLOGICAL AND BEHAVIOURAL;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","1;1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2020,148,15.2635135135135,2.97297297297297,0.324324324324324,0.371621621621622,0.439189189189189,2.69938650306748,1.33333333333333,1.57142857142857,1.625,0.75,1,58,43,15,2,0.39,0.29,0.1,0.01,23.28,0.924012234790275,6.93289841565702,0.439189189189189,0.966216216216216,0.528,0.457,0.488,0.453,"FABRIZIA LATTANZIO;ANTONIO CHERUBINI;ANDREA CORSONELLO;PAOLO FABBIETTI;ANNA RITA BONFIGLI;MIRKO DI ROSA;MAURO PROVINCIALI;FABIOLA OLIVIERI;JACOPO SABBATINELLI;RICCARDO SARZANI;ROBERTINA GIACCONI;FRANCESCO MATTACE‐RASO;REGINA ROLLER‐WIRNSBERGER;LISANNE TAP;TOMASZ KOSTKA;RAFAEL MORENO‐GONZÁLEZ;ELLEN FREIBERGER;FRANCESÇ FORMIGA;GIULIANO ENZI;JOHAN ÄRNLÖV","23;21;21;18;16;15;15;14;10;10;10;10;10;10;9;9;9;9;9;9","GIOVANNI LAMURA;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;ANDREA PRINCIPI;MARCO SOCCI;ANDREA CORSONELLO;DANIELE CASTELLANI;PAOLO FABBIETTI;MIRKO DI ROSA;FABIOLA OLIVIERI;RICCARDO SARZANI;ANNA RITA BONFIGLI;SARA SANTINI;FRANCESCO SPANNELLA;MARCO MASCITTI;ANDREA SANTARELLI;MAURO PROVINCIALI;MARCO DELLABELLA;MARTA BALIETTI;JACOPO SABBATINELLI","2.44;1.56;1.56;1.51;1.44;1.3;1.28;1.22;1.22;1.21;1.15;0.98;0.96;0.96;0.95;0.95;0.94;0.88;0.88;0.86","FABRIZIA LATTANZIO;ANTONIO CHERUBINI;ANDREA CORSONELLO;PAOLO FABBIETTI;ANNA RITA BONFIGLI;MIRKO DI ROSA;MAURO PROVINCIALI;FABIOLA OLIVIERI;RICCARDO SARZANI;ROBERTINA GIACCONI;GIULIANO ENZI;DANIELE CASTELLANI;FRANCESCO GUARASCI;ANDREA SANTARELLI;MARCO SOCCI;SONIA D’ALIA;FEDERICA LENCI;SILVIA BUSTACCHINI;ROBERTA GALEAZZI;GIOVANNI LAMURA","23;21;21;18;16;15;15;14;10;10;9;9;8;8;7;7;7;7;7;7","GIOVANNI LAMURA;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;ANDREA PRINCIPI;MARCO SOCCI;ANDREA CORSONELLO;DANIELE CASTELLANI;PAOLO FABBIETTI;MIRKO DI ROSA;FABIOLA OLIVIERI;RICCARDO SARZANI;ANNA RITA BONFIGLI;SARA SANTINI;FRANCESCO SPANNELLA;ANDREA SANTARELLI;MAURO PROVINCIALI;MARCO DELLABELLA;MARTA BALIETTI;FIORENZO CONTI;CHIARA DI PENTIMA","2.44;1.56;1.56;1.51;1.44;1.3;1.28;1.22;1.22;1.21;1.15;0.98;0.96;0.96;0.95;0.94;0.88;0.88;0.82;0.81","FABIOLA OLIVIERI;JACOPO SABBATINELLI;ANGELICA GIULIANI;ANTONIO CHERUBINI;ANNA RITA BONFIGLI;FABRIZIA LATTANZIO;MASSIMILIANO BONAFÉ;FRANCESCO PRATTICHIZZO;ANDREA CORSONELLO;ANTONIO DOMENICO PROCOPIO;MIRKO DI ROSA;MIRKO PETROVIĆ;GIANLUCA STORCI;MAURO PROVINCIALI;PAOLO FABBIETTI;DANIELE CASTELLANI;ANDREA LANZA;E. GUFFANTI;ENRICO CLINI;FRANCESCO GIGLIOTTI","686;631;584;584;476;435;408;400;354;322;304;294;288;276;276;254;246;246;246;246","FABIOLA OLIVIERI;ANTONIO CHERUBINI;FABRIZIA LATTANZIO;ANNA RITA BONFIGLI;ANDREA CORSONELLO;ANTONIO DOMENICO PROCOPIO;PAOLO FABBIETTI;DANIELE CASTELLANI;E. GUFFANTI;MIRKO DI ROSA;MAURIZIO CARDELLI;ANDREA SANTARELLI;ALESSIA FUMAGALLI;MAURO PROVINCIALI;RICCARDO SARZANI;FIORELLA MARCHESELLI;RINA RECCHIONI;GIOVANNI LAMURA;MARCO SOCCI;GEORGIA CASANOVA","630;584;435;372;340;322;276;254;246;200;191;183;172;172;150;144;144;129;127;108","FABRIZIA LATTANZIO;ANTONIO CHERUBINI;ANDREA CORSONELLO;PAOLO FABBIETTI;FABIOLA OLIVIERI;ANNA RITA BONFIGLI;DANIELE CASTELLANI;RICCARDO SARZANI;MAURO PROVINCIALI;MIRKO DI ROSA;ANDREA SANTARELLI;GIOVANNI LAMURA;MARCO SOCCI;ANDREA PRINCIPI;FRANCESCO SPANNELLA;MARCO MALAVOLTA;ROBERTO ANTONICELLI;CARLO COTA;CHIARA DI PENTIMA;FIORENZA ORLANDO","23;22;20;18;11;10;9;9;9;9;8;7;7;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PSYCHOLOGY;ECONOMICS;SOCIOLOGY;POLITICAL SCIENCE;CHEMISTRY;COMPUTER SCIENCE;BUSINESS;PHYSICS;MATHEMATICS;PHILOSOPHY;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;GEOLOGY;HISTORY","139;42;27;20;19;18;15;14;11;10;9;7;5;4;3;2;1","INTERNAL MEDICINE;PATHOLOGY;GERONTOLOGY;PSYCHIATRY;SURGERY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;NURSING;PHYSICAL THERAPY;ENDOCRINOLOGY;LAW;GENETICS;ECONOMIC GROWTH;IMMUNOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;SOCIAL SCIENCE;DEMOGRAPHY;GASTROENTEROLOGY;PALEONTOLOGY;SOCIAL PSYCHOLOGY","96;32;31;29;24;22;21;20;19;18;15;14;13;11;10;10;10;10;9;9;9;9","DISEASE;POPULATION;GENE;PSYCHOLOGICAL INTERVENTION;RANDOMIZED CONTROLLED TRIAL;CANCER;DIABETES MELLITUS;COGNITION;HEALTH CARE;REHABILITATION;BLOOD PRESSURE;COHORT;INFLAMMATION;KIDNEY DISEASE;RENAL FUNCTION;ALTERNATIVE MEDICINE;ANTIOXIDANT;BODY MASS INDEX;COMORBIDITY;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);IMMUNE SYSTEM;OBSERVATIONAL STUDY","34;20;14;13;12;11;11;10;10;8;7;7;7;7;7;6;6;6;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;TYPE 2 DIABETES;MICRORNA;POLYPHENOL;POPULATION AGEING;PROSTATE;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;GENE EXPRESSION;HAZARD RATIO;PHENOTYPE;PROTOCOL (SCIENCE);ACTIVE AGEING;ACUTE CORONARY SYNDROME;COGNITIVE IMPAIRMENT;DYSLIPIDEMIA;HEALTHY AGEING;NEUROPSYCHOLOGY;PERCUTANEOUS CORONARY INTERVENTION","14;8;7;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);COGNITIVE DECLINE;DNA METHYLATION;AJCC STAGING SYSTEM;FALL PREVENTION;FEAR OF FALLING;GERIATRIC DEPRESSION SCALE;MICROVESICLES;NEUROPSYCHOLOGICAL TEST;TRAIL MAKING TEST;TRANSCRIPTOME;VERBAL FLUENCY TEST;ANGIOTENSIN RECEPTOR BLOCKERS;ANTIRETROVIRAL THERAPY;BECK ANXIETY INVENTORY;BRAIN-DERIVED NEUROTROPHIC FACTOR;CANCER METASTASIS;CARDIAC RESYNCHRONIZATION THERAPY;CAREGIVER BURDEN;CD11C;CD163;CELLULAR SENESCENCE;COENZYME Q – CYTOCHROME C REDUCTASE;COMPARATIVE GENOMIC HYBRIDIZATION;DIFFUSE REFLECTANCE INFRARED FOURIER TRANSFORM;DOUBLE BLIND;EQ-5D;EXHALED NITRIC OXIDE;FGF21;GLYCEMIC INDEX;HAPLOTYPE;HETEROPLASMY;IL-2 RECEPTOR;INTERCLASS CORRELATION;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KILLIP CLASS;LACUNARITY;LOWER URINARY TRACT SYMPTOMS;LYMPHOVASCULAR INVASION;MEMORY SPAN;MIGRAINE WITH AURA;MINI–MENTAL STATE EXAMINATION;MITOCHONDRIAL FUSION;MULTIPARAMETRIC MRI;NEUROPSYCHOLOGICAL ASSESSMENT;PLACENTA;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PRASUGREL;PROSTATE BIOPSY;PROSTATECTOMY;PSYCHOMOTOR DISORDER;QUANTITATIVE COMPUTED TOMOGRAPHY;SACUBITRIL;SACUBITRIL, VALSARTAN;SIDA;SKIN INFECTION;SOLITARY FIBROUS TUMOR;TFAM;TRANSURETHRAL RESECTION OF THE PROSTATE;TUMOR-INFILTRATING LYMPHOCYTES;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;VANCOMYCIN","14;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;AGED;MALE;AGED, 80 AND OVER;ITALY;EUROPE;RENAL INSUFFICIENCY, CHRONIC;MIDDLE AGED;COVID-19;ADULT;CORONAVIRUS INFECTIONS;AGING;PNEUMONIA, VIRAL;CROSS-SECTIONAL STUDIES;SARS-COV-2;BIOMARKERS;POLYPHENOLS;RISK FACTORS","72;70;49;48;46;41;29;23;22;20;19;17;15;14;14;12;12;11;10;10","SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;CORONAVIRUS DISEASE 2019;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;LIFESTYLE MIGRATION AND RETIREMENT MOBILITY;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;IMPACT OF RETIREMENT ON AGING WORKFORCE;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIVERSITY AND FUNCTION OF GUT MICROBIOME","7;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PANDEMIC;SOCIAL ISOLATION;AGING;COGNITIVE DECLINE;DELPHI METHOD;DIETARY PATTERNS;POPULATION AGEING;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;DIETARY IMPACT;HEALTHY EATING INDEX;INTESTINAL PERMEABILITY;NUTRITIONAL STATUS;SENESCENCE;ACTIVE AGEING;AGING WORKFORCE;ATTENDANCE;CAREGIVING;DELPHI;DEPRESSION (ECONOMICS)","7;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","CONTROLLED TRIAL;KIDNEY FUNCTION;RANDOMISED CONTROLLED;TYPE DIABETES;CARDIOVASCULAR RISK;CHRONIC KIDNEY;EUROPEAN COUNTRIES;INTESTINAL PERMEABILITY;KIDNEY DISEASE;SQUAMOUS CELL;ACUTE CORONARY;ACUTE RESPIRATORY;ALZHEIMERS DISEASE;CELL CARCINOMA;COGNITIVE IMPAIRMENT;CORONARY SYNDROME;COVID- PATIENTS;DELPHI STUDY;DIETARY PATTERN;ELDERLY PATIENTS;GERIATRIC MEDICINE;HEALTHY AGING;ITALIAN SOCIETY;LONG-TERM CARE;MAPLE RANDOMISED;POLYPHENOL-RICH DIETARY;RANDOMIZED CONTROLLED;SOCIAL NETWORKING;STUDY PROTOCOL;TONGUE SQUAMOUS","8;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","COGNITIVE IMPAIRMENT;KIDNEY DISEASE;CHRONIC KIDNEY;SCLEROTIC FIBROMA-LIKE;HR CI;ORIGINAL MAGNIFICATION;DISEASE CKD;UROLOGICAL SERVICES;EUROPEAN COUNTRIES;HEALTH CARE;POLYPHENOL INTAKE;SCOPE STUDY;SOCIAL ISOLATION;CELL CARCINOMA;CLINICALTRIALSGOV NCT;DNA METHYLATION;FLUID OVERLOAD;KIDNEY FUNCTION;NATIONAL HEALTH;PHYSICAL PERFORMANCE;TRIAL REGISTRATION;BODY MASS;CONTROLLED TRIAL;CORONAVIRUS DISEASE;COVID- PATIENTS;ELECTRONIC CIGARETTES;ENDOTHELIAL CELLS;EOSIN ORIGINAL;HEALTHY AGING;HEART FAILURE","14;13;12;11;10;10;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",93,0.63,9.5,9,1,1,0,2,1,1,1,13,1,1,11.25,1.25,3.5,2,4.75,7.5,4,0,0,85,85,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4,5130.5,1.28,2,1,321,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Japan;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1","CLINICAL RESEARCH;ASTHMA;ATHEROSCLEROSIS;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;LUNG;PREVENTION","2;1;1;1;1;1;1;1","CARDIOVASCULAR;RESPIRATORY","2;1",NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_INRCA",2021,109,14.6422018348624,3.11926605504587,0.403669724770642,0.422018348623853,0.486238532110092,2.22222222222222,1.25714285714286,1.48387096774194,1.43243243243243,0.73394495412844,2,38,42,9,6,0.35,0.39,0.08,0.06,11.86,0.769250196398916,7.03239556692245,0.422018348623853,0.944954128440367,0.499,0.328,0.393,0.441,"ANTONIO CHERUBINI;MIRKO DI ROSA;FABRIZIA LATTANZIO;MARCO SOCCI;LUCA SORACI;P. ORLANDONI;GIOVANNI LAMURA;FABIOLA OLIVIERI;PAOLO FABBIETTI;CRISTINA ANDRÉS‐LACUEVA;TOMÁS MEROÑO;MARCO MALAVOLTA;GIUSEPPE PELLICCIONI;GIUSEPPE BELLELLI;NICOLE HIDALGO‐LIBERONA;ROBERTO ANTONICELLI;FRANCESCO SPANNELLA;ELVIRA MARANESI;DANIELE CASTELLANI;ANDREA CORSONELLO","23;15;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5","ANTONIO CHERUBINI;MIRKO DI ROSA;PAOLO FABBIETTI;GIOVANNI LAMURA;PAOLO LISSONI;MARCO SOCCI;ELPIDIO SANTILLO;FIORENZO CONTI;GEORGIA CASANOVA;FABRIZIA LATTANZIO;FABIOLA OLIVIERI;FRANCESCO SPANNELLA;DANIELA PUZZO;MARIA VELIA GIULIETTI;ANNA VESPA;RICCARDO SARZANI;ELVIRA MARANESI;DANIELE CASTELLANI;GIORGIO RAPPELLI;LUCA AQUILANTI","2.14;1.62;1.32;1.19;1.09;1.04;1;0.81;0.79;0.71;0.66;0.66;0.62;0.62;0.62;0.58;0.58;0.56;0.53;0.53","ANTONIO CHERUBINI;MIRKO DI ROSA;FABRIZIA LATTANZIO;MARCO SOCCI;LUCA SORACI;P. ORLANDONI;GIOVANNI LAMURA;FABIOLA OLIVIERI;PAOLO FABBIETTI;MARCO MALAVOLTA;GIUSEPPE PELLICCIONI;ROBERTO ANTONICELLI;FRANCESCO SPANNELLA;ELVIRA MARANESI;DANIELE CASTELLANI;ANDREA CORSONELLO;ROBERTA GALEAZZI;ROBERTA BEVILACQUA;SARA SANTINI;LORENA ROSSI","23;15;8;7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4","ANTONIO CHERUBINI;MIRKO DI ROSA;PAOLO FABBIETTI;GIOVANNI LAMURA;PAOLO LISSONI;MARCO SOCCI;ELPIDIO SANTILLO;FIORENZO CONTI;GEORGIA CASANOVA;FABRIZIA LATTANZIO;FABIOLA OLIVIERI;FRANCESCO SPANNELLA;MARIA VELIA GIULIETTI;ANNA VESPA;RICCARDO SARZANI;ELVIRA MARANESI;DANIELE CASTELLANI;GIORGIO RAPPELLI;SARA SANTINI;LORENA ROSSI","2.14;1.62;1.32;1.19;1.09;1.04;1;0.81;0.79;0.71;0.66;0.66;0.62;0.62;0.58;0.58;0.56;0.53;0.51;0.5","ANTONIO CHERUBINI;MIRKO DI ROSA;MARCO MALAVOLTA;ALEXANDER BÜRKLE;BEATRIX GRUBECK‐LOEBENSTEIN;CLAUDIO FRANCESCHI;EFSTATHIOS S. GONOS;EUGÈNE JANSEN;EWA SIKORA;FRANCESCO PIACENZA;MARTIJN E.T. DOLLÉ;MIKKO HURME;MIRIAM CAPRI;NICOLLE BREUSING;OLIVIER TOUSSAINT;P. ELINE SLAGBOOM;TILMAN GRUNE;FIORENZO CONTI;MARCELLO MELONE;CRISTINA ANDRÉS‐LACUEVA","309;171;140;129;129;129;129;129;129;129;129;129;129;129;129;129;129;111;106;101","ANTONIO CHERUBINI;MIRKO DI ROSA;MARCO MALAVOLTA;FRANCESCO PIACENZA;FIORENZO CONTI;MARCELLO MELONE;MARCO SOCCI;FABIOLA OLIVIERI;ANDREA BASSO;GIOVANNI LAMURA;P. ORLANDONI;ANTONIO DOMENICO PROCOPIO;LUCA SORACI;ANDREA CORSONELLO;MAURO PROVINCIALI;PAOLO FABBIETTI;ELVIRA MARANESI;FABRIZIA LATTANZIO;ROBERTINA GIACCONI;ROBERTA BEVILACQUA","309;171;140;129;111;106;100;91;90;80;73;69;66;64;64;62;61;61;61;57","ANTONIO CHERUBINI;MIRKO DI ROSA;FABRIZIA LATTANZIO;MARCO SOCCI;P. ORLANDONI;GIOVANNI LAMURA;PAOLO FABBIETTI;ELVIRA MARANESI;FABIOLA OLIVIERI;ROBERTO ANTONICELLI;ANDREA CORSONELLO;DANIELE CASTELLANI;FRANCESCO SPANNELLA;LUCA SORACI;MARCO MALAVOLTA;C. MINAGLIA;FIORENZO CONTI;FRANCESCO PIACENZA;GIUSEPPE PELLICCIONI;MAURO PROVINCIALI","23;15;8;7;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4","MEDICINE;PSYCHOLOGY;BIOLOGY;COMPUTER SCIENCE;ECONOMICS;SOCIOLOGY;CHEMISTRY;MATHEMATICS;BUSINESS;POLITICAL SCIENCE;GEOGRAPHY;PHILOSOPHY;PHYSICS;ENGINEERING;ART","102;29;27;16;12;11;9;9;6;6;5;5;5;4;2","INTERNAL MEDICINE;GERONTOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;GENETICS;PHYSICAL THERAPY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NURSING;SURGERY;ARTIFICIAL INTELLIGENCE;ECONOMIC GROWTH;PHYSIOLOGY;EMERGENCY MEDICINE;GASTROENTEROLOGY;PALEONTOLOGY;SOCIAL SCIENCE","73;23;22;20;18;12;12;10;10;10;10;10;10;10;9;9;8;7;7;7;7","DISEASE;POPULATION;GENE;OBSERVATIONAL STUDY;BLOOD PRESSURE;CANCER;COHORT;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;COGNITION;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);HEALTH CARE;AGEING;ALTERNATIVE MEDICINE;COHORT STUDY;INFLAMMATION;INTERVENTION (COUNSELING);PROPORTIONAL HAZARDS MODEL;PSYCHOLOGICAL INTERVENTION;QUALITATIVE RESEARCH;SARCOPENIA","32;18;11;9;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;ACTIVE AGEING;PROSTATE;ALZHEIMER'S DISEASE;ANGIOTENSIN II;COGNITIVE IMPAIRMENT;HEALTHY AGEING;LUNG FUNCTION;16S RIBOSOMAL RNA;2019-20 CORONAVIRUS OUTBREAK;AMBULATORY BLOOD PRESSURE;BONE MINERAL;CLINICAL ENDPOINT;DYSLIPIDEMIA;ENTERAL ADMINISTRATION;GENE EXPRESSION;HAZARD RATIO;MICRORNA;MULTICENTER STUDY;MYCOSIS FUNGOIDES;NEURODEGENERATION;ODDS;OFFSPRING;POPULATION AGEING;PROTOCOL (SCIENCE);ROBOTICS;THEMATIC ANALYSIS;URINATION","15;10;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);CAREGIVER BURDEN;COGNITIVE DECLINE;DIFFUSING CAPACITY;LOWER URINARY TRACT SYMPTOMS;OSTEOPENIA;ANGIOTENSIN RECEPTOR;ATYPICAL ANTIPSYCHOTIC;BIFIDOBACTERIUM;BLADDER OUTLET OBSTRUCTION;CARDIAC RESYNCHRONIZATION THERAPY;CATHELICIDIN;CLINICAL DEMENTIA RATING;COMET ASSAY;CONCENTRIC HYPERTROPHY;CUTANEOUS T-CELL LYMPHOMA;DEBULKING;DNA METHYLATION;DOCOSAHEXAENOIC ACID;DOMESTIC VIOLENCE;ELDER ABUSE;FIRMICUTES;GENETICALLY MODIFIED MOUSE;LACUNARITY;MEMORY SPAN;MIGRAINE WITH AURA;MINI–MENTAL STATE EXAMINATION;QUANTITATIVE COMPUTED TOMOGRAPHY;REPRESSOR;SACUBITRIL;SACUBITRIL, VALSARTAN;SANGER SEQUENCING;SEVERE DEMENTIA;SEXUAL ABUSE;SOD1;SUBSTANTIA NIGRA;SUBTELOMERE;TRANSURETHRAL RESECTION OF THE PROSTATE;URAPIDIL;VANCOMYCIN;VENTRAL TEGMENTAL AREA","15;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;AGED;MALE;FEMALE;ITALY;AGED, 80 AND OVER;CROSS-SECTIONAL STUDIES;SARCOPENIA;BIOMARKERS;AGING;ALZHEIMER DISEASE;COVID-19;DELIRIUM;MIDDLE AGED;PROGNOSIS;RISK FACTORS;ANIMALS;CARDIOVASCULAR DISEASES;HYPERTENSION","59;45;42;24;22;14;13;13;13;11;10;9;8;8;8;8;7;6;6;6","DIVERSITY AND FUNCTION OF GUT MICROBIOME;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;TECHNOLOGY ADOPTION AND AGING POPULATION;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;LIFESTYLE MIGRATION AND RETIREMENT MOBILITY;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ATRIAL FIBRILLATION;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;COMPUTATIONAL METHODS IN DRUG DISCOVERY;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMPACT OF PARENTAL ILLNESS ON CHILDREN AND FAMILIES;MECHANISMS OF ALZHEIMER'S DISEASE;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;OSTEOPOROSIS;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY","5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","AGING;PANDEMIC;ACTIVE AGEING;ASSOCIATION (PSYCHOLOGY);CAREGIVER BURDEN;DELPHI METHOD;DIETARY PATTERNS;HEALTHY AGEING;HYPERTENSION;INFORMAL CAREGIVING;NUTRITIONAL STATUS;SUCCESSFUL AGING;2019-20 CORONAVIRUS OUTBREAK;AFFECT (LINGUISTICS);AGING IN PLACE;AGING SOCIETIES;AGING WORKFORCE;ATRIAL FIBRILLATION;BIOMARKERS;CAREGIVER STAFFING","6;6;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ALZHEIMERS DISEASE;ELDERLY PATIENTS;COVID- PANDEMIC;MOUSE MODEL;PATIENTS AFFECTED;PILOT STUDY;ACTIVE AGEING;BACTERIAL DNAEMIA;BLOOD PRESSURE;CARDIOVASCULAR RISK;CARE BURDEN;COGNITIVE IMPAIRMENT;CONTROLLED TRIAL;COVID- PATIENTS;CROSS-SECTIONAL STUDY;DELIRIUM DAY;EUROPEAN POPULATION;HOSPITALIZED COVID-;ILL HOSPITALIZED;MARK-AGE STUDY;NON-CRITICALLY ILL;NUTRI-COVID STUDY;NUTRITIONAL PARAMETERS;OBSERVATIONAL STUDY;ORAL HEALTH;ORAL TONGUE;PATIENTS DISCHARGED;PERSONALITY TRAITS;PRESSURE CONTROL;PROGNOSTIC INTERPLAY","6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACTIVE AGEING;HR CI;IN-HOSPITAL MORTALITY;IRCCS INRCA;BP CONTROL;MUSCLE MASS;DNA METHYLATION;ACCETTAZIONE GERIATRICA;AMBULATORY BP;BODY MASS;CENTRO DI;DI RICERCA;GERIATRIA ACCETTAZIONE;INRCA ANCONA;LINVECCHIAMENTO IRCCS;MASS INDEX;NUTRITION INTERVENTION;TRIPLE THERAPY;CORONAVIRUS DISEASE;COVID- PANDEMIC;CROSS-SECTIONAL STUDY;DIETARY BIOMARKERS;DNA DAMAGE;EUROPEAN COUNTRIES;FOOD INTAKE;PROTEIN INTAKE;ANCONA ITALYSEARCH;CXR SCORE;INTESTINAL PERMEABILITY;LOW SKELETAL","13;11;11;11;10;10;9;8;8;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6",61,0.56,9.6,10,1,1,0,3.5,0,1,1,11,1.25,0,10.5,1,1,2,7.5,7,5,0,0,49,49,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0.29,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"STARNARI ROBERTO","1","INRCA","1","42 HEALTH SCIENCES;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE;49 MATHEMATICAL SCIENCES","1;1;1",NA,NA,NA,NA,"A61B17/34;A61M25/00","1;1","A61B17/3401;A61B17/3415;A61B17/3417;A61M2025/0007","1;1;1;1",1,2,1067,0.66,0,0,127,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BIOENGINEERING;BRAIN DISORDERS;CLINICAL RESEARCH;PATIENT SAFETY;PREVENTION;STROKE","1;1;1;1;1;1","STROKE","1",NA,NA,NA,NA,NA,NA,1,3998220,333185,3,12,5,1,20,340012.189583333,0.320576742067905,"AGE PLATFORM EUROPE;ARCHDIOCESE OF COLOGNE;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ENGINEERING (ITALY);FRAUNHOFER SOCIETY;INSTITUT MINES-TÉLÉCOM;INSTITUTE FOR EXPERIMENTAL PSYCHOPHYSIOLOGY (GERMANY);ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;LEIPZIG UNIVERSITY;MARCHE POLYTECHNIC UNIVERSITY;TOHOKU UNIVERSITY;UNIVERSITY OF SIEGEN","1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE;4608 HUMAN-CENTRED COMPUTING","1;1;1","PREVENTION","1",NA,NA,"7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,1,"FRONTIERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","2;1;1","AGING;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CLINICAL RESEARCH;REHABILITATION","1;1;1;1;1;1",NA,NA,NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"IRCCS_INRCA",2022,130,14.8769230769231,4.30769230769231,0.407692307692308,0.415384615384615,0.453846153846154,2.41379310344828,1.35897435897436,1.6875,1.63888888888889,0.861538461538462,4,42,46,9,6,0.32,0.35,0.07,0.05,8.64,0.967698766257825,6.97983193277312,0.4,0.907692307692308,0.617,0.421,0.44,0.467,"MIRKO DI ROSA;ANNA RITA BONFIGLI;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;FABIOLA OLIVIERI;MARCO SOCCI;PAOLO FABBIETTI;ANDREA CORSONELLO;JACOPO SABBATINELLI;ROBERTO ANTONICELLI;GIOVANNI LAMURA;ANGELICA GIULIANI;MAURO PROVINCIALI;ROBERTA BEVILACQUA;ROBERTINA GIACCONI;ELVIRA MARANESI;GIULIA MATACCHIONE;SARA SANTINI;FRANCESCO PIACENZA;GIUSEPPE PELLICCIONI","19;16;15;15;14;13;13;13;12;12;11;10;10;9;9;9;9;8;8;8","ALHASSAN HASSAN;GIOVANNI LAMURA;MARCO SOCCI;MIRKO DI ROSA;ANNA RITA BONFIGLI;SARA SANTINI;SABRINA QUATTRINI;PAOLO FABBIETTI;FABIOLA OLIVIERI;BARBARA D’AMEN;ANTONIO CHERUBINI;A HASSAN;ROBERTO ANTONICELLI;JACOPO SABBATINELLI;FABRIZIA LATTANZIO;MARIA GABRIELLA MELCHIORRE;ROBERTA BEVILACQUA;ELVIRA MARANESI;GIUSEPPE PELLICCIONI;ANGELICA GIULIANI","3;2.29;2.27;1.83;1.38;1.31;1.19;1.18;1.12;1.11;1.06;1;0.97;0.94;0.92;0.85;0.78;0.78;0.78;0.75","MIRKO DI ROSA;ANNA RITA BONFIGLI;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;FABIOLA OLIVIERI;MARCO SOCCI;PAOLO FABBIETTI;ANDREA CORSONELLO;ROBERTO ANTONICELLI;GIOVANNI LAMURA;MAURO PROVINCIALI;ROBERTA BEVILACQUA;ROBERTINA GIACCONI;ELVIRA MARANESI;SARA SANTINI;FRANCESCO PIACENZA;GIUSEPPE PELLICCIONI;MARCO MALAVOLTA;ROBERTA GALEAZZI;BARBARA D’AMEN","19;16;15;15;14;13;13;13;12;11;10;9;9;9;8;8;8;7;7;7","ALHASSAN HASSAN;GIOVANNI LAMURA;MARCO SOCCI;MIRKO DI ROSA;ANNA RITA BONFIGLI;SARA SANTINI;SABRINA QUATTRINI;PAOLO FABBIETTI;FABIOLA OLIVIERI;BARBARA D’AMEN;ANTONIO CHERUBINI;A HASSAN;ROBERTO ANTONICELLI;FABRIZIA LATTANZIO;MARIA GABRIELLA MELCHIORRE;ROBERTA BEVILACQUA;ELVIRA MARANESI;GIUSEPPE PELLICCIONI;CRISTINA GAGLIARDI;OLGA PROTIC","3;2.29;2.27;1.83;1.38;1.31;1.19;1.18;1.12;1.11;1.06;1;0.97;0.92;0.85;0.78;0.78;0.78;0.64;0.63","ANTONIO CHERUBINI;FABRIZIA LATTANZIO;REGINA ROLLER‐WIRNSBERGER;CORNEL SIEBER;FABIOLA OLIVIERI;ROBERTO BERNABEI;JACOPO SABBATINELLI;EMANUELE MARZETTI;FRANCESCO LANDI;MARCELLO MAGGIO;RICCARDO CALVANI;ACHILLE TCHALLA;ALAN J. SINCLAIR;ALFONSO J. CRUZ‐JENTOFT;ANNA SKALSKA;ANNEMIE M.W.J. SCHOLS;BRUNO VELLAS;CARMEN GOROSTIAGA AYESTARÁN;EVA TOPINKOVÁ;HARMONIE GOYEAU","330;324;233;230;203;191;185;172;172;172;172;167;167;167;167;167;167;167;167;167","ANTONIO CHERUBINI;FABRIZIA LATTANZIO;FABIOLA OLIVIERI;ANNA RITA BONFIGLI;MIRKO DI ROSA;MARCO SOCCI;ANDREA CORSONELLO;DEBORAH RAMINI;GIOVANNI LAMURA;FRANCESCO PIACENZA;PAOLO FABBIETTI;ELVIRA MARANESI;ROBERTA BEVILACQUA;MARCO MALAVOLTA;ROBERTINA GIACCONI;MAURO PROVINCIALI;ROBERTA GALEAZZI;RICCARDO SARZANI;GIUSEPPE PELLICCIONI;ROBERTO ANTONICELLI","306;301;163;146;119;110;105;95;91;87;78;71;71;69;69;68;67;66;64;60","MIRKO DI ROSA;ANNA RITA BONFIGLI;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;MARCO SOCCI;ANDREA CORSONELLO;PAOLO FABBIETTI;FABIOLA OLIVIERI;GIOVANNI LAMURA;ROBERTO ANTONICELLI;ELVIRA MARANESI;MAURO PROVINCIALI;ROBERTA BEVILACQUA;FRANCESCO PIACENZA;GIUSEPPE PELLICCIONI;RICCARDO SARZANI;ROBERTINA GIACCONI;SARA SANTINI;BARBARA D’AMEN;MARCO MALAVOLTA","18;15;14;13;12;12;12;11;11;10;9;9;9;8;8;8;8;7;7;7","MEDICINE;PSYCHOLOGY;BIOLOGY;ECONOMICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;PHYSICS;MATHEMATICS;BUSINESS;CHEMISTRY;GEOGRAPHY;ENGINEERING;PHILOSOPHY;MATERIALS SCIENCE;HISTORY","118;36;26;22;21;18;13;12;11;10;9;8;6;6;3;1","INTERNAL MEDICINE;PATHOLOGY;GERONTOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;NURSING;ECONOMIC GROWTH;ENDOCRINOLOGY;CARDIOLOGY;IMMUNOLOGY;SURGERY;PHYSICAL THERAPY;SOCIAL PSYCHOLOGY;CLINICAL PSYCHOLOGY;GENETICS;LAW;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;ARCHAEOLOGY;BIOCHEMISTRY;DEMOGRAPHY;FAMILY MEDICINE;PALEONTOLOGY;SOCIAL SCIENCE","81;34;32;26;24;23;15;13;12;12;12;11;11;10;10;10;9;9;8;8;8;8;8;8","DISEASE;POPULATION;HEALTH CARE;CANCER;COHORT;CONTEXT (ARCHAEOLOGY);LOGISTIC REGRESSION;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;DIABETES MELLITUS;HEART FAILURE;INFLAMMATION;ALTERNATIVE MEDICINE;BLOOD PRESSURE;INTERVENTION (COUNSELING);MYOCARDIAL INFARCTION;OLDER PEOPLE;PROPORTIONAL HAZARDS MODEL;PSYCHOLOGICAL INTERVENTION;COGNITION;GENE;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL;RENAL FUNCTION","30;22;13;11;11;11;11;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;TYPE 2 DIABETES;2019-20 CORONAVIRUS OUTBREAK;PROSTATE;SOCIOECONOMIC STATUS;CLINICAL ENDPOINT;DYSLIPIDEMIA;INJURY PREVENTION;PHENOTYPE;PLACEBO;POPULATION AGEING;PROTOCOL (SCIENCE);TROPONIN;UNIVARIATE ANALYSIS;ACTIVE AGEING;ACUTE CORONARY SYNDROME;BREAST CANCER;COGNITIVE INTERVENTION;GENE EXPRESSION;HAZARD RATIO;INSULIN RESISTANCE;NEUROTROPHIC FACTORS;POLYPHENOL;PROINFLAMMATORY CYTOKINE;PROSTATE CANCER;ROBOTICS;SUICIDE PREVENTION;SYSTEMIC INFLAMMATION","14;13;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);COGNITIVE DECLINE;CAREGIVER BURDEN;CROSSOVER STUDY;DNA METHYLATION;FEAR OF FALLING;LOWER URINARY TRACT SYMPTOMS;ADIPOSE TISSUE MACROPHAGES;BRADYCARDIA;BRAIN-DERIVED NEUROTROPHIC FACTOR;BREAST SURGERY;CD38;CELLULAR SENESCENCE;CILIARY NEUROTROPHIC FACTOR;CUTANEOUS T-CELL LYMPHOMA;DIFFUSING CAPACITY;DOUBLE BLIND;ELLAGIC ACID;ENALAPRIL;FKBP5;GESTALT THERAPY;HETEROPLASMY;HONEYCOMBING;HUMAN GENOME;IVACAFTOR;LACUNARITY;LDL RECEPTOR;LYMPH NODE METASTASIS;MASKED HYPERTENSION;MODIFIED RANKIN SCALE;MTORC1;PNEUMONIA SEVERITY INDEX;PRASUGREL;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;ROBOT CONTROL;SACUBITRIL;SACUBITRIL, VALSARTAN;SINGLE-NUCLEOTIDE POLYMORPHISM;TAKOTSUBO SYNDROME;TELEHEALTH;TRANSPOSABLE ELEMENT;TRASTUZUMAB;TROPONIN COMPLEX;VENTRAL TEGMENTAL AREA","14;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;AGED;;COVID-19;MALE;CAREGIVERS;FEMALE;DIABETES MELLITUS, TYPE 2;DEMENTIA;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;BIOMARKERS;COGNITIVE DYSFUNCTION;CROSS-SECTIONAL STUDIES;PROGNOSIS;TREATMENT OUTCOME;AGING;CARDIOVASCULAR DISEASES;ITALY;QUALITY OF LIFE","80;52;47;29;18;17;15;13;12;12;11;11;10;10;10;9;8;8;8;8","TECHNOLOGY ADOPTION AND AGING POPULATION;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;QUALITY AND PRACTICES IN NURSING HOME CARE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIVERSITY AND FUNCTION OF GUT MICROBIOME;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;IMPACT OF PARENTAL ILLNESS ON CHILDREN AND FAMILIES;PATHOPHYSIOLOGY AND CLINICAL CHARACTERISTICS OF STRESS-INDUCED CARDIOMYOPATHY;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION","11;6;6;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","INFORMAL CAREGIVING;AGING;PANDEMIC;CAREGIVER BURDEN;CAREGIVING;DEPRESSION (ECONOMICS);SENESCENCE;BLOOD PRESSURE;DEMENTIA;DIABETES;FAMILY CAREGIVERS;GERIATRIC ASSESSMENT;LONG-TERM CARE;SOCIAL SUPPORT;YOUNG CARERS;AFFECT (LINGUISTICS);AGING SOCIETIES;ALZHEIMER'S DISEASE;CAREGIVER STAFFING;CLINICAL ENDPOINT","13;8;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3","INFORMAL CAREGIVERS;IN-HOSPITAL MORTALITY;COVID- PATIENTS;HEART FAILURE;DIGITAL SUPPORT;ELDERLY PATIENTS;QUALITATIVE STUDY;SUPPORT SERVICES;TYPE DIABETES;ACUTE HEART;CARDIAC TROPONIN;CELL CARCINOMA;COHORT STUDY;COVID- PANDEMIC;HIGH-SENSITIVITY CARDIAC;LONG-TERM CARE;MULTICENTER STUDY;PARKINSONS DISEASE;RETROSPECTIVE STUDY;TAKOTSUBO SYNDROME;ACUTE CORONARY;ADMISSION HIGH-SENSITIVITY;ALZHEIMERS DISEASE;BACTERIAL DNAEMIA;BLOOD PRESSURE;BREAST CANCER;CHRONIC KIDNEY;COGNITIVE DECLINE;COGNITIVE IMPAIRMENT;COMPARATIVE STUDY","8;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","INFORMAL CAREGIVERS;DIGITAL SUPPORT;SUPPORT SERVICES;TYPE DIABETES;CARE RECIPIENT;BLOOD PRESSURE;IN-HOSPITAL MORTALITY;COVID- PATIENTS;HEART FAILURE;IN-HOSPITAL DEATH;PR CI;CARE RECIPIENTS;MULTICOMPONENT INTERVENTION;PHYSICAL PERFORMANCE;CFTR MODULATOR;COGNITIVE IMPAIRMENT;DAILY LIVING;HR CI;LOGISTIC REGRESSION;LONG-TERM CARE;MODULATOR THERAPY;CL CL;CONFIDENCE INTERVAL;INCREASED RISK;MORTALITY RISK;PRESCRIBING CASCADES;ALL-CAUSE MORTALITY;COVID- PANDEMIC;CROSS-SECTIONAL STUDY;ELDERLY PATIENTS","20;18;17;17;15;14;14;12;12;12;12;11;11;11;10;10;10;10;10;10;10;9;9;9;9;9;8;8;8;8",65,0.5,8.05,9,1,1,0,3,1,1,1,10,2,0,9,0,1,1.5,3,7.5,4.5,0,0,30,30,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,730,0.54,0,0,78,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;PREVENTION","1;1;1;1;1","METABOLIC AND ENDOCRINE","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,1,2836559,709139.75,4,4,1,1,0,392300.720833333,0.331378437755228,"CONSORZIO INTERUNIVERSITARIO NAZIONALE PER L'INFORMATICA;GIANNI BENZI PHARMACOLOGICAL RESEARCH FOUNDATION;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;MARCHE POLYTECHNIC UNIVERSITY","1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","DIGITAL EUROPE PROGRAMME (DIGITAL) (PROGRAMME)","1","46 INFORMATION AND COMPUTING SCIENCES;4602 ARTIFICIAL INTELLIGENCE","1;1","CLINICAL RESEARCH;HEALTH SERVICES","1;1","GENERIC HEALTH RELEVANCE","1","7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,3,"FRONTIERS","3","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","6;3;3",NA,NA,NA,NA,"7.1 INDIVIDUAL CARE NEEDS","3","HEALTH SERVICES & SYSTEMS","3","HEALTH SERVICES RESEARCH","3","NOT SITE-SPECIFIC CANCER","3",NA,NA
"IRCCS_INRCA",2023,127,14.4173228346457,4.18897637795276,0.448818897637795,0.425196850393701,0.511811023622047,2.6078431372549,1.46153846153846,1.54285714285714,1.66666666666667,0.905511811023622,1,48,28,3,7,0.38,0.22,0.02,0.06,5.24,1.19464148633003,6.49920382165607,0.362204724409449,0.976377952755906,0.533,0.457,0.499,0.463,"MIRKO DI ROSA;FABRIZIA LATTANZIO;FABIOLA OLIVIERI;RICCARDO SARZANI;FRANCESCO SPANNELLA;ANNA RITA BONFIGLI;ANTONIO CHERUBINI;JACOPO SABBATINELLI;ROBERTINA GIACCONI;ROBERTA GALEAZZI;FRANCESCO PIACENZA;ANGELICA GIULIANI;ROBERTA BEVILACQUA;CHIARA DI PENTIMA;ELVIRA MARANESI;ANDREA CORSONELLO;FEDERICO GIULIETTI;MASSIMILIANO ALLEVI;DEBORAH RAMINI;PAOLO FABBIETTI","16;15;15;14;14;13;13;12;11;10;10;10;9;9;9;9;9;8;8;8","MIRKO DI ROSA;FRANCESCO SPANNELLA;FABIOLA OLIVIERI;RICCARDO SARZANI;FABRIZIA LATTANZIO;GIOVANNI LAMURA;ANDREA CORSONELLO;FEDERICO GIULIETTI;CLAUDIO MARIA MAFFEI;ROBERTINA GIACCONI;MASSIMILIANO ALLEVI;JACOPO SABBATINELLI;ANNA RITA BONFIGLI;CHIARA DI PENTIMA;MARCO SOCCI;PAOLO FABBIETTI;ROBERTA BEVILACQUA;ROBERTA GALEAZZI;ANTONIO CHERUBINI;FRANCESCO PIACENZA","1.48;1.41;1.34;1.29;1.28;1.08;1.02;1.02;1;0.99;0.98;0.97;0.93;0.92;0.91;0.91;0.89;0.89;0.86;0.83","MIRKO DI ROSA;FABRIZIA LATTANZIO;FABIOLA OLIVIERI;RICCARDO SARZANI;FRANCESCO SPANNELLA;ANNA RITA BONFIGLI;ANTONIO CHERUBINI;ROBERTINA GIACCONI;ROBERTA GALEAZZI;FRANCESCO PIACENZA;ROBERTA BEVILACQUA;CHIARA DI PENTIMA;ELVIRA MARANESI;ANDREA CORSONELLO;FEDERICO GIULIETTI;MASSIMILIANO ALLEVI;DEBORAH RAMINI;PAOLO FABBIETTI;MAURO PROVINCIALI;SARA SANTINI","16;15;15;14;14;13;13;11;10;10;9;9;9;9;9;8;8;8;8;7","MIRKO DI ROSA;FRANCESCO SPANNELLA;FABIOLA OLIVIERI;RICCARDO SARZANI;FABRIZIA LATTANZIO;GIOVANNI LAMURA;ANDREA CORSONELLO;FEDERICO GIULIETTI;CLAUDIO MARIA MAFFEI;ROBERTINA GIACCONI;MASSIMILIANO ALLEVI;ANNA RITA BONFIGLI;CHIARA DI PENTIMA;MARCO SOCCI;PAOLO FABBIETTI;ROBERTA BEVILACQUA;ROBERTA GALEAZZI;ANTONIO CHERUBINI;FRANCESCO PIACENZA;ELVIRA MARANESI","1.48;1.41;1.34;1.29;1.28;1.08;1.02;1.02;1;0.99;0.98;0.93;0.92;0.91;0.91;0.89;0.89;0.86;0.83;0.78","ANTONIO CHERUBINI;ALFONSO J. CRUZ‐JENTOFT;GÜLISTAN BAHAT;GRAZIANO ONDER;AÐALSTEINN GUÐMUNDSSON;MICHAEL DENKINGER;DENIS O’MAHONY;MIRKO PETROVIĆ;NATHALIE VAN DER VELDE;ANNA RENOM‐GUITERAS;DENIS CURTIN;JEAN‐BAPTISTE BEUSCART;WILMA KNOL;CORNEL SIEBER;ANNA RITA BONFIGLI;FABIOLA OLIVIERI;JACOPO SABBATINELLI;ANDREAS S. LAPPAS;DANIEL PINTO;FEDERICA LIMONGI","346;285;285;280;264;264;256;256;256;248;248;248;248;68;66;66;60;58;58;58","ANTONIO CHERUBINI;ANNA RITA BONFIGLI;MIRKO DI ROSA;FABIOLA OLIVIERI;FABRIZIA LATTANZIO;ELVIRA MARANESI;ANDREA CORSONELLO;FRANCESCO PIACENZA;ROBERTA BEVILACQUA;DEBORAH RAMINI;ROBERTINA GIACCONI;GIULIO AMABILI;PAOLO FABBIETTI;ARIANNA MARGARITINI;MAURO PROVINCIALI;LUCA SORACI;ROBERTA GALEAZZI;FRANCESCO SPANNELLA;MARCO MALAVOLTA;ANTONIO DOMENICO PROCOPIO","346;65;54;50;47;43;41;41;39;37;33;30;29;28;28;27;27;26;23;22","MIRKO DI ROSA;FABRIZIA LATTANZIO;FRANCESCO SPANNELLA;ANTONIO CHERUBINI;FABIOLA OLIVIERI;ANNA RITA BONFIGLI;RICCARDO SARZANI;FRANCESCO PIACENZA;ROBERTINA GIACCONI;ELVIRA MARANESI;ROBERTA GALEAZZI;CHIARA DI PENTIMA;FEDERICO GIULIETTI;ANDREA CORSONELLO;ROBERTA BEVILACQUA;DEBORAH RAMINI;MASSIMILIANO ALLEVI;PAOLO FABBIETTI;GIULIO AMABILI;MAURO PROVINCIALI","15;15;14;13;12;12;12;10;10;9;9;9;9;9;9;8;8;8;7;7","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;BUSINESS;ENGINEERING;PHYSICS;GEOGRAPHY;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;ART;GEOLOGY","109;40;34;25;16;13;12;12;11;6;6;5;5;5;3;1;1","INTERNAL MEDICINE;PSYCHIATRY;GERONTOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;NURSING;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;PHYSICAL THERAPY;SURGERY;ENDOCRINOLOGY;GENETICS;IMMUNOLOGY;LAW;PSYCHOTHERAPIST;CELL BIOLOGY;HUMAN–COMPUTER INTERACTION;PALEONTOLOGY;ECONOMIC GROWTH;SOCIAL PSYCHOLOGY","62;31;28;28;26;21;20;14;12;12;12;11;11;11;11;11;10;10;10;9;9","DISEASE;POPULATION;GENE;QUALITY OF LIFE (HEALTHCARE);PSYCHOLOGICAL INTERVENTION;CONTEXT (ARCHAEOLOGY);HEALTH CARE;INTERVENTION (COUNSELING);OBSERVATIONAL STUDY;CANCER;COHORT;DIABETES MELLITUS;INFLAMMATION;PROSPECTIVE COHORT STUDY;USABILITY;CHOLESTEROL;COGNITION;CONFIDENCE INTERVAL;CROSS-SECTIONAL STUDY;LOGISTIC REGRESSION;OUTBREAK;PROPORTIONAL HAZARDS MODEL;SENESCENCE;SERVICE (BUSINESS);SOCIAL SUPPORT","32;23;14;13;12;9;9;8;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;2019-20 CORONAVIRUS OUTBREAK;HAZARD RATIO;POPULATION AGEING;GENE EXPRESSION;MICRORNA;PROINFLAMMATORY CYTOKINE;PROSTATE;ACTIVE AGEING;AMBULATORY BLOOD PRESSURE;DOWNREGULATION AND UPREGULATION;LIPOPROTEIN;PHENOTYPE;SOCIOECONOMIC STATUS;ADENOCARCINOMA;ADIPOGENESIS;ANTIBIOTIC RESISTANCE;DIASTOLE;EFFECTS OF SLEEP DEPRIVATION ON COGNITIVE PERFORMANCE;EHEALTH;FAMILIAL HYPERCHOLESTEROLEMIA;HEMOTHORAX;HUMAN–ROBOT INTERACTION;OVERWEIGHT;PREVALENCE;PROSTATE CANCER;PROTOCOL (SCIENCE);REMINERALISATION;SUPEROXIDE DISMUTASE;THEMATIC ANALYSIS;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;UMBILICAL VEIN","14;11;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);COGNITIVE DECLINE;LDL RECEPTOR;LOWER URINARY TRACT SYMPTOMS;DNA METHYLATION;TRANSCRIPTOME;AMPK;ANTIBIOTIC STEWARDSHIP;ANTIMICROBIAL STEWARDSHIP;APOLIPOPROTEIN A1;BLADDER OUTLET OBSTRUCTION;CELLULAR SENESCENCE;CROSSOVER STUDY;CUTANEOUS LYMPHOMA;CUTANEOUS T-CELL LYMPHOMA;DIFFUSING CAPACITY;DIPEPTIDYL PEPTIDASE-4;GABA TRANSPORTER;GLUTATHIONE PEROXIDASE;GROUND-GLASS OPACITY;HEART-TYPE FATTY ACID BINDING PROTEIN;HERPESVIRIDAE;HESPERETIN;HETEROPLASMY;HUMAN MITOCHONDRIAL GENETICS;HYDROXYTYROSOL;INTERNATIONAL HEALTH;LACUNARITY;MACE;MECP2;MICROVESICLES;MIRBASE;MITOCHONDRIAL DISEASE;MITOCHONDRIAL ENCEPHALOMYOPATHY;NARINGENIN;NON-CODING RNA;NON-MENDELIAN INHERITANCE;ONCOGENE;OSTEOPOROTIC FRACTURE;PCR TEST;PROMOTER;PROSTATE-SPECIFIC ANTIGEN;SOD2;SPHINGOMYELIN PHOSPHODIESTERASE;THIOREDOXIN REDUCTASE;TOOTH REMINERALIZATION;TRANSURETHRAL RESECTION OF THE PROSTATE","14;4;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;AGED;MALE;COVID-19;FEMALE;CARDIOVASCULAR DISEASES;DIABETES MELLITUS, TYPE 2;AGED, 80 AND OVER;MICRORNAS;CROSS INFECTION;RENAL INSUFFICIENCY, CHRONIC;AGING;ITALY;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;ANIMALS;CAREGIVERS;CHILD;CURCUMIN","62;62;33;21;18;18;9;9;8;8;7;7;6;6;6;6;5;5;5;5","TECHNOLOGY ADOPTION AND AGING POPULATION;CHOLESTEROL-LOWERING TREATMENT;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;IMPACT OF PARENTAL ILLNESS ON CHILDREN AND FAMILIES;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ACTIVITY RECOGNITION IN PERVASIVE COMPUTING ENVIRONMENTS;ATOPIC DERMATITIS AND SKIN MICROBIOME;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;IMPACT OF RETIREMENT ON AGING WORKFORCE;IMPACT OF SOCIAL FACTORS ON HEALTH OUTCOMES;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS","8;7;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","AGING;GERIATRIC ASSESSMENT;PANDEMIC;TECHNOLOGY USE;2019-20 CORONAVIRUS OUTBREAK;CROSS-SECTIONAL STUDY;DEMENTIA;INFORMAL CAREGIVING;POPULATION AGEING;SENESCENCE;COGNITIVE DECLINE;COMPREHENSIVE GERIATRIC ASSESSMENT;FRAILTY;PROINFLAMMATORY CYTOKINE;YOUNG CARERS;ACTIVE AGEING;AGING WORKFORCE;BLOOD PRESSURE;CARDIAC ULTRASOUND;HYPERTENSION","8;7;7;7;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3","BLOOD PRESSURE;COVID- PANDEMIC;COVID- PATIENTS;ALZHEIMERS DISEASE;HYPERTENSIVE POPULATION;MUSCLE SYMPTOMS;PILOT STUDY;SCOPE STUDY;STUDY PROTOCOL;ATOPIC DERMATITIS;BACTERIAL DNA;BONE MARROW;CARDIAC DEVICE;CARDIOVASCULAR RISK;CHEST X-RAY;CLINICAL INDEX;COGNITIVE DECLINE;COGNITIVE IMPAIRMENT;CURCUMIN POLYDATIN;DEVICE IMPLANTATION;DIGITAL COACHING;EDUCATIONAL PROGRAMME;ENDOTHELIAL CELLS;EUROPEAN COUNTRIES;EXPERT OPINION;EXPLORATORY STUDY;FAMILIAL HYPERCHOLESTEROLEMIA;FATTY ACID;GERIATRIC PATIENTS;HEALTHY AGEING","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HR CI;IN-HOSPITAL MORTALITY;MUSCLE SYMPTOMS;PHYSICAL ACTIVITY;COGNITIVE DECLINE;COVID- PANDEMIC;DIGITAL SUPPORT;DIGITAL TECHNOLOGIES;SENESCENT CELLS;COVID- PATIENTS;HEALTH LITERACY;CV RISK;INFORMAL CAREGIVERS;OBSERVATIONAL STUDY;SOCIAL ISOLATION;SUPPORT SERVICES;BACTERIAL DNA;BLOOD PRESSURE;HEALTHY AGEING;MECHANICAL COMPLICATIONS;MENTAL HEALTH;ENDOTHELIAL CELLS;MAGNETIC RESONANCE;RISK FACTOR;SIGNIFICANT DIFFERENCES;ATOPIC DERMATITIS;CLINICAL PRACTICE;CORONA SCORE;EMERGENCY DEPARTMENT;EQ-VAS DECLINE","18;18;18;16;12;12;11;11;11;10;10;9;9;9;9;9;8;8;8;8;8;7;7;7;7;6;6;6;6;6",51,0.4,5.45,8,1,1.75,0,1,0,1,0,8.5,1,0,8.75,1,0,2,2,5.75,3,0,0,10,10,2,0,0,4,0,0,0,0,0,0,0,0,2,0,2,0,6,4.51,3,0,4,2,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ATLANTE SANDRA;DE ROSA MARIA CRISTINA;FARSETTI ANTONELLA;GAETANO CARLO;MALAVOLTA MARCO;PIROLLI DAVIDE","4;4;4;4;4;4","CONSIGLIO NAZIONALE RICERCHE;INRCA;ISTITUTI CLINICI SCIENT MAUGERI SPA SB","4;4;4","34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY;32 BIOMEDICAL AND CLINICAL SCIENCES","6;4;2",NA,NA,"5.1 PHARMACEUTICALS","1","A61K;A61P11/00;A61P13/12;A61P17/00;A61P25/28;A61P27/02;A61P35/00;A61P43/00;A61K31/15;A61K31/44","2;2;2;2;2;2;2;2;1;1","A61P11/00;A61P13/12;A61P17/00;A61P25/28;A61P27/02;A61P35/00;A61P43/00;A61Q19/08;A61K31/15;A61K31/44","4;4;4;4;4;4;4;4;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2675527,121614.86,4,22,10,1,0,352849.436742424,0.359926888852336,"AGE PLATFORM EUROPE;DEPARTMENT OF HEALTH;GOETHE UNIVERSITY FRANKFURT;GREATER MANCHESTER COMBINED AUTHORITY;HASSELT UNIVERSITY;INSTITUTE OF TRANSPORT ECONOMICS;INTERNATIONAL FEDERATION ON AGEING;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;MANCHESTER METROPOLITAN UNIVERSITY;MARCHE POLYTECHNIC UNIVERSITY;MASARYK UNIVERSITY;OPEN UNIVERSITY IN THE NETHERLANDS;OSLOMET – OSLO METROPOLITAN UNIVERSITY;UNITED NATIONS ECONOMIC COMMISSION FOR EUROPE;UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND;UNIVERSITY OF BUSINESS IN PRAGUE;UNIVERSITY OF GALWAY;UNIVERSITY OF MANCHESTER;UTRECHT UNIVERSITY;VILANS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-MSCA-2021-DN-01 (CALL FOR PROPOSAL);HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA DOCTORAL NETWORKS (FUNDING SCHEME);HORIZON.1.2 - MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) (PROGRAMME)","1;1;1","44 HUMAN SOCIETY;4406 HUMAN GEOGRAPHY","1;1",NA,NA,"GENERIC HEALTH RELEVANCE","1",NA,NA,NA,NA,NA,NA,"C20 SOCIAL WORK AND SOCIAL POLICY","1","11 SUSTAINABLE CITIES AND COMMUNITIES","1",2,"ZENODO","2","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","2;2;2",NA,NA,NA,NA,NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA
"IRCCS_INRCA",2024,153,16.6601307189542,3.26143790849673,0.38562091503268,0.372549019607843,0.418300653594771,2.42233009708738,1.20408163265306,1.46153846153846,1.30612244897959,0.803921568627451,2,52,29,4,2,0.34,0.19,0.03,0.01,0.87,0.909570917217905,5.56109725685786,0.405228758169935,0.967320261437909,0.529,0.432,0.482,0.47,"FABIOLA OLIVIERI;FABRIZIA LATTANZIO;MIRKO DI ROSA;ANTONIO CHERUBINI;ANNA RITA BONFIGLI;PAOLO FABBIETTI;ANDREA CORSONELLO;GIOVANNI LAMURA;JACOPO SABBATINELLI;FRANCESCO SPANNELLA;RICCARDO SARZANI;MARCO SOCCI;LUCA SORACI;ANGELICA GIULIANI;SARA SANTINI;SABRINA QUATTRINI;FRANCESCO MATTACE‐RASO;LISANNE TAP;GIUSEPPE BRONTE;RAFAEL MORENO‐GONZÁLEZ","19;15;14;14;13;13;13;12;10;10;9;8;8;8;7;7;7;7;6;6","GIOVANNI LAMURA;FABIOLA OLIVIERI;PAOLO FABBIETTI;SOFIA CECCHI;MARCO SOCCI;MARCO MALAVOLTA;SABRINA QUATTRINI;ANTONIO CHERUBINI;FIORENZO CONTI;MIRKO DI ROSA;MARIA GABRIELLA MELCHIORRE;FABRIZIA LATTANZIO;ANDREA CORSONELLO;JACOPO SABBATINELLI;ANNA RITA BONFIGLI;SARA SANTINI;ANGELICA GIULIANI;FRANCESCO SPANNELLA;GIUSEPPE BRONTE;MARTA BALIETTI","2.58;1.87;1.54;1.4;1.4;1.32;1.26;1.25;1.09;1.02;1;0.99;0.95;0.9;0.85;0.84;0.75;0.73;0.67;0.67","FABIOLA OLIVIERI;FABRIZIA LATTANZIO;MIRKO DI ROSA;ANTONIO CHERUBINI;ANNA RITA BONFIGLI;PAOLO FABBIETTI;ANDREA CORSONELLO;GIOVANNI LAMURA;JACOPO SABBATINELLI;FRANCESCO SPANNELLA;RICCARDO SARZANI;MARCO SOCCI;LUCA SORACI;SARA SANTINI;SABRINA QUATTRINI;GIUSEPPE BRONTE;ROBERTA BEVILACQUA;RINA RECCHIONI;FRANCESCO PIACENZA;GIUSEPPE PELLICCIONI","19;15;14;14;13;13;13;12;10;10;9;8;8;7;7;6;6;6;6;6","GIOVANNI LAMURA;FABIOLA OLIVIERI;PAOLO FABBIETTI;SOFIA CECCHI;MARCO SOCCI;MARCO MALAVOLTA;SABRINA QUATTRINI;ANTONIO CHERUBINI;FIORENZO CONTI;MIRKO DI ROSA;MARIA GABRIELLA MELCHIORRE;FABRIZIA LATTANZIO;ANDREA CORSONELLO;JACOPO SABBATINELLI;ANNA RITA BONFIGLI;SARA SANTINI;FRANCESCO SPANNELLA;GIUSEPPE BRONTE;MARTA BALIETTI;GEORGIA CASANOVA","2.58;1.87;1.54;1.4;1.4;1.32;1.26;1.25;1.09;1.02;1;0.99;0.95;0.9;0.85;0.84;0.73;0.67;0.67;0.58","FABIOLA OLIVIERI;MARIA RITA RIPPO;DANIELA MARZIONI;GIOVANNI TOSSETTA;SONIA FANTONE;ANGELO SIRICO;FEDERICA PIANI;NICOLETTA DI SIMONE;FRANCESCO PRATTICHIZZO;VALERIA PELLEGRINI;CHIARA FRIGÉ;ANTONIO CERIELLO;ARTURO CESARO;CARLO FUMAGALLI;CARMINE PIZZI;CELESTINO SARDU;CIRO MAURO;DAVIDE D’ANDREA;GIUSEPPE PAOLISSO;LUDOVICA VITTORIA MARFELLA","49;40;32;32;32;31;31;31;21;21;19;11;11;11;11;11;11;11;11;11","FABIOLA OLIVIERI;SONIA FANTONE;ROBERTO ANTONICELLI;ANTONIO CHERUBINI;ELENA TORTATO;FABIO SALVI;FRANCESCO SPANNELLA;GIOVANNI LAMURA;GIUSEPPE BRONTE;PAOLO FABBIETTI;ANNA RITA BONFIGLI;ANDREA CORSONELLO;LUCA SORACI;SARA SANTINI;DANIELE CASTELLANI;MARCO DELLABELLA;SABRINA QUATTRINI;ANTONIO DOMENICO PROCOPIO;CHIARA GIORDANI;CINZIA GIAMMARCHI","49;32;11;8;7;7;7;7;7;7;6;5;5;5;4;4;4;3;3;3","FABIOLA OLIVIERI;FABRIZIA LATTANZIO;ANTONIO CHERUBINI;MIRKO DI ROSA;GIOVANNI LAMURA;PAOLO FABBIETTI;ANDREA CORSONELLO;ANNA RITA BONFIGLI;FRANCESCO SPANNELLA;LUCA SORACI;MARCO SOCCI;RICCARDO SARZANI;SARA SANTINI;ELENA TORTATO;SABRINA QUATTRINI;FRANCESCO PIACENZA;GIUSEPPE BRONTE;ROBERTA BEVILACQUA;ANTONIO DOMENICO PROCOPIO;FIORENZO CONTI","17;15;14;13;12;12;12;12;9;8;8;8;7;7;7;6;6;6;5;5","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;PHYSICS;ENGINEERING;SOCIOLOGY;POLITICAL SCIENCE;CHEMISTRY;GEOGRAPHY;BUSINESS;MATHEMATICS;GEOLOGY;MATERIALS SCIENCE;PHILOSOPHY;HISTORY;ART","140;36;27;19;17;14;13;13;11;7;6;5;5;4;4;4;2;1","INTERNAL MEDICINE;GERONTOLOGY;PATHOLOGY;PSYCHIATRY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;SURGERY;NURSING;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PHYSICAL THERAPY;ECONOMIC GROWTH;GENETICS;NEUROSCIENCE;OPTICS;RADIOLOGY;CELL BIOLOGY;LAW;MECHANICAL ENGINEERING;ONCOLOGY;SOCIAL PSYCHOLOGY","89;33;33;25;19;19;19;18;17;16;13;13;11;9;9;9;8;8;7;7;7;7;7","DISEASE;DIABETES MELLITUS;GENE;POPULATION;CANCER;RANDOMIZED CONTROLLED TRIAL;INFLAMMATION;BLOOD PRESSURE;ALTERNATIVE MEDICINE;COHORT;HEALTH CARE;QUALITY OF LIFE (HEALTHCARE);KIDNEY DISEASE;STROKE (ENGINE);CLINICAL TRIAL;HEART FAILURE;INCIDENCE (GEOMETRY);INTERVENTION (COUNSELING);MENTAL HEALTH;OBSERVATIONAL STUDY;OLDER PEOPLE","34;14;14;12;11;11;10;9;8;8;8;8;7;7;6;6;6;6;6;6;6","DEMENTIA;INFECTIOUS DISEASE (MEDICAL SPECIALTY);TYPE 2 DIABETES;CLINICAL ENDPOINT;ISCHEMIC STROKE;MICRORNA;WARFARIN;2019-20 CORONAVIRUS OUTBREAK;ADENOCARCINOMA;COGNITIVE IMPAIRMENT;MICROGLIA;MINOR STROKE;NEUROINFLAMMATION;OSTEOARTHRITIS;POPULATION AGEING;PROTOCOL (SCIENCE);ACTIVE AGEING;ASTROCYTE;C-REACTIVE PROTEIN;COLORECTAL CANCER;DIABETIC FOOT;DOWNREGULATION AND UPREGULATION;DRUG REACTION;EJECTION FRACTION;FETUS;GENE EXPRESSION;GLUTAMATE RECEPTOR;HEALTHY AGEING;INFLAMMATORY BOWEL DISEASE;MULTICENTER STUDY;NEUROTRANSMISSION;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;PLACEBO;PROINFLAMMATORY CYTOKINE;PROSTATE;THROMBIN;THROMBOLYSIS;TYPE 2 DIABETES MELLITUS","10;10;8;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);CAREGIVER BURDEN;DABIGATRAN;LOWER URINARY TRACT SYMPTOMS;MICROVESICLES;AMPA RECEPTOR;ANGIOTENSIN RECEPTOR BLOCKERS;ARTHROPATHY;AUTONOMIC NERVOUS SYSTEM;BIG FIVE PERSONALITY TRAITS AND CULTURE;C2C12;CALPROTECTIN;CELLULAR SENESCENCE;COGNITIVE DECLINE;COLONOSCOPY;COOPERATIVENESS;COPD EXACERBATION;CREB;CROSSOVER STUDY;DAPAGLIFLOZIN;DIFFUSING CAPACITY;DISCOVERY AND DEVELOPMENT OF DIRECT THROMBIN INHIBITORS;DNA METHYLATION;DOUBLE BLIND;FALL PREVENTION;FALLS IN OLDER ADULTS;FEAR OF FALLING;GERIATRIC DEPRESSION SCALE;GLUTAMATERGIC;GROUND-GLASS OPACITY;HARM AVOIDANCE;HETEROPLASMY;MACE;MEDIAL MENISCUS;MENIERE DISEASE;MIGRAINE WITH AURA;MODIFIED RANKIN SCALE;MYELOID-DERIVED SUPPRESSOR CELL;NEUROPSYCHOLOGICAL ASSESSMENT;NOVELTY SEEKING;OLIGODENDROCYTE;ORAL ANTICOAGULANT;OSTEOPENIA;PEMBROLIZUMAB;PEMETREXED;PLACENTA;POLISTES;PRENATAL DIAGNOSIS;PYRIN DOMAIN;RIVAROXABAN;ROS1;SEED DORMANCY;SERINE PROTEASE;SYNAPTIC AUGMENTATION;SYNAPTIC FATIGUE;SYNOVIAL FLUID;SYSTOLE;TAUROURSODEOXYCHOLIC ACID;TELEREHABILITATION;TEMPERAMENT AND CHARACTER INVENTORY;TRANSCRIPTOME;TRANSPOSABLE ELEMENT","10;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;AGED;FEMALE;MALE;AGED, 80 AND OVER;MIDDLE AGED;ITALY;CROSS-SECTIONAL STUDIES;RISK FACTORS;EUROPE;RETROSPECTIVE STUDIES;BIOMARKERS;DIABETES MELLITUS, TYPE 2;TREATMENT OUTCOME;ADULT;AGING;HYPERTENSION;PREVALENCE;ANTIHYPERTENSIVE AGENTS","89;62;39;39;37;24;20;15;12;12;9;9;8;7;7;6;6;6;6;5","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;INTERGENERATIONAL FAMILY RELATIONSHIPS AND SUPPORT;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;TECHNOLOGY ADOPTION AND AGING POPULATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;IMPACT OF PARENTAL ILLNESS ON CHILDREN AND FAMILIES;INFLUENCE OF AGING ON EMOTIONAL EXPERIENCE AND WELL-BEING;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;QUALITY AND PRACTICES IN NURSING HOME CARE;STANDARDISATION AND MANAGEMENT OF COPD;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BODY COMPOSITION ASSESSMENT AND ANALYSIS;DENTAL RESTORATIVE MATERIALS;EFFECTS OF KETOGENIC DIET ON HEALTH;FEMOROACETABULAR IMPINGEMENT SYNDROME AND HIP PATHOLOGY;IMPACT OF SOCIAL FACTORS ON HEALTH OUTCOMES;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH","6;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","AGING;DIABETES;HYPERTENSION;PANDEMIC;STROKE (ENGINE);ANTICOAGULANT THERAPY;INFARCTION TREATMENT;INFORMAL CAREGIVING;INTERQUARTILE RANGE;SUCCESSFUL AGING;TYPE 2 DIABETES;CLINICAL ENDPOINT;CROSS-SECTIONAL STUDY;GERIATRIC ASSESSMENT;HEALTHY AGEING;SENESCENCE;TECHNOLOGY USE;TREATMENT;AGEISM;ATRIAL FIBRILLATION","12;7;7;7;7;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3","TYPE DIABETES;ELDERLY PATIENTS;CONTROLLED TRIAL;COVID- PANDEMIC;HEART FAILURE;ISCHEMIC STROKE;PEOPLE AGEING;PILOT STUDY;STUDY PROTOCOL;ANTIPLATELET TREATMENT;CARDIOVASCULAR RISK;CHRONIC KIDNEY;COGNITIVE IMPAIRMENT;DUAL ANTIPLATELET;EUROPEAN SOCIETY;KIDNEY DISEASE;LONG-TERM CARE;MORTALITY RISK;PHYSICAL PERFORMANCE;RANDOMIZED CONTROLLED;READAPT STUDY;ADVANCED CHRONIC;ADVERSE DRUG;ALZHEIMERS DISEASE;ARTERY DISEASE;ATRIAL FIBRILLATION;BLOOD PRESSURE;C-REACTIVE PROTEIN;CHRONIC RENAL;CLINICAL TRIAL","8;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","RISK FACTORS;HR CI;KIDNEY DISEASE;CHRONIC KIDNEY;CLINICAL PRACTICE;MARCHE REGION;PSYCHOLOGICAL WELL-BEING;TTV VIREMIA;TYPE DIABETES;BLOOD PRESSURE;HOME CARE;CARE RECIPIENTS;CAREGIVING BURDEN;FAMILY CAREGIVERS;CARE SERVICES;COGNITIVE IMPAIRMENT;COMPUTED TOMOGRAPHY;HEART FAILURE;ISCHEMIC STROKE;LOGISTIC REGRESSION;MENTAL WELL-BEING;PATIENTS AGED;RISK FACTOR;VIREMIA LOG;AGE-RELATED DISEASES;CARDIOVASCULAR EVENTS;CARE PROFESSIONALS;CROSS-SECTIONAL STUDY;DEMENTIA CARE;DISEASE CKD","17;12;11;10;10;10;10;10;10;9;9;8;8;8;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6",1,0.01,22.5,29,0,0,0,1,0,0,0,29,0,0,28,0,0,0,5,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
